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Abstract 
Pleuromutilin has potential as a next-generation antibiotic, and many semi-synthetic 
pleuromutilin derivatives have been developed. Recently, characterization of 
individual enzymatic steps involved in the production of pleuromutilin has been carried 
out. A linear pathway of pleuromutilin biosynthesis was established; however, there is 
a possibility of alternative or shunt pathways.  
Thus, the first part of this thesis aimed to investigate if any other possible routes could 
lead to the biosynthesis of pleuromutilin. Two alternative pathways were identified 
from the expression of various combinations of pleuromutilin biosynthetic genes in 
Aspergillus oryzae. However, neither route led to mature pleuromutilin due to the lack 
of activity of P450-3. It was shown that most of the tailoring enzymes except for P450-
3 exhibited a more relaxed substrate specificity as they were able to catalyze reactions 
in different premutilin intermediates. The structure-activity of pleuromutilin and its 
derivatives, including one synthesized by a semi-synthetic approach, was also 
investigated through antibacterial assay against Bacillus subtilis. It was observed that 
missing the substituents, 3-ketone, 11-OH or 14-acetyl from the pleuromutilin core 
affected the antibacterial activity of the pleuromutilin. Thus, it was important to retain 
the three side groups on the pleuromutilin core to maintain the bioactivity of the 
pleuromutilin, although further modification can be done on the C-14 to improve its 
activity.  
The second part of this study evaluated the potential of using the A. oryzae secondary 
host as a platform for further in vivo derivatization of the pleuromutilin core through 
the expression of foreign genes. However, no accumulation of new pleuromutilin 
analogs could be detected, which suggested the difficulties in achieving pleuromutilin 
hybrid products through combinatorial biosynthesis. Further knowledge of the 
interaction between enzymes and their substrates may be required to find suitable 
hybrid enzyme combinations that could lead to the biosynthesis of compounds with 
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Chapter 1. BACKGROUND 
1.1 Development of antibiotics 
Antibiotics are a large class of compounds with therapeutic properties used to treat 
bacterial infection. These kinds of compounds were used for decades even before the 
antibiotic era. For example, traces of tetracycline have been found in human skeletons 
from the late Roman period while artemisinin was discovered from Artemisia herbs 
which have long been used in traditional Chinese medicine (TCM) to treat malaria 
(Cook et al. 1989). The first antibiotic, Salvarsan was synthesized in 1910 by Paul 
Ehrlich and Alfred Bertheim (Williams 2009). Inspired by the highly toxic drug 
Atoxyl, Ehrlich and Bertheim synthesized hundreds of Atoxyl analogs and tested 
against syphilis. Salvarsan and its derivative Neosalvarsan showed promising activities 
against bacteria which causes syphilis and were used for chemotherapy for almost 20 
years.  
The beginning of the modern antibiotic era started with Alexander Fleming’s discovery 
of penicillin from Penicillium mold (Fleming 1929). Although there were attempts to 
isolate and synthesize antibiotics prior to this, it is penicillin which successfully made 
its way to the market and became recognized as one of the greatest advances in the 
medical field. Penicillin belongs to the large b-lactam family. Antibiotics in this family 
share a common mode of action by inhibiting the activity of enzymes responsible for 
the synthesis of peptidoglycan in the bacterial cell wall, leading to cell lysis. In the late 
1940s, another b-lactam compound, cephalosporin was found from Acremonium 
chrysogenum (Abraham et al. 1955) by Giuseppe Brotzu. In the following years, 
several types of cephalosporin were successfully isolated from the fungus including 
cephalosporin P, cephalosporin N and cephalosporin C. Among all the cephalosporins 
discovered, cephalosporin C has a wide spectrum of activity, being able to inhibit many 
Staphylococcus aureus strains including the strains with penicillin-resistant properties 
(Muñiz et al. 2007). 
Alongside the significant discovery of penicillin and cephalosporin, several new 
bacterial-derived antibiotics classes were explored and studied including tyrothricin 
from Bacillus brevis (Lask 1948), streptomycin from Actinomyces griseus (Schatz et 
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al. 1944), tetracylines from Actinomycetes (Nelson and Levy 2011), chloramphenicol 
from Streptomyces venezuelae (Ehrlich et al. 1947), azomycin from Streptomyces 
eurocidicus (Nakamura 1955) and erythromycins isolated from Saccharopolyspora 
erythraea (McGuire et al. 1952).  
In the early 1960s, another unnatural antibiotic was synthesized called trimethoprim 
(Roth et al. 1962). This molecule was reported to be active against both Gram-positive 
and negative bacteria. Remarkably the drug showed strong synergistic effects when 
taken together with sulfonamides. This has led to the development of antibiotic 
formulation consisting of both drugs and it was marketed as co-trimoxazole. Another 
milestone in the history of antibiotics was the development of semi-synthetic drugs. 
While diverse antibiotic products can be isolated from plants, fungi or microorganisms, 
many of them are toxic and have either a very short or long half-life, which often limits 
their usefulness. Thus, to overcome these problems, the chemical modification was 
attempted with the aim to improve the antibiotic properties, stability and to make them 
less toxic to the host. One example is the development of semi-synthetic products from 
penicillin G to improve resistance towards β-lactamase, stability in an acidic 
environment and the broad antibiotic spectrum. The semi-synthetic penicillins include 
ampicillin, methicillin, carbenicillin and amoxicillin and each of them has enhanced 
properties (Oshiro 1999). Another two successful stories of semi-synthetic analogs 
approved for clinical purposes are telavancin (Damodaran and Madhan 2011) and 
retapamulin (Parish et al. 2006) originating from vancomycin and pleuromutilin 
respectively. 
Much research was carried out, resulting in the discovery of many antibiotics especially 
between the 1950s and 1970s where this period is known as the golden era of 
antibiotics. Unfortunately, the following years have seen a marked decrease in the 




1.1.1 Growing antibiotic-resistance threatens human health  
Antibiotic resistance is the ability of bacteria to evade the action of antibiotics that once 
were active against them. The bacteria undergo evolutionary changes which involve 
alteration or rearrangement of the antibiotic-resistance genes. It is also reported that 
certain bacteria can acquire resistance genes, either directly from other bacteria or from 
DNA in the environment (Munita and Arias 2016). There are three main mechanisms 
of drug resistance: (1) through enzymatic modification of the drugs where the bacteria 
produce enzymes that can modify the antibiotic molecule thus inhibiting the activity of 
the antibiotic before it reaches its targets; (2) changing the permeability of the cell to 
avoid penetration of the antibiotic; (3) alteration of the drug target site by protection or 
modification on the target site. This mechanism will evade attachment of the antibiotics 
to the binding site and prevent the activity of the antibiotic (Munita and Arias 2016).  
The emergence of resistant bacteria threatens the ability to treat common infectious 
diseases. The number of bacteria resistant to the drugs used to treat them have been 
rising every year and at present have reached dangerously high levels in which the 
occurrence of resistance is really worrying.  The increase in frequency of resistance 
against several important antibiotics is shown in Figure 1.1 with up to 25 % of strains 
now showing resistance to fluoroquinolones.  
The situation has worsened with the low number of new agents reaching the market, 
halving since the year 2000. There are a number of factors that may play a role in the 
shortage of new antibiotics in the market, for instance lack of antibiotic research. Due 
to the high cost of antibiotic development, many pharmaceutical companies dropped 
out of antibiotic discovery as it was not giving a profitable return on the investment. 
Besides, the difficulties of obtaining regulatory approval for new antibiotics have led 




















The World Health Organization (WHO) has issued a report of 480, 000 incidents 
related to drug-resistant tuberculosis infection taking place every year. Out of these 
numbers, only half of the cases were successfully treated (WHO 2014). In the United 
States, at least 23, 000 people die each year from antibiotic-resistant bacteria in which 
the highest percentage of death was due to methicillin-resistant Staphylococcus aureus 
(MRSA) infection (U.S Centres for Disease Control and Prevention 2013).  
Figure 1.1 Trends displayed the development of resistant bacteria and the release of 
new antibiotics. The spread of resistance in bacteria against common antibiotics was 
shown in A (Reardon 2015) and B showed the number of new antibiotics approved 




In European countries, resistance has increased, especially in the south and south east 
of Europe. Although the resistant situation for some of the bacteria is stabilizing in 
certain countries, a significant increasing trend could be noted especially for resistant 
E. coli and vancomycin-resistant Enterococcus faecium between the year 2013 and 
2016 (European Centre for Disease Prevention and Control 2017).  
Recent news from the WHO disclosed an on-the-rise threat of antibiotic resistant 
gonorrhoea (Alirol et al. 2017). The spread of the resistant gonorrhoea bacteria is of 
great concern as it was reported to evolve rapidly every time a new class of antibiotics 
was used to treat the infection, making it much harder to control. The last alternative 
treatment for gonorrhoea using the 3rd generation of cephalosporin also has failed to 
treat the infection as reported in countries like Australia, Austria, Canada, France, 
Japan, Norway, Slovenia, South Africa, Sweden and the United Kingdom. 
The consequences of antimicrobial resistance are destructive not only to the economy 
but also to the population’s health in terms of morbidity and mortality. Due to this 
alarming situation the WHO has outlined a global action plan to combat the resistance 
crisis (WHO 2015). One of the plans is to urge all countries to increase investment in 
development of new antibiotics to encourage pharmaceutical companies and 
researchers to return to antibiotic discovery programmes. This is hoped to bring more 
drugs to the market which are urgently needed and to ensure people will have 
continuous access to new medicines in the future. 
1.2 Fungal secondary metabolites as antibiotics 
1.2.1 Classification of fungal secondary metabolites  
Fungi are capable of producing many secondary metabolites in response to their 
competitive environments. In order to strive for the same limited resources with other 
organisms especially bacterial species, fungi tend to secrete a range of compounds that 
are toxic to their competitors. This may yield advantages to the fungus in exploitation 
of environmental resources. The secretion of secondary metabolites by fungi is largely 
influenced by the interactions with other organisms, thus sometimes they might not 
produce the metabolites in the laboratory condition. 
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Secondary metabolites are substances which are not involved directly in the growth 
and development of an organism, as in, despite the absence of these compounds the 
organism can still grow. Unlike primary metabolites, the compounds that make up 
secondary metabolites contribute to the fungi’s ability to survive and serve defense 
functions to the microorganisms. In preceding studies, many of the secondary 
metabolites have been reported to have biological activities. According to Pelaez 
(2004), a literature survey from 1993 to 2001 found that more than half of all fungal 
metabolites exhibited potent activities against bacteria, fungi and also had antitumor 
properties. More than 22% of the antibiotics in the world are produced by filamentous 
fungi and are mostly used to treat cancer, hepatitis and cardiovascular diseases (Tang 
and Zhong 2004; Khan et al. 2010). In fungi, secondary metabolites can be divided into 
polyketides, non-ribosomal peptides (NRPS), indole alkaloids and terpenes (Keller et 
al. 2005). 
1.2.1.1 Polyketides 
A large proportion of polyketides are produced by fungi through polyketide 
biosynthetic pathways. They are typically synthesized by type I polyketide synthases 
(PKSs) and reveal a large diversity of form and function with potent bioactive 
properties. A prominent example of a fungal polyketide antibiotic is griseofulvin from 
Penicillium griseofulvum in the 1930s (Oxford et al. 1939). Its potential as an 
antifungal was not discovered until the late 1950s after a successful screening against 
dermatophytes after it was administered orally in pigs. Griseofulvin inhibits mitosis of 
fungal cells by binding to tubulin and disturbing the microtube function. The WHO has 
listed this antibiotic as one of the essential medicines for basic health-care system to 
treat fungal infections on skin, hair and nails (WHO 2015). Although the spectrum of 
activity for the griseofulvin antibiotic was narrow, it is strong against dermatophytes 
such as Epidermophyton floccosum (Richardson and Warnock 2003). Other examples 
of polyketides include the cholesterol-lowering compounds lovastatin, aflatoxin and 
naphthopyrone (Keller et al. 2005). 
1.2.1.2 Non-ribosomal peptides (NRPS) 
Non-ribosomal peptides (NRPS) are built from the incorporation of proteinogenic 
amino acids and non-proteinogenic amino acids by peptide bond.  A linear or cyclic 
form of NRPS can be further modified by the respective tailoring enzymes (Keller et 
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al. 2005). A multitude of cyclisations and modifications can take place generating 
diverse structures of peptides. These diverse structures exhibit many different 
biosynthetic activities. One notable series of antibiotics discovered from this class 
includes penicillin and its β-lactams derivatives such as cephalosporins, cephamycins 
and cephabacins (Brakhage 1998). Figure 1.2 shows the structure of β-lactam 
compounds isolated from fungi. These molecules can inhibit the formation of 
peptidoglycan, the main constituent of bacterial cell wall by binding to the bacterial 
enzyme, transpeptidase, resulting in digestion of the peptidoglycan (Fernandes et al. 
2013). β-lactam antibiotics are mostly active against Gram positive bacteria, but many 
synthetic molecules with a β-lactam core structure have been developed to work against 
Gram negative bacteria. Other important NRPS in medicinal history are cyclosporins 
found in fungus Tolypocladium inflatum. They are widely used as immunosuppressants 
to reduce immune system activity (T-cell) (Bushley et al. 2013). Cyclosporins’ 
discovery brought on a new age of immunosuppressive drugs which in turn 
revolutionized the field of organ transplants. They were widely used in transplant 
surgical procedures to avoid rejection of the new organ and have significantly increased 
the survival rate of transplant patients. Cyclosporins act by inhibiting calcineurin 
activity which is responsible for activating T- cells and the reduced function of effector 
T-cells (Tedesco and Haragsim 2012).  
1.2.1.3 Indole alkaloids 
Another class of secondary metabolites are the indole alkaloids, these are derived from 
prenylation of tryptophan followed by methylation of dimethylallyl pyrophosphate. 
The prenylation step is initialized by dimethylallyl tryptophan synthetase. Although 
biochemical pathways of certain indole alkaloids like ergotamine have been elucidated, 
there are alkaloids that undergo one or more additional prenylation steps which are not 
fully described yet. For instance, fumigaclavines, paxilline and communesin are 
examples of indole alkaloids isolated from A. fumigatus (dos Santos et al. 2002).  
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Figure 1.2 Examples of naturally occurring antibiotics from fungi according to their 
secondary metabolite classes.  
 
1.2.1.4 Terpenes 
The last major secondary metabolite class is terpenes. They are a wide and diverse class 
of natural products which include nearly 30,000 compounds. Due to their diverse 
structure, many terpene compounds have exhibited biological activities against 
bacteria, fungi and viruses. As an example, fusidic acid was isolated from a fungal 
parasite, Fusidium coccineum living in a Speedwell plant. This antibiotic compound 










































































































able to kill penicillin-resistant bacteria (Godtfredsen et al. 1962; Crosbie 1963). These 
promising results sped up the clinical development and fusidic acid was introduced to 
the market the same year as its discovery. Fusidic acid works by inhibiting bacterial 
protein synthesis where it binds to the elongation factor (EF-G)-ribosome complex to 
prevent the protein elongation process (Dobie and Gray 2004). It has been more than 
50 years since its first discovery, but fusidic acid is still widely used throughout the 
world especially as an alternative to fighting against penicillin and meticillin-resistant 
S. aureus.  At present, many fusidic acid analogs have been synthesized chemically to 
explore possibilities to broaden the spectrum of its antimicrobial activity. Another 
example is diterpene pleuromutilin from Clitopilus passeckerianus, which was the 
subject of this study. Similar to fusidic acid, pleuromutilin have gone through several 
chemical modifications and one of its derivatives retapamulin have been approved for 
human use (Kavanagh et al. 1952; Parish et al. 2006).  
The past few decades have seen a significant number of antibiotics being studied and 
isolated from fungi. The ability to synthesize many complex compounds with 
promising antibacterial properties make fungi a great source for medicinal chemicals. 
Furthermore, the global antibiotics market has seen fungal antibiotic products such as 
cephalosporins and penicillins dominate in the worldwide market which proved the 
importance of sourcing antibiotics from fungi (Figure 1.3). Despite many fungal 
compounds having been discovered from fungi, only a small fraction of the estimated 
fungal biodiversity worldwide has been studied. As shown by Nielsen et al. (2017), 
among the 61% of secondary metabolite gene clusters found in Penicillium species, 
only 16% of gene clusters could be correlated to a pathway while the rest remain 
unannotated. This demonstrates the potential for the further study of fungal secondary 
metabolites with the objective of identifying novel pharmaceutical compounds. 
Considering the potential of fungal species as a mine of bioactive compounds, more 
















1.3 Pleuromutilin  
1.3.1 Isolation and biological activity 
 Pleuromutilin is a diterpene isolated from the basidiomycete fungus Clitopilus 
scyphoides and Clitopilus passeckerianus by (Kavanagh et al. 1952). It has a 
‘propellane-like’ structure due to the three rings; 8-, 6- and 5-membered which are 
fused together (Figure 1.4). Its structure was elucidated in the early 1960s by Birch et 













Figure 1.3 The fungi-derived antibiotics accounted for the biggest sale in 2009 
according to The Global antibiotics market. Figure adapted from Hamad 
(2010). 
Figure 1.4 Pleuromutilin chemical structure isolated from C. passeckerianus. 
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Pleuromutilin molecules were not only reported to have antimicrobial activity against 
Gram positive bacteria, but according to Anchel (1952) and Szybalski (1954) it also 
inhibited Gram negative bacteria, namely Haemophilus influenzae and Moraxella 
catarrhalis.  Little attention had been given to the antibiotic pleuromutilin during the 
earliest years of its discovery. Only after the 1980s, a significant number of studies 
were carried out on pleuromutilin class of antibiotics in order to explore their potential 
on human use. It has a unique mode of action which can inhibit prokaryotic protein 
synthesis by binding to the bacterial 50S ribosomal subunit, but has no activity against 
eukaryotic protein synthesis (Hodgin and Hogenauer 1974). Thus, pleuromutilin has 
rarely shown cross resistance to the marketed antibacterial drugs. Coincidentally, with 
the rapid spread of MRSA during that time, this mechanism of action was effective 
against common pathogens which are involved in skin and respiratory infections 
(Hidron et al. 2009).  
1.3.2 Development of derivatives from pleuromutilin  
Since the first identification of pleuromutilin in 1952, numerous efforts have been taken 
to modify the structure with the hope of improving its effectiveness. Egger and 
Reinshagen (1976) were the first to discover that the C-14 side chain could be modified 
for optimization of its antibacterial activities. They reported the importance of this side 
chain in the antibacterial screening in which pleuromutilins with a free C-14 hydroxy 
were shown to be inactive. Conversely other pleuromutilin derivatives with bearing 
substituents at C-14 were all biologically active though the activity varied depending 
on the esters that attached to the C-14. Similar results were also reported by Hunt 
(2000) which showed that pleuromutilin with thio-ether substituents at the C-14 side 
chain were very active. There have been several pleuromutilin derivatives successfully 
developed, but most of them were mainly approved for veterinary purpose. For 
instance, tiamulin (Figure 1.5) was used to treat pneumonia, prophylaxis of dysentery 
and mycoplasmal infections in pig and poultry (Hunt 2000; Schlunzen et al. 2004). In 
later years, an improvement on the side chain was carried out by Hannan et al. (1997) 
and has led to the synthesis of valnemulin, the first veterinary formulation approved 
across European countries. Although both tiamulin and valnemulin were successfully 
applied in veterinary medicine, due to their rapid metabolism they were not suitable for 
human use. Thus, further research has seen a number of new pleuromutilin derivatives 
 12 
being developed and entering clinical studies such as azamulin (Hildebrandt et al. 
1982), but they failed in the clinical screening. In 2007, retapamulin was approved by 
the Food and Drug Administration (FDA) to treat human skin infection, 56 years since 
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Figure 1.5 Chemical structures of pleuromutilin derivatives with modification to the 
C-14 side chain (Davidovich et al. 2007). 
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Another significant improvement made on the C-14 side chain was the introduction of 
acyl-carbamate substituents (Hunt 2000). Like 14-ester derivatives, a broad spectrum 
of activity was possessed by 14-carbamate analogs. Interestingly, introducing the 
amino group to the 14-carbamate side chain could improve solubility while 
maintaining the antibacterial activity (Tang et al. 2012). Recent modification by 
Hirokawa et al. (2009) was able to prepare a new class of pleuromutilin with purine 
and piperazine ring spacer attached on their C-14 side chain.  The group reported that 
the new modifications displayed a strong in vivo efficacy against S. aureus infection in 
mice and have good solubility in water which implies a very promising profile to be 
further developed. 
Previous studies have mostly seen modifications carried out on C-14 pleuromutilin. 
However, despite having strong antibacterial activity, most of the semi-synthetic 
products of pleuromutilin suffer from rapid metabolism by liver P450 enzymes which 
make the molecule unstable due to hydroxylation at C-2 and C-8. In addition, the other 
limitation that some of the pleuromutilin derivatives might have is a lack of solubility 
in water. This results in poor oral absorption which limits their bioavailability and 
could impact on the transportation of the molecules to the site of infection. One way 
put forward to overcome this problem is to introduce a substituent on both carbon 
positions to either shield the sites or alter them to make the hydrogen atom less 
favorable for abstraction by the iron–oxo complex of the cytochrome. There have been 
varieties of C-2 and C-8 analogs developed in the past. Some of the C-2 derivatives 
were reported to retain a good antibacterial activity, this includes 2-florination and 2-
hydroxylation derivatives (Fu et al. 2010). But no further clinical data was reported 
from this study. Substitution on the C-8 of pleuromutilin with any other substituents 
like ketone and hydroxyl however produced poorly active analogs (Springer et al. 
2003). The same result was observed when C-6 sites were modified with an epimer 
which indicates that maintaining the environment of the cyclohexyl ring in 




1.3.3 Biosynthetic gene cluster of fungal diterpene 
The discovery of gene clusters has been important, allowing understanding and 
manipulation of the biosynthetic pathway of bioactive compounds. In fungi, 
modification of the hydrocarbon terpene skeleton is performed by genes clustered at a 
single genetic locus (Osbourn 2010). This has benefited the fungus as it can carry out 
the gene regulation efficiently. Some of the gene clusters which have already been 
identified include those for the biosynthesis of: aphidicolin in Phoma betae (Toyomasu 
et al. 2004); gibberellic acid (GA) in Gibberella fujikuroi and F. fujikuroi (Tudzynski 
and Hölter 1998; Malonek et al. 2005); penicillin in P. chrysogenum (Šmidák et al. 
2010); paspaline and paxilline in P. paxilli (Saikia et al. 2007; Saikia et al. 2012); 
lolitrem in Neotyphodium lolii and Epichloe festucae (Saikia et al. 2012); aflatrem in 
A. flavus (Nicholson et al. 2009); brassicicene in Alternaria brassicicola (Hashimoto 
et al. 2009); trichothecene in Fusarium sporotrichioides (Kimura et al. 2007) and 
pleuromutilin in Clitopilus passeckerianus (Bailey et al. 2016). Comparison of 
diterpene gene clusters in various fungi are shown in Figure 1.6.   
Fungal diterpene gene clusters almost always contain a geranyl-geranyl diphosphate 
synthase gene (GGS), required to assemble linear geranyl-geranyl diphosphate 
(GGPP), the precursor of diterpene molecule and this is in addition to housekeeping 
GGS for carotene synthesis (Yao 2007). The reason why the organisms need the 
pathway-specific GGS gene is not well understood yet. It could be that one in a cluster 
could function as part of that regulator of the gene expression so that sufficient GGPP 
can be produced for the downstream steps in the biosynthetic pathway. Besides, the 
enzyme encoded by the pathway-specific GGS gene may form a multi-enzyme 
complex with the other tailoring enzymes in the cluster to convert GGPP into the final 
product.   
Along with GGS, diterpene gene clusters also tend to contain terpene cyclase (CYC) 
for cyclisation of the linear GGPP and modifying the hydrocarbon skeleton (Toyomasu 
et al. 2004). Cytochrome P450s constitute a superfamily of haem-thiolate enzymes and 
have been identified in animal, plant, microorganism and even viruses. According to 
Nelson (2009), by 2009 more than 10, 000 distinct P450s are known or have been 
identified from various organisms. Cytochrome P450s are involved in many enzymatic 
reactions, which metabolize numbers of metabolites in organisms (Tudzynski and 
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Hölter 1998; Scott et al. 2013). The P450s also have been used as decomposers to a 









A recent study highlighted the importance of P450s in secondary metabolism which 
function to add hydroxyl groups to the side chain of diterpene core structures on 
transfers of electrons from one molecule to another or oxidize substrates. It also 
catalyzes a variety of reactions including epoxidation, deamination, dealkylation and 
demethylation (Ortiz de Montellano and De Voss 2005; Gillam and Hunter 2007). In 
fungi, P450 genes have been reported to play a significant role in the construction of 
many secondary metabolites. For instance, from 25 enzymes that catalyze the aflatoxin 
production in Aspergillus parasiticus, five enzymes have characteristics of cytochrome 
P450s with distinct functions of epoxidation, oxidation, hydroxylation and desaturation 
(Bhatnagar et al. 2003; Ehrlich et al. 2004). In addition, cytochrome P450s have been 
reported to be involved in diterpene biosynthesis such as paxilline in P. paxilli (Saikia 
et al. 2007) and gibberellin in F. fujikuroi (Tudzynski and Hölter 1998; Malonek et al. 
2005). Butchko et al. (2006) also reported the involvement of two P450 enzymes in the 
biosynthesis of fumonisins in the maize pathogen F. verticillioides. 
 
Figure 1.6 Genes involved in the biosynthesis of fungal diterpenes. GGS and 
cytochrome P450s as shown in yellow and green arrows respectively are often present 
in a diterpene gene cluster. The red arrows represent cyclase gene while the blue arrows 
denote the other genes involved in the clusters. 
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Cytochrome P450s are also associated with the production of various antibiotic 
compounds. For instance, McLean et al. (2015) produced the active drug, pravastatin 
by using a single step fermentation. This step involved the expression of a cytochrome 
P450 from Amycolatopsis orientalis in compactin-producing P. chrysogenum to 
hydrolyze the compactin skeleton. Through this method, pravastatin was produced in 
a high yield. In addition, P450s have also been used in biotransformation of drug 
compounds including the conversion of cortexolone to hydrocortisone by feeding 
cortexolone in cultures of different fungi expressing the P450s. Isolates of 
Cunninghamella blakesleeana, C. echinulata and Curvularia lunata have been 
reported to yield abundant amounts of hydrocortisone (Manosroi et al. 2006). 
Many P450s have versatile activities, exhibiting relaxed substrate specificity. For 
example Anzai et al. (2008) reported MycG, a member of the P450 family from 
Micromonospora griseorubida, that catalyzed hydroxylation and epoxidation in the 
biosynthesis of mycinamicin macrolide antibiotics. Moreover, several P450s from 
soybean, liquorice and Medicago truncatula have been expressed in yeast through 
heterologous expression. All of these P450s hydroxylate β-amyrin but at different 
carbon positions. P450 from soybean added the hydroxyl group at position C-24, while 
the P450 from liquorice and M. truncatula could hydroxylate and oxydize β-amyrin at 
C11 and C28 respectively (Shibuya et al. 2006; Seki et al. 2008; Carelli et al. 2011). 
These studies have revealed the versatility of activities possessed by P450s, which 
would be advantageous for exploitation of the potent diterpene biosynthesis. By 
introducing the P450s to the diterpene biosynthetic pathway, it could tailor different 
modifications of the diterpene core structure and could possibly lead to the production 
of new compounds with promising antibiotic properties. As reported by Tevyashova et 
al. (2013) modification of the hydroxyl group position on amphotericin B has 
significantly influenced the antifungal activity. These findings could open up the 
possibility of using the P450s to engineer the production of novel compounds.  
1.3.3.1 Biosynthetic gene cluster of pleuromutilin 
Based on genomic work done by Bailey et al. (2016), it is shown that genes responsible 
for the production of pleuromutilin in C. passeckerianus are clustered within the same 
genomic region. Seven genes have been isolated and sequenced as summarized in 
Figure 1.7 and Table 1.1. GGS is the key enzyme responsible for the synthesis of 
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GGPP. Almost all diterpenes gene cluster in fungi contain GGS, as the precursor of 
diterpene biosynthesis is GGPP. Cyclase otherwise is known to trigger the cyclisation 
of GGPP to form the tricyclic structure of pleuromutilin. Along with GGS and cyclase 
genes, the pleuromutilin gene cluster also contains three cytochrome P450s responsible 
for addition of hydroxyl groups to the core structure and on the acetyl side chain of 
pleuromutilin.  The addition of acetyl group to mutilin giving 14-acetyl-mutilin, is 
thought to be initiated by acetyl-transferase (ATF) while short-chain 
dehydrogenase/reductase enzyme (SDR) was responsible for oxidizing the hydroxyl 







Table 1.1 Genes predicted from the pleuromutilin gene cluster. Adapted from (Bailey 
et al. 2016). 







GGS 1291 4 350 Geranylgeranyl pyrophosphate synthetase 
Cyclase 3040 3 959 Terpene Cyclase 
P450-1 2286 13 523 P450 monooxygenase 
P450-2 2124 11 525 P450 monooxygenase 
P450-3 2108 10 522 P450 monooxygenase 
ATF 1304 3 377 Acetyltransferase 
SDR 945 3 254 Short-chain dehydrogenase 
Figure 1.7 Biosynthetic gene cluster for pleuromutilin in C. passeckerianus. 
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1.3.4 Fungal diterpene biosynthetic pathway 
 Terpenes are synthesized from isopentenyl diphosphate (IPP) and dimethylallyl 
diphosphate (DMAPP) through the mevalonate pathway. Addition of IPP to DMAPP 
generates geranyl diphosphate (GPP), which is the common precursor of 
monoterpenes. Further condensation and addition of the IPP unit gives rise to the 
precursors of sesquiterpenes and diterpenes, farnesyl diphosphate (FPP) and geranyl 
diphosphate (GGPP) respectively (Figure 1.8). These linear precursors then undergo 
cyclizations, rearrangements and various modifications such as oxidations, reductions, 
isomerizations and hydrations resulting in a variety of terpene compounds for instance, 
gibberellin and paxilline (Malonek et al. 2005; Saikia et al. 2007). 
 
 
Figure 1.8 Biosynthesis of terpene through the mevalonate pathway. Head-to-tail 1-
4 condensations of isopentenyl (IPP) units to dimethylallyl diphosphate (DMAPP) 
gives rise to geranyl diphosphate (GPP). Further condensation with an additional one 
or two IPP units generates farnesyl diphosphate (FPP) or geranylgeranyl diphosphate 
(GGPP) respectively. These linear precursors are undergone carbocation-derived 
cyclization and rearrangement to form various diterpene scaffolds. 
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According to Schmidt-Dannert (2015), two different cyclization routes were involved 
in generating diterpene core; either one (monofunctional enzyme) or two cyclization 
steps (bifunctional enzyme) as shown in Figure 1.9. The first one-step route follows 
cleavage of diphosphate and migration of subsequent carbocation and is mostly found 
to occur in the diterpene biosynthesis in Ascomycota. One example of diterpenes which 
follows the monofunctional cyclization is fusicoccane from Phomopsis amygdali.  
Meanwhile, the two-step route requires the generation of carbocation on C-14 and C-
15 of GGPP first, with cyclization triggered to form a bicyclic diphosphate, followed 
by the diphosphate cleavage to form carbocation which finally triggers the second 
cyclization to yield the final tricyclic product. The best-known example of diterpene 
compound follows the two-step cyclization and is gibberellic acid (GA) which can be 
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Two-steps route of diterpene core biosynthasis
fusicoccane skeleton
Figure 1.9 Cyclization of GGPP by fungal diterpene synthase involved in generating 
various diterpenes core. Figure adapted from Schmidt-Dannert (2015). 
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Following the cyclization of diterpene core, several biosynthetic reactions are usually 
taking place by tailoring enzymes from a gene cluster to convert the molecule to the 
final product according to their corresponded clusters. The tailoring enzymes 
particularly P450s were responsible for the production of diverse diterpenes that can 
be obtained from fungi.   
1.4 Heterologous expression in Aspergillus oryzae 
The urgent need for new antibiotics to counter the wide spread of resistant bacteria has 
generated many platforms that will allow the production of novel drugs. One of the 
promising approaches is through genetic manipulation of antibiotic-producing fungi. 
In many cases, genetic manipulation was done by targeting the native producer aiming 
to increase the titer of antibiotic production or modification of the product to a more 
desirable molecule. However, some challenges could be encountered when using the 
native host for gene manipulation including accumulation of toxic products that could 
affect the fungal growth and transformation frequency. Often, these problems make the 
native hosts difficult to work with and unsuitable for genetic manipulation (Bartlett and 
Entzeroth 2006). In such cases, heterologous expression in the secondary host offers 
an alternative strategy for manipulation of desired genetic information. The host for 
heterologous expression could be any of a range of organisms, however the closely 
related species could be the most appropriate host to be used due to the likenesses of 
protein secretion systems and codon usage. This would potentially avoid problems with 
the expression, missplicing and protein missfolding. Nevertheless, there were many 
well-developed hosts which have been established recently and have proved to 
efficiently express biosynthetic genes from unrelated species (Yamada et al. 2015).  
In the case of pleuromutilin, previous attempts to silence specific gene clusters in the 
native host C. passeckerianus have proved difficult when dealing with this fungus as 
the silencing of the specific pleuromutilin gene have impacted on the regulation of the 
other genes in the cluster (Hayes 2014). Recently, A. oryzae was used to heterologously 
express the pleuromutilin gene cluster. The attempt was successful in synthesizing an 
increasing the titer of pleuromutilin and allows the characterization of the biosynthetic 
pathway (Bailey et al. 2016; Alberti et al. 2017).  
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A. oryzae is an ascomycete fungus and has been used widely in food industries and can 
be found in soy sauce and vinegar production. It is known to have potential application 
in biotechnology and has been used commercially especially for genetic engineering 
purposes. In 1988, this fungus was first used in the production of lipase for detergent 
(Christensen et al. 1988).  
A. oryzae has been given the status of Generally Recognized as Safe (GRAS) from the 
United States Food and Drug Administration which designated that enzymes and many 
compounds engineered from this fungus are safe for human use (Barbesgaard et al. 
1992). Among the eukaryotes, this fungus has the highest protein secretion capability. 
According to Lubertozzi and Keasling (2009), the production of metabolites in A. 
oryzae is ten times higher than in S. cerevisiae.  Moreover, the availability of various 
efficient transformation protocols of A. oryzae makes it attractive for heterologous 
expression.  
A number of studies dealt with the expression of various heterologous genes in A. 
oryzae have been reported to yield an increasing amount of product. For example, Sakai 
et al. (2008) characterized the gene cluster for production of citrinin. They introduced 
the genes into A. oryzae with the additional copies of an activator gene, resulting in 
high citrinin production. Also, the expression of tenellin biosynthetic gene cluster in A. 
oryzae was able to produce higher production of tenellin compared with in the native 
host Beauvaria bassiana (Heneghan et al. 2010). In addition, Marui et al. (2010) also 
reported that penicillin production was significantly increased after heterologous 
expression of the biosynthetic genes in A. oryzae.  
1.5 Combinatorial biosynthesis strategies  
Combinatorial biosynthesis is an approach used in the genetic engineering of a natural 
product biosynthesis to obtain new molecules. This approach was undertaken to 
improve antibacterial activity of potent compounds. Isolating antibiotics molecules 
from a natural product sometime can be difficult due to several limiting factors such as 
metabolism rate which is time-consuming and expensive. The semi-synthetic and 
chemical synthesis routes do offer an alternative platform for drugs development 
however the results are sometime low in efficiency due to the difficulties in the 
synthetic reaction. Thus, other platforms such as combinatorial biosynthesis using 
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enzymes of the biosynthetic pathways could be an option in order to access diverse 
antibiotic molecules. Much work has been done to understand the biosynthetic pathway 
of antibiotic compounds. The whole-genome sequencing has uncovered hundreds of 
secondary metabolic pathways and many of the gene clusters have been cloned and 
characterized. This allows the manipulation of the biosynthetic gene cluster to be 
carried out in order to expand the structural diversity of antibiotic molecules through a 
combinatorial study. 
A recent report described the genetic manipulation carried out on benzenediol lactone 
(BDL) polyketides. BDLs are biosynthesized by coexpressing random BDL 
biosynthetic genes from different fungi such as Acremonium zeae and Lasiodiplodia 
theobromae in yeast cells. The results revealed the biosynthesis of structurally diverse 
polyketides including lasicicol and monocillin (Xu et al. 2014). The same results can 
be observed during co-expression of indolocarbazole biosynthetic enzymes from 
different pathways. The enzymes seem to have useful degrees of substrate flexibility, 
as they are able to process different intermediates to yield novel derivatives (Sanchez 
et al. 2006).  
The generation of diverse labdane-type diterpenes in yeast was a remarkable success. 
By expressing terpene enzymes from different module-specific parts, numbers of 
labdane-type scaffolds were generated (Ignea et al. 2015). Further achievement in 
combinatorial studies was reported by Eustaquio et al. (2004) who were able to 
biosynthesis novobiocin–clorobiocin hybrid compounds. Though there was no 
improvement on the bioactivity of the hybrid compounds, the results provide an 
understanding the flexibility of the combinatorial system to engineer new pathways for 
production of aminocoumarins derivatives.  
Significant results reported from the heterologous expression in A. oryzae have proved 
the versatility of this system. Incorporating this system in the combinatorial 
biosynthesis study would open the possibility to engineer a system that could 





Pleuromutilin and its derivatives are antibacterial drugs that inhibit prokaryotic protein 
synthesis by binding to the bacterial 50S ribosomal subunit. As they have no activities 
against eukaryotic protein synthesis, they have the potential to be developed as a new 
class of antibiotics to be used in humans. However, up to now, there is only one 
pleuromutilin derivative approved for use in humans while others are mostly used for 
veterinary purposes. Thus, modification of the pleuromutilin core structure by 
heterologous expression of diterpene genes from other fungi appears to be a promising 
approach for the search for a new pleuromutilin derivatives candidate that can be taken 
orally by humans.  
1.7 Aims and objectives 
The aim of my PhD project is to understand and to exploit the biosynthesis of 
pleuromutilin-based antibiotics in order to synthesize new chemical entities. In the first 
part of the study, the function of pleuromutilin tailoring enzymes will be explored 
further with the aim to isolate new products of the pleuromutilin pathway. The second 
and third parts of the thesis will describe the attempts to produce new pleuromutilin 




• To further characterise the activity of the enzymes involved in the biosynthesis 
of pleuromutilin and isolate each intermediate compound, therefore producing 
a more detailed picture of the biosynthetic pathway for pleuromutilin.  
• To evaluate the antimicrobial activity of pleuromutilin analogs isolated from 
the transformation system. 
• To evaluate the ability of the genes GGS, cyclase and P450s from other 
diterpene gene clusters to further modify pleuromutilin intermediate product. 
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Chapter 2. MATERIALS AND METHODS 
Chemicals and media components used in this study were obtained from Sigma, Fisher, 
Oxoid, ForMedium, Melford, Bioline, Thermo Scientific or VWR unless otherwise 
stated. Media were prepared and sterilized by autoclaving using a standard program at 
121 °C for 15 minutes. Deionized water was used for all solutions unless indicated. 
2.1 Maintenance of microbial strains 
2.1.1 Fungal isolates origin and maintenance  
Fungal strains used in this study were grown in various media and growth conditions 
as shown in Table 2.1. For long-term storage, hyphal plugs were placed in a freezing 
vial with approximately 0.5 mL of 30% sterile glycerol. 
Table 2.1 Growth condition for fungal strains 
Species Strain Source Static growth maintenance 
Liquid growth 
condition 
Aspergillus oryzae NSAR1 (niaD-,sC-, ΔargB, adeA-)  28 °C in MEA+4 
28 °C in ME+4 at 
200 rpm 






28 °C in MEA 28 °C in ME at   200 rpm 






28 °C in MEA 28 °C in ME at  200 rpm 
Penicillium paxilli 
Bainier  ATCC 26601 CBS-KNAW 28 °C in MEA 
28 °C in ME at  
200 rpm 
Penicillium 
aethiopicum  IBT 5753 CBS-KNAW 28 °C in MEA 




BY4742 (MATα, his3Δ1, 
leu2Δ0, lys2Δ0, ura3Δ0)  28 °C in YPADa 
28 °C in YPAD at  
200 rpm 
Lepista sordida not reported The Down, Bristol 25 °C in MEA 




ME/A+4: 15 g L-1 malt extract, 1.5 g L-1 methionine, 2 g L-1 ammonium sulphate,                 
0.1 g L-1 adenine, 1 g L-1 arginine / 15 g L-1 agar. 
ME/A: 15 g L-1 malt extract / 15 g L-1 agar. 
YPAD/a: 10 g L-1 yeast extract, 20 g L-1 bactopeptone, 20 g L-1 D-glucose, 40 mg L-1 
adenine hemisulfate / 15 g L-1 agar. 
2.1.2 Bacterial isolates 
Growth conditions for bacterial isolates are as follow:  
 
Table 2.2 Growth conditions for bacterial isolates 




coli DH5α 37 °C in LBA 37 °C in LB at 200 rpm 
Escherichia 
coli 
One Shot® ccdB 
SurvivalTM 2 T1R 37 °C in LBA 37 °C in LB at 200 rpm 
Bacillus 
subtilis ATCC 6633 30 °C in TSB 30 °C in TSA at 200 rpm 
 
LB/A: 10 g L-1 NaCl, 10 g L-1 tryptone, 5 g L-1, yeast extract / 15 g L-1 agar. 
TSB/A: 30 g L-1 tryptic soy broth / 15 g L-1 agar. 
 
2.1.3 Storage condition of microbial isolates 
Long-term storage of fungal cultures was achieved by adding 1 mL of filter-sterilized 
glycerol (20% v/v in water) to the agar plugs of growing mycelia, then rapid freezing 
in liquid nitrogen and storing at -80 °C. Liquid cultures of bacterial and yeast isolates 
were mixed with an equal volume of 40% filter sterilized glycerol and rapidly frozen 
before being stored at -80 °C. 
2.2 Molecular methods 
2.2.1 Purification of nucleic acids 
2.2.1.1 Plasmid DNA purification 
Plasmid DNA was routinely purified from E. coli using the GeneJET Plasmid Miniprep 
Kit (Thermo Scientific) according to the manufacturer’s guidelines. Pelleted overnight 
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cells were subjected to alkaline lysis to release the plasmid DNA and denature 
chromosomal DNA and proteins. The lysate was then neutralized to precipitate the 
chromosomal DNA and proteins while retaining the plasmid DNA. The supernatant 
was purified on a column and the plasmid DNA was absorbed. After several washings, 
the plasmid DNA was then eluted with 10 mM Tris-HCl solution. 
Extraction of plasmid DNA from yeast was carried out using the ZymoprepTM Yeast 
Plasmid Miniprep I (Zymo Research) following the manufacturer’s instructions. Yeast 
colonies were firstly resuspended and mixed with zymolase enzyme. The mixture was 
incubated for 2 hours at 37 °C before added with ethanol mixture to precipitate the 
chromosomal DNA and proteins. After centrifugation, 400 µL of isopropanol was 
added to the supernatant to precipitate the plasmid DNA. TE buffer was then used to 
resuspend the pelleted plasmid DNA. 
2.2.1.2 Small-scale fungal genomic DNA purification 
DNA was extracted from growing fungal by adding 1 mm3 clump of mycelia to 500 
µL of lysis buffer in 1.5 mL Eppendorf tube. The mycelia were then disrupted with a 
sterile tip, vortexed for 15 seconds and then left at room temperature for 10 min. 150 
µL of potassium acetate solution was then added to the lysate, vortexed briefly and 
centrifuged at 10,000 x g for 1 min. The supernatant was removed to a new tube and 
once again centrifuged at 10,000 x g for 1 min. An equal volume of isopropanol was 
added after transferring the supernatant to a new tube and mixed by inversion, followed 
by centrifugation at 10,000 x g for 2 min. The supernatant was discarded, and the pellet 
was washed with 300 µL of 70% ethanol, centrifuged again at 10,000 x g for 1 min and 
the supernatant was discarded. The DNA pellet was air-dried and stored in 50 µL of 
TE buffer at -20 °C.  
 
Lysis buffer: 400 mM Tris-HCl (pH 8.0), 60 mM EDTA (pH 8.0), 150 mM NaCl, 1% 
sodium dodecyl sulphate. 
Potassium acetate solution: 60 mL of 5 M potassium acetate, 11.5 mL of glacial acetic 
acid, and 28.5 mL of distilled water; pH 4.8. 
TE buffer:  10 mM Tris-HCl, 1 mM EDTA; pH 8.0.  
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2.2.1.3 RNA purification from fungi 
Spores or a plug of growing fungal mycelium was used to inoculate 100 mL of 
appropriate liquid medium in a 250 mL Erlenmeyer flask. After 7 days incubation at a 
suitable temperature, the mycelium was harvested by centrifugation at 7,000 x g for 3 
minutes followed by rapid freezing in liquid nitrogen. The mycelium was then 
subjected to freeze-drying. A starting material of 25 mg of dried mycelium was ground 
in mortar and pestle with liquid nitrogen. The RNA extraction was then carried out on 
the ground mycelium using the E.Z.N.A. ® Plant RNA Kit (Omega Bio-Tek) according 
to the manufacturer’s instructions. The purified RNA was screened for the presence of 
genomic DNA on 1% agarose gel. When needed, the RNA was treated with RNase-
free DNase I (Qiagen) to eliminate the trace amount of genomic DNA.  
The DNase treatment was carried out by adding 1 µL of 10x reaction buffer with MgCl2 
and 1 µL of DNase I to 1 µg of the purified RNA. Water was then added to a final 
volume of 10 µL. The mixture was incubated at 37 °C for one hour. After the addition 
of 1 µL of 0.5 M EDTA, the reaction was inactivated at 65 °C for 10 min. 
2.2.2 First strand cDNA synthesis 
The first strand cDNA synthesis Kit (Thermo Scientific) was used to synthesize cDNA 
from the purified RNA. The reaction mixture was prepared by adding 1 µL of 100 µM, 
Oligo(dT)18 primer to 1 µg of DNase-treated RNA. The volume was then made up to 
11 µL with DEPC treated water, prior to incubation at 65 °C for 5 minutes. After being 
chilled on ice, the following reagents were added to the mixture: 4 µL of 5x Reaction 
Buffer, 1 µL of RiboLock RNase Inhibitor, 2 µL of 10 mM dNTPs and 2 µL of M-
MuLV Reverse Transcriptase (20 U µL-1). The mixture was briefly centrifuged and 
incubated at 37°C for 60 minutes followed by 70°C for 5 minutes to terminate the 
reaction.  
2.2.3 Restriction digestion of DNA 
Restriction digestion was performed on the backbone vector to linearize the plasmid 
prior to yeast-based homologous recombination. It was also used as part of the 
screening process to confirm the identity of the correct recombinant construct of the 
plasmid purified from E. coli. All restriction enzymes were obtained from Thermo 
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Fisher Scientific, and the FastDigest enzyme was routinely used following the 
manufacturer’s protocols. This rapid DNA digestion can digest up to 1µg of plasmid 
DNA in 15 minutes at 37 °C. The following reaction components were combined as 
indicated unless otherwise specified:  
Water  Up to a final volume of 10 µL  
Plasmid DNA 1 µg 
FastDigest enzyme 1 µL 




2.2.4.1 Conventional PCR  
Conventional PCR reactions were used to amplify cDNA fragments, check ligation 
reactions and screen A. oryzae transformants. The reaction was carried out using 
DreamTaq Green DNA Polymerase (Thermo Scientific). A 2X DreamTaq Green Mix 
stock solution was prepared as follows:  
10X DreamTaq Green Buffer 2 mL 
10 mM dNTPs 0.4 mL 
DreamTaq DNA Polymerase (5U/ µl) 0.1 mL 
Water Up to 10 mL 
 
When needed to set up PCR reactions, 10 µL of 2X DreamTaq Green Mix was added 
to 1 µL of 10 µM forward primer, 1 µL of 10 µM reverse primer, 1 µL of template DNA 
and made up to 20 µL with water.  
A PTC-200 DNA Engine Thermal Cycler (Biorad) was used to carry out PCR 









Initial denaturation 95 3 min 1 
Denaturation 95 30 s  
Annealing Tannealing 30 s 35 
Extension 72 1 min/kb 
(depending on the length of 
the expected PCR product) 
 
Final extension 72 10 min 1 
T
annealing was calculated as Tmelting (melting temperature) - 3°C, starting from the lower Tmelting 
between the two primers used, according to the melting temperature of the primers 
 
2.2.4.2 Colony PCR 
Colony PCR was carried out to test for the presence of recombinant plasmid. The 
protocol follows steps previously described in conventional PCR, however, a half 
colony was used as the template instead of DNA and resuspended directly in the PCR 
reaction mixture. The same PCR programme was used, although the initial 
denaturation step was extended to 10 minutes. The PCR product was then run on the 
gel electrophoresis to visualize the DNA bands. An overnight culture in appropriate 
selective liquid media was set up using the other half colony showing amplicon of the 
expected size for plasmid purification. 
2.2.4.3 Phusion High-Fidelity PCR 
In order to prepare DNA fragments to be cloned into vectors, PCR amplification was 
performed using Phusion ® High-Fidelity DNA Polymerase from Thermo Scientific. 
A 20 µL reaction mixture was prepared as follow: 
 
5x Phusion ® HF Buffer 4 µL 
10 mM dNTPs 0.4 µL 
10 µM forward primer 1 µL 
10 µM reverse primer 1 µL 
Template DNA 1 µL 
Phusion ® DNA Polymerase (2U/ µL) 0.2 µL 





The following program was used to carry out PCR reaction: 
 





Initial denaturation 98 30 s 1 
Denaturation 98 10 s  
Annealing *Tannealing 30 s 35 
Extension 72 20 s/kb 
(depending on the length of 
the expected PCR product) 
 
Final extension 72 10 min 1 
*For primers >20nt, T
annealing = Tm (melting temperature) of the lower Tm primer - 3°C 
                      £20nt, T
annealing = Tm (melting temperature) of the lower Tm primer 
2.2.5 Primers 
Primers used in this study were purchased from Integrated DNA Technologies (IDT). 
Each primer was diluted 1:10 in sterile water to give a concentration of 10 µM and 
stored in -20 °C. 
Table 2.5 Primers 
Primers Sequence (5'-3') Description 
Cp GGS FF ATG AGA ATA CCT AAC GTC TTT CTC T  
Amplification of 
genes from C. 
passeckerianus 
Cp GGS RR CTA CTC TGC GAT GTA CAA CTT TTC C  
Cp CYC FF ATG GGT CTA TCT GAA GAT CTT CAT G  
Cp CYC RR TCA ATG GTG GAT TCC ATT GCT CCC G  
Cp P450-1 FF ATG CTG TCC GTC GAC CTC CCG TCT G 
Cp P450-1 RR CTA CAA CGC AGC GAA CGC TTC CTT A  
Cp P450-2 FF ATG AAT CTT TCT GCT CTG AAG GCT G  
Cp P450-2 RR CTA ATA GTC TGC AAC ATC GTG GAT C  
Cp P450-3 FF ATG GCT CCG TCA ACG GAA CGT GCT C  
Cp P450-3 RR CTA GCC ACT AGC AGG CTT CGT GAA C  
Cp ATF FF ATG AAG CCC TTC TCA CCA GAA CTT C  
Cp ATF RR CTA CTG TGC TAC ACG AGG GGG ATT C  
Cp SDR FF ATG GAA GGC AAG GTC GCA ATC GTC A  
Cp SDR RR CTA AAT GAC ACT CCA CCC GTT ATC G  
Ff P450_1_FF ATG GCG AAC CAT TCT TCT TCT TAC TAC CAT 
Amplification of 
genes from F. 
fujikuroi 
Ff P450_1_RR TCA AAT CGC AAT CTC CTC CTT TCT GCG ACG 
Ff P450_2_FF ATG AGC ATC TTC AAT ATG ATC ACC AGC TAT 
Ff P450_2_RR TCA AAT TGC TTC CAA ATC CAA CTC AAC TGA 
Ff P450_3_FF ATG AAA TAC ACA ACA TGC CAA ATG AAT ATA 
Ff P450_3_RR TCA TCT CCT TCG CAT CTC AAG ACC AGC TTT 
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Padh Ff P450-1 FF TTT CTT TCA ACA CAA GAT CCC AAA GTC AAA ATG 
GCG AAC CAT TCT TCT TC 
Amplification of 
genes from F. 





Teno Ff P450-1 RR GGT TGG CTG GTA GAC GTC ATA TAA TCA TAC TCA 
AAT CGC AAT CTC CTC CT 
Padh Ff P4502 FF TTT CTT TCA ACA CAA GAT CCC AAA GTC AAA ATG 
AGC ATC TTC AAT ATG AT 
Teno Ff P4502 RR GGT TGG CTG GTA GAC GTC ATA TAA TCA TAC TCA 
AAT TGC TTC CAA ATC CA 
Padh Ff P450-3 FF TTT CTT TCA ACA CAA GAT CCC AAA GTC AAA ATG 
AAA TAC ACA ACA TGC CA 
Teno Ff P450-3 RR GGT TGG CTG GTA GAC GTC ATA TAA TCA TAC TCA 
TCT CCT TCG CAT CTC AA 
Ef ltmP FF ATG TTA ATG TTG CAC GCT GTC CCA GTG GGT 
Amplification of 
genes from E. 
festucae 
Ef ltmP RR TCA ACA TAC GGT AAC TGT CTT CTC CAA GCG 
Ef ltmQ FF ATG AAG ATG TTA ACA GAG CAT TTT GAC TTT 
Ef ltmQ RR TCA CAG ATT CTT CTC CCT AGC TCT TTT CTC 
Padh Ef ltmP FF TTT CTT TCA ACA CAA GAT CCC AAA GTC AAA TCA 
ACA TAC GGT AAC TGT CT Amplification of 
genes from E. 





Teno Ef ltmP RR GGT TGG CTG GTA GAC GTC ATA TAA TCA TAC ATG 
TTA ATG TTG CAC GCT GT 
Padh Ef ltmQ FF TTT CTT TCA ACA CAA GAT CCC AAA GTC AAA ATG 
AAG ATG TTA ACA GAG CA 
Teno Ef ltmQ RR GGT TGG CTG GTA GAC GTC ATA TAA TCA TAC TCA 
CAG ATT CTT CTC CCT AG 
Pp PaxP FF ATG GAT CTA TCC GAT TTC CAC ATC TCA ACA 
Amplification of 
genes from P. 
paxilli 
Pp PaxP RR TTA CGC CTT TGT AGC CCG ACG CTT GAT GAG 
Pp PaxQ FF ATG GAT TTC GTG TTA TCA GCC TTA CAG AGA 
Pp PaxQ RR TCA TGC CGA GAC AGA CTT TCT GGC TTT CAA 
Padh Pp paxP FF TTT CTT TCA ACA CAA GAT CCC AAA GTC AAA TTA 
CGC CTT TGT AGC CCG AC Amplification of 
genes from P. 





Teno Pp paxP RR GGT TGG CTG GTA GAC GTC ATA TAA TCA TAC ATG 
GAT CTA TCC GAT TTC CA 
Padh Pp paxQ FF TTT CTT TCA ACA CAA GAT CCC AAA GTC AAA TCA 
TGC CGA GAC AGA CTT TC 
Teno Pp paxQ RR GGT TGG CTG GTA GAC GTC ATA TAA TCA TAC ATG 
GAT TTC GTG TTA TCA GC 
Pa vrtE FF ATG TTC ATC GCC GCC GTC ACG CAC AAC TGG 
Amplification of 
genes from P. 
aethiopicum 
Pa vrtE RR CAG GGC AAG GGG CTA CAA AGC ATG GCA TAG 
Pa vrtK FF ATG GCT TTC TCC ACC TAT CTA GGA AGT TTG 
Pa vrtK RR TCA CTT TGT GTT AAT GCG CGC ATG ACC ATT 
Padh Pa vrtE FF TTT CTT TCA ACA CAA GAT CCC AAA GTC AAA CTA 
TGC CAT GCT TTG TAG CC Amplification of 
genes from P. 





Teno Pa vrtE RR GGT TGG CTG GTA GAC GTC ATA TAA TCA TAC ATG 
TTC ATC GCC GCC GTC AC 
Padh Pa vrtK FF TTT CTT TCA ACA CAA GAT CCC AAA GTC AAA ATG 
GCT TTC TCC ACC TAT CT 
Teno Pa vrtK RR GGT TGG CTG GTA GAC GTC ATA TAA TCA TAC TCA 
CTT TGT GTT AAT GCG CG 
Lep GGS FF ATG GAT TCG AAG GCC TTT CCA TGT CCA TTT 
Amplification of 
genes from L. 
sordida 
Lep GGS RR CTA CTC GAT TTT GTA CAA TTT CTC CAA GAA 
Lep CYC FF ATG GGT TTA TCT GAA GAT CTC CAT ACT CGC 
Lep CYC RR CTA GGC AGC AGT CTT AAT ACG TTT TGC CCC 
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Lep P450-1 FF ATG CCA TCA ATC GAC CTT CAG TCT GCT GCG 
Lep P450-1 RR TTA CAG AGC GGC GAA TGC TTC TCT GAT CAA 
Lep P450-2 FF ATG GAT ATC ACT ACT CTC AAA GAA TGG TGG 
Lep P450-2 RR CTA CCC CTC CGA TGC GTG TCG AAT TAC TTC 
Lep P450-3 FF ATG GGA ATA TCT TCT GGA ACC ACT TTC CCT 
Lep P450-3 RR TTA GAA GGG TTT CAC ACT TGT GAG AGG ACA 
Lep ATF FF ATG AAG CGT TTC TCA CCT ACA CTT TTG CTT 
Lep ATF RR CTA CTG CAC TGC ACG AGG AGG GGT CCA TTC 
Lep SDR FF ATG GAA GGC AAG ATT GTC ATT ATT ACA GGT 
Lep SDR RR TTA AAT GAC ACT CCA AGC ATT ATC CAC TGG 
Padh Lep GGS FF TCT TTC AAC ACA AGA TCC CAA AGT CAA AGG ATG 
GAT TCG AAG GCC TTT CC 
Amplification of 
genes from         





Tadh Lep GGS RR CAT TCT ATG CGT TAT GAA CAT GTT CCC TGG CTA 
CTC GAT TTT GTA CAA TT 
PamyB Lep CYC 
FF 
GTA AAA CAC AAC ATA TCC AGT CAT ATT GGC ATG 
GGT TTA TCT GAA GAT CT 
TamyB Lep CYC 
RR 
TCC ACC CTT CAC GAG CTA CTA CAG ATC CCC CTA 
GGC AGC AGT CTT AAT AC 
Padh Lep P450-1 
FF 
TCT TTC AAC ACA AGA TCC CAA AGT CAA AGG ATG 
CCA TCA ATC GAC CTT CA 
Tadh Lep P450-1 
RR 
ATT CTA TGC GTT ATG AAC ATG TTC CCT GGT TAC 
AGA GCG GCG AAT GCT TC 
PgpdA Lep P450-2 
FF 
CAG CTA CCC CGC TTG AGC AGA CAT CAC CGG ATG 
GAT ATC ACT ACT CTC AA 
TgpdA Lep P450-2 
RR 
GAC AAT GTC CAT ATC ATC AAT CAT GAC CGG CTA 
CCC CTC CGA TGC GTG TC 
PgpdA Lep P450-3 
FF 
CAG CTA CCC CGC TTG AGC AGA CAT CAC CGG ATG 
GGA ATA TCT TCT GGA AC 
TgpdA Lep P450-3 
RR 
GAC AAT GTC CAT ATC ATC AAT CAT GAC CGG TTA 
GAA GGG TTT CAC ACT TG 
Peno Lep ATF FF CGA CTG ACC AAT TCC GCA GCT CGT CAA AGG ATG 
AAG CGT TTC TCA CCT AC 
Teno Lep ATF RR TTG GCT GGT AGA CGT CAT ATA ATC ATA CGG CTA 
CTG CAC TGC ACG AGG AG 
Peno Lep SDR FF CGA CTG ACC AAT TCC GCA GCT CGT CAA AGG ATG 
GAA GGC AAG ATT GTC AT 
Teno Lep SDR RR TTG GCT GGT AGA CGT CAT ATA ATC ATA CGG TTA 
AAT GAC ACT CCA AGC AT 
Padh Lep GGS FF TTT CTT TCA ACA CAA GAT CCC AAA GTC AAA ATG 
GAT TCG AAG GCC TTT CC 
TgpdA Lep GGS 
RR 
ACG ACA ATG TCC ATA TCA TCA ATC ATG ACC CTA 
CTC GAT TTT GTA CAA TT 
Peno Lep CYC FF GTC GAC TGA CCA ATT CCG CAG CTC GTC AAA ATG 
GGT TTA TCT GAA GAT CT 
Teno Lep CYC RR GGT TGG CTG GTA GAC GTC ATA TAA TCA TAC CTA 
GGC AGC AGT CTT AAT AC 
Peno Cp CYC FF GTC GAC TGA CCA ATT CCG CAG CTC GTC AAA ATG 
GGT CTA TCT GAA GAT CT  Amplification of 
genes from                             
C. passeckerianus 




Teno Cp CYC RR GGT TGG CTG GTA GAC GTC ATA TAA TCA TAC TCA 
ATG GTG GAT TCC ATT GC  
Padh Cp GGS FF TTT CTT TCA ACA CAA GAT CCC AAA GTC AAA ATG 
AGA ATA CCT AAC GTC TT  
TgpdA Cp GGS RR ACG ACA ATG TCC ATA TCA TCA ATC ATG ACC CTA 
CTC TGC GAT GTA CAA CT  
Padh Cp P450-3 FF TTT CTT TCA ACA CAA GAT CCC AAA GTC AAA ATG 
GCT CCG TCA ACG GAA CG 
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Tadh Cp P450-3 
RR 
ACG TAT TTC AGT GTC GAA AGA TCC ACT AGA GCG 
TTT TCG AGA CGA AAC AG 
PgpdA Cp ATF FF AAC AGC TAC CCC GCT TGA GCA GAC ATC ACC ATG 
AAG CCC TTC TCA CCA GA 
TgpdA Cp ATF RR ACG ACA ATG TCC ATA TCA TCA ATC ATG ACC CTA 
CTG TGC TAC ACG AGG GG 
 
 
2.2.6 Gel electrophoresis 
In order to visualize RNA, genomic or plasmid DNA and PCR product, gel 
electrophoresis was carried out on a 1% agarose gel (w/v). An appropriate amount of 
agarose (Type I, Molecular Biology, Bioline) was dissolved in 1x TAE buffer (40 mM 
Tris, 20 mM acetic acid, 1 mM EDTA) and Midori Green Advance Nucleic Acid Stain 
(5 µL/100 mL) was added to the melted gel as a stain. Nucleic acids were always run 
alongside 5 µL of Hyperladder I (Bioline) for visual comparison of band size (bp) and 
concentration of nucleic acids (ng/band). Gels were electrophoresed at 100 Volts for 
30 min in 1x TAE buffer, using a PowerPac Basic Power Supply (Bio-Rad). The gels 
were then observed under UV light using a Universal Hood II GelDoc Imager (Bio-
Rad) equipped with UVP transilluminator and a charge coupled device (CCD) camera 
for capturing of the images. Quantity One® 1-D analysis software (Bio-Rad) was used 
to visualize and save the images in digital format. 
2.2.7 Purification of PCR product 
Purification of PCR product was routinely carried out after gel electropheresis to 
remove other components in the PCR mixture. After 20 µL of PCR product was 
electrophoresed, the expected fragment was visualised on a UV-light box and excised 
using a razor blade. GeneJET Gel Extraction Kit (Thermo Scientific) was then used to 
purify the fragment following the manufacterer’s protocols. In order to assess its 
concentration for further use in pJET cloning and yeast-based homologous 
recombination, 3 µL of purified fragment was electropheresed at 100 Volts for 30 
minutes. 
2.2.8 Cloning of PCR product 
Purified PCR fragments were cloned into a blunt cloning vector pJET1.2 using 
CloneJET PCR Cloning Kit (Thermo Scientific). Blunt-ended PCR product was 
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amplified through High-Fidelity PCR using Phusion ® High-Fidelity DNA Polymerase 
(Thermo Scientific). The following reagents was set up according to the manufacturer’s 
protocols: 
 
2X Reaction Buffer 10 µL 
Purified PCR product 50 ng 
pJET 1.2/blunt cloning vector (50 ng µL-1) 1 µL 
T4 DNA ligase 1 µL 
Water Up to 20 µL 
 
The reaction mixture was incubated at room temperature for 5 minutes, and 2-5 µL of 
the mixture was transformed directly to competent E. coli cells. 
2.2.9 Sequencing 
In order to confirm the sequences of the plasmid constructed, the DNA of such 
plasmids were sent to GATC Biotech for sequencing. The sample was prepared 
according to the company’s instruction. Plasmid DNA (100 ng µL-1) was added with 5 
µL of primer (5 µM). The output data was analyzed using Clone Manager Suite 7.    
2.2.10 Yeast-based homologous recombination 
Yeast-based homologous recombination was carried out when a new plasmid needed 
to be constructed. The linear plasmid backbone was prepared by restriction digest using 
appropriate enzymes while the inserts with 30-bp overlap with each adjacent fragment 
amplified through high-fidelity PCR and purified using GeneJET Gel Extraction Kit. 
A 10 mL overnight culture of yeast Saccharomyces cerevisiae Y10000 was prepared 
in YPAD liquid medium at 28 °C and shaken at 200 rpm. The culture was then used to 
inoculate 40 mL of YPAD and was shaken further for another 4.5 hours. After 
centrifugation at 8000 x g for 30 s, the cell pellet was washed with 40 mL of sterile 
water and then with 1 mL of 0.1 M LiOAc solution. Cells were pelleted again and 
resuspended in 400 µL of 0.1 M LiOAc solution. A volume of 50 µL of the suspension 
was aliquoted to new 1.5 mL tubes and then centrifuged. To each tube was added: 240 
µL of 50% PEG 3350 solution, 36 µL of 1 M LiOAc solution, 50 µL of salmon sperm 
single-stranded DNA (2 mg mL-1) and 34 µL of DNA fragments (typically 10 µL of 
linearized backbone plasmid and 5 µL of each PCR product then made up with distilled 
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water). The mixture was incubated at 30 °C for 30 minutes, then at 42 °C for 30 
minutes. Cells were then centrifuged and resuspended in 500 µL of sterile water. The 
yeast was plated on synthetic medium SM lacking uracil and incubated at 28°C for 2-
3 days. Plasmid DNA was purified from the transformant yeast colonies using the 
Zymoprep Yeast Plasmid Miniprep I (Zymo Research) as described previously and 
transformed into E. coli for plasmid propagation.  
 
YPAD: 10 g L-1 yeast extract, 20 g L-1 bactopeptone, 40 mg L-1 adenine hemisulfate, 
20 g L-1 D- glucose. 
SM: 1.7 g L-1 Yeast Nitrogen Base without amino acids, 5 g L-1 ammonium sulphate, 
20 g L-1 D-glucose, 0.77 g L-1 Yeast Synthetic Drop-out Medium Supplements without 
uracil, 20 g L-1 agar. 
2.2.11 Transformation of E. coli  
Transformation of E. coli was routinely carried out for plasmid DNA propagation. 
Electrocompetent E. coli ccdB cells were prepared prior to transformation by 
inoculating 5 mL LB with a single colony and incubating overnight at 37 °C and 200 
rpm. The overnight culture was used to inoculate 4x100 mL LB and further incubated 
in the same conditions until OD600= 0.3 to 0.4. Cultures were then decanted into eight 
50 mL tubes and centrifuged at 4000 x g for 10 min at 4 °C. The pelleted cells were 
resuspended in 50 mL ice-cold deionized water and centrifuged as before.  The cells 
were resuspended in 25 mL ice-cold deionized water, the samples were pooled into 
four 50 mL tubes and again centrifuged as before. Each pellet cell was resuspended in 
10 mL ice-cold 20 % glycerol and pooled into a single 50 mL tube and made up to 50 
mL with 20% glycerol. The suspension was centrifuged at 2000 x g for 10 min at 4 °C. 
After the supernatant was discarded, 1.2 mL of ice-cold 20 % glycerol was used to 
resuspended the cells and 50 µL was aliquoted into 1.5 mL tubes, frozen and stored at 
-80 °C until use. 
When needed for E. coli transformation, 50 µL of electrocompetent E. coli was mixed 
with 1-2 µg of plasmid DNA or 10 µL of plasmid DNA purified from yeast and 
transferred into pre-chilled and sterile 0.2 mm gap cuvette. The mixture was 
electroporated at 2.5 kV using the MicroPulserTM Electroporator (Bio-Rad). The cells 
were quickly resuspended in 200 µL of SOC solution and transferred into a 1.5 mL 
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tube. The cell suspension was allowed to recover without antibiotic selection for 30 
minutes at 37 °C, 200 rpm. Aliquots of cells were plated onto LB agar with appropriate 
antibiotics and incubated overnight at 37 °C.  
 
SOC: 0.5% (w/v) yeast extract, 2% (w/v) tryptone, 10 mM NaCl, 2.5 mM KCl, 20 mM 
MgSO4, 20 mM glucose filter sterilized. 
 
2.2.12  Transformation of A. oryzae 
Protoplast-mediated transformation of A. oryzae strain NSAR1 (nitrate non-utilizer, 
sulphate non-utilizer, adenine auxotroph, arginine auxotroph) was carried out with the 
expression vectors as described by Halo et al. (2008). When exploiting the ArgB or 
AdeA selectable markers to transform A. oryzae, selection and maintenance of 
transformants were made on CZDS plates selective for arginine and adenine 
respectively. The conidia of A. oryzae collected from a 10 days old plate were used to 
inoculate 50 mL GN liquid medium and incubated overnight at 28 °C, 200 rpm. The 
suspension was centrifuged at 8000 x g for 10 minutes. The pelleted conidia were 
resuspended in 10 mL protoplasting solution and incubated with gentle mixing at room 
temperature for 1.5 hours. The protoplasts were separated from hyphae by filtration 
through Miracloth. The filtrate was then centrifuged at 3000 x g for 5 minutes and 
resuspended in 100 µL of solution 1. The concentration of protoplast suspension was 
measured using a haemocytometer and then diluted to 1x107 mL-1 in solution 1. The 
suspension was divided into 100 µL aliquots, and 5-10 µg of plasmid DNA was added 
to each aliquot then incubated on ice for 2 minutes. One mL of solution 2 was added 
to the mixture and further incubated at room temperature for 20 minutes. Aliquots of 
the transformation mixture were mixed with 5 mL of appropriate melted selective 
CZDS top medium and poured over pre-prepared 15 mL of selective CZDS base 
medium. The plates were incubated for 3-5 days at 28 °C until the transformants 
colonies formed, then the colonies were subcultured onto new selective CZDS base 
plates at least 3 times to ensure the mycelia would be homokaryotic for the genes 
inserted. 
CZDS selective for ArgB: 35 g L-1 Czapek-dox broth, 1 M sorbitol, 1.5 g L-1 
methionine, 0.1 g L-1 adenine, 2 g L-1 ammonium sulphate, 15 g L-1 agar. 
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CZDS selective AdeA: 35 g L-1 Czapek-dox broth, 1 M sorbitol, 1.5 g L-1 methionine, 
1 g L-1 arginine, 2 g L-1 ammonium sulphate, 15 g L-1 agar. 
GN: 10 g L-1 D-glucose, 20 g L-1 Nutrient broth no.2 (LabM). 
Protoplasting solution: 20 g L-1 lysing enzyme from Trichoderma harzianum,              
10 g L-1 Driselase from Basidiomycetes sp., 0.8 M NaCl.  
Solution 1: 0.8 M NaCl, 10 mM CaCl2, 50 mM Tris-HCl [pH 7.5]. 
Solution 2: 600 g L-1 PEG 3,350, 10 mM CaCl2, and 50 mM Tris-HCl [pH 7.5].  
2.3 Assessing antimicrobial activity 
Fungal transformants and compounds purified in this study were tested against Bacillus 
subtilis to study the antibiotic activity of the strains or compounds. The spores of B. 
subtilis were prepared by inoculating 50 mL TSB broth and incubating at 28 °C, 200 
rpm overnight. One mL of the overnight culture was used to inoculate pre-prepared 
TSA which has been set horizontally in a Thompson bottle and incubated for 6 days at 
30 °C. The spores culture was harvested using sterile distilled water and heat activated 
at 70 °C for 30 min. The spores suspension was diluted to a concentration of 1x109 
spores mL-1 and kept at 4 °C until use. 
To test the fungal strains for their antibacterial activity, a plug of each strain was used 
to centrally inoculate a 20 mL CMP agar plate and grown at 28 °C for 3 days. Five mL 
of melted TSAg containing 5 µL of B. subtilis and 37.5 µL of 4% 2,3,5-triphenyl-2H-
tetrazolium chloride (TTC) was overlayed onto each plate and incubated overnight at 
28 °C. Clearing zones were then observed and measured. In order to test the antibiotic 
activity of purified compounds, 5 mL overlay of B. subtilis and TTC in TSAg was first 
poured into pre-prepared 20 mL TSB plate. The purified compound at concentrations 
of 100, 25, 5 and 1 µg mL-1 were pipetted on individual 6 mm paper discs and placed 
on the bacterial lawn. All the plates were incubated overnight at 28 °C, and the 
inhibition zones were then measured. 
 
TSB/A: 30 g L-1 tryptic soy/ 15 g L-1 agar.  
TSAg: 30 g L-1 tryptic soy broth premix, 5 g L-1 agar, 10 g L-1 glucose.  
CMP:  35 g L-1 Czapek-dox broth premix, 20 g L-1 maltose, 10 g L-1 peptone, 15 g L-
1 agar. 
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2.4 Chemical analysis of A. oryzae transformants  
2.4.1 Fungal chemical extractions  
Spores from A. oryzae NSAR1 and A. oryzae transformant strains were used to 
inoculate 100 ml of CMP broth in a 200 mL flask with foam bung and grown at 28°C 
with shaking at 200 rpm for ten days. Mycelial cultures of A. oryzae NSAR1 and A. 
oryzae transformants were each homogenized after adding an equal volume of water.  
pH was adjusted to a value of 3 units with concentrated HCl, and then an equal volume 
of ethyl acetate was added to the homogenized culture. The mixture was stirred for 20-
30 min, and then the two phases were allowed to separate in a separating funnel. The 
organic phase was collected, and the water phase was extracted again with an equal 
volume of ethyl acetate three times and pooled with the previously collected organic 
phases. The organic extract was dried by adding anhydrous MgSO4 to remove any 
water residues and was then concentrated using a rotary evaporator at 37°C. The dried 
crude extract was resuspended in methanol (10 mg mL-1) then extracted with an equal 
volume of hexane, and shaken in a separation funnel to defat the sample. The hexane 
phase was removed, and the methanol phase was subjected to two additional rounds of 
defatting. The methanol phase was collected in a pre-weighed vial and dried under a 
flow of dry N2 gas and weighted. The dried crude extract was resuspended in 
acetonitrile (10 mg mL-1) and transferred to an LC- MS vial.  
2.4.2 Analytical LC-MS  
LC-MS analysis was performed to screen fungal extracts for the production of novel 
compounds. The LC-MS equipped with a Waters 2767 HPLC system, a Waters 2545 
pump system, a reverse-phase Phenomenex LUNA column (2.6 µ, C18, 100 Å, 4.6 × 
100 mm) and a Phenomenex Security Guard precolumn (Luna C5 300 Å). UV 
absorbance was detected between 200-400 nm with Waters 2998 diode array detector 
while a mass range between 150 and 800 Da in positive and negative mode was scanned 
by the Waters Quattro Micro spectrometer. Chromatography was achieved using a 
gradient of solvents (A, HPLC grade H2O containing 0.05% formic acid; B, HPLC 
grade CH3CN containing 0.045% formic acid) with the following program: 0 minutes, 
20% B; 15 minutes, 90% B; 16 minutes 95% B; 17 minutes 95% B; 18 minutes 10% 
B, 20 minutes 10% B. Flow rate was set at 1 mL min-1.  
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2.4.3 Thin layer chromatography 
Thin layer chromatography (TLC) was carried out prior to the purification step in 
column chromatography to determine appropriate solvent systems to be used. It was 
also used as an alternative method to preparative LC-MS to purify compounds from 
the crude extract. For analytical TLC, the crude extract was subjected to a 2x10 cm 
aluminium-backing TLC plate (TLC silica gel 60 F254; Merck, Darmstadt, Germany) 
and separated with an appropriate mixture of petroleum ether and ethyl acetate. The 
plate was then treated with potassium permanganate solution (KMnO4) to visualize the 
compounds, and the Rf was recorded. For the preparative TLC, a 20x20 cm glass 
backing plate was used, and the crude extract was deposited in a thin horizontal line 
across the bottom of the plate. The plate was then run in an appropriate mixture of 
petroleum ether and ethyl acetate. A 1 cm strip from one side of the edge of the plate 
was removed and treated with a KMnO4 solution. The targeted product was scrapped 
off the untreated area of the plate corresponding to the visualised spots developed after 
the KMnO4 treatment. Methanol was used to extract the purified product from the 
silica.  
 
KMnO4 solution: 7.5 g L-1 KMnO4, 50 g L-1 K2CO3, 6.25 mL L-1 of 10% NaOH. 
 
2.4.4 Preparative scale separation 
Compound purification from fungal crude extracts was carried out either through 
column chromatography or preparative HPLC. Purification through column 
chromatography was achieved by passing the concentrated crude extract through 
packed silica gel 60 (Merck) in a column. An appropriate gradient solvent system 
consists of various mixtures of ethyl acetate:petroleum ether (9:1 to 7:3, v/v) was used 
to elute the metabolites into fractions. Initially, dried crude extract from a 1L fungal 
culture was dissolved in minimal amount of solvent and applied on top of the column. 
The eluting solvents were then sequentially added to the column. Roughly 7 mL 
fractions were collected in each test tube. After 20-30 fractions had been collected, 
analytical TLC was carried out to examine the fractions. Fractions with the targeted 
compound were pooled in a round bottom flask and dried in the rotary evaporator. The 
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purified compound was then submitted to HPLC and Nuclear Magnetic Resonance 
Spectroscopy (NMR) for structure elucidation.  
For preparative HPLC, a similar system with analytical HPLC was used to carry out 
compound purification. Separation of the complex mixture of metabolites was 
performed through a Phenomenex LUNA column (5µ, C18, 100 Å, 10 × 250 mm) with 
flow rate at 16 mL min-1. The mobile phase was a gradient mixture of acetonitrile and 
formic acid in water following the elution program: 0 minutes, 5% B; 1 minutes, 5% 
B; 2 minutes, 40% B; 15 minutes 90% B; 17 minutes 95% B; 18 minutes 5% B, 20 
minutes 5% B (A, HPLC grade H2O containing 0.05% formic acid; B, HPLC grade 
CH3CN containing 0.045% formic acid). The eluent was monitored by UV and mass 
detector at 200-400 nm and mass range from 100-600 Da.  Targeted compound or peak 
was isolated and collected in glass tubes. Fractions of the compound were then pooled, 
dried and submitted to NMR. 
2.4.5 Nuclear Magnetic Resonance Spectroscopy  
Nuclear Magnetic Resonance Spectroscopy (NMR) was routinely used to study the 
chemical structure of purified products. Dried compound was dissolved in roughly 700 
µL of deuterated chloroform (CDCl3) and submitted to NMR. NMR analyses were 
conducted on Agilent VNMRS500 or Agilent V400-MR spectrometer with 1H NMR 
at either 500 or 400 MHz and 13C NMR at 125 MHz. Chemical shifts were recorded in 
parts per million (ppm) and coupling constant (J) in Hz. One dimensional technique 
(1D-NMR) and two-dimensional technique (2D-NMR) involving protons (1H) and 
carbons (13C) are used to determine the structure of purified molecules. The common 
2D-NMR experiments were employed including Heteronuclear Single-Quantum 
Correlation (HSQC), Heteronuclear Multiple-Bond Correlation (HMBC) as well as 
Correlation Spectroscopy (COSY). HSQC study the chemical shift correlation between 
coupled 1H and 13C atoms while HMBC detects long range coupling (two or three 
bonds away) between 1H and 13C. COSY shows coupling among neighbouring protons, 
aiding to determine their relative position on carbon in a molecule. 
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2.4.6 Software used for chemical analysis 
MassLynxTM V4.1 Software (Waters) was used to analyze LC-MS data. NMR 
spectroscopy data were analyzed using MestReNova V9.0.1 (Mestrelab Research). 
ChemDraw Ultra V12.0.3.1216 (CambridgeSoft) was used to draw chemical structures 
of compounds. The online software Reaxys® (https://www.reaxys.com/) was used as 
a database to look for published NMR spectra of compounds.  
2.5 Bioinformatics software 
DNA sequences of the P450 genes used in this study are available in The National 
Centre for Biotechnology Information (NCBI) while the genome data of L. sordida 
can be accessed through a local blastable database: 
http://www.cerealsdb.uk.net/cerealgenomics/fungal_blast.htm.  
SnapGene was used to visualize the sequence data of the genes worked in this thesis. 
The program allows designing maps of the expression vectors harboring the selected 
gene/s.  Primers design and selection of the enzymes for restriction digestion were also 





Chapter 3. ANALYSIS OF TAILORING STEPS IN 
PLEUROMUTILIN BIOSYNTHESIS 
3.1 Current knowledge on pleuromutilin biosynthesis 
Pleuromutilin is synthesized through the mevalonate pathway (see Figure 1.7). The first 
attempt to identify the pleuromutilin gene cluster was made by screening a λ-phage 
genomic DNA library of Clitopilus passeckerianus (Bailey et al. 2016). After a 
thorough expression analysis, it has been shown that seven genes - geranyl-geranyl 
diphosphate synthase (GGS), Cyclase (Cyc), P450-1, P450-2, P450-3, short-chain 
dehydrogenase/reductase (SDR) and acetyltransferase (ATF)- are responsible for 
pleuromutilin biosynthesis. This has been proved by the expression of the seven genes 
in the secondary host, A. oryzae which subsequently produced pleuromutilin. 
Interestingly, a significant increase in the production of pleuromutilin was observed in 
the Aspergillus oryzae strain harboring the seven genes of pleuromutilin in comparison 
to the native C. passeckerianus (Bailey et al. 2016). 
Alberti et al. (2017) further described the role of each gene in pleuromutilin 
biosynthesis. The research group cross-referenced the protein sequences of the 
pleuromutilin genes with public databases and carried out stepwise heterologous 
expression in A. oryzae to demonstrate the function of each gene. Based on the 
alignment of the protein sequences, GGS and cyclase were predicted to be responsible 
for the synthesis of the precursor geranylgeranyl diphosphate (GGPP) while cyclase 
then triggers the cyclization of GGPP. The expression of the two genes in A. oryzae 
confirmed their function as together these give the first tricyclic intermediate, 3-deoxo-
11-dehydroxymutilin (see Figure 3.1). According to Yao (2007), cyclase mediates two 
reaction cyclization steps. The first step involves protonation-initiated cyclization of 
GGPP to copalyl diphosphate (CPP).  Next, ionization of CPP to initiate the carbocation 
cascade, followed by the trapping of carbocation with water, which gave rise to the 





     
 










































































































































































































































































































































































Along with the GGS and Cyclase genes, the pleuromutilin gene cluster also contains two 
cytochrome P450s responsible for the addition of hydroxyl groups to the core structure of 
the pleuromutilin and other P450 acts on the acetate side chain. Cytochrome P450 
oxidoreductases constitute a large family that has diverse functions which can catalyze 
various chemical reactions on the substrate for instance oxidation, hydroxylation and 
epoxidation (Durairaj et al. 2016). Saikia et al. (2007), Hu et al. (2011) and Seki et al. 
(2008) are among well-known studies that reported the versatile functions of P450 in fungi. 
In the case of pleuromutilin biosynthesis, P450s are known to introduce the hydroxyl group 
on C-3, C-11 and C-22 catalyzed by P450-2, P450-1 and P450-3 respectively. Meanwhile, 
the conversion of hydroxyl on C-3 to a ketone is catalyzed by SDR. Based on the stepwise 
heterologous expression in A. oryzae, a proposed order of reactions of the pleuromutilin 
biosynthetic pathway is as shown (Figure 3.1). Installation of hydroxyl on C-11 and C-3 
by P450s occurred after cyclization of the first pleuromutilin precursor followed by 
acetylation at C-14 and oxidation of hydroxyl on C-3 catalyzed by ATF and P450-3 
respectively. The last step of the hydroxylation reaction happened on C-22 which finally 
converts the molecule to pleuromutilin.  
It was also found that P450-2 can act independently on the substrate which is the first 
product of GGS and Cyc, 3-deoxo-11-dehydroxymutilin 2 and led to the accumulation of 
3-dihydro-11-dehydroxy-mutilin 7 (Figure 3.2) (Alberti 2015; Yamane et al. 2017). 
According to Yamane et al. (2017), metabolite 7 can be converted into 4 by enzyme P450-
1, in which the next synthesis reactions would follow the main biosynthetic pathway. 
Otherwise, with the absence of P450-1, compound 2 was able to bypass the reaction of 11-
oxidation and modified by P450-2 and SDR to produce metabolite 8 (Alberti 2015). While 
Figure 3.1 shows one linear route for pleuromutilin biosynthesis, this result suggested it is 
possible that other routes may also exist. It is quite common that more than one route can 
be found in the biosynthetic pathway of secondary metabolites. For instance, the 
actinorhodin biosynthetic gene cluster from Streptomyces coelicolor was reported to 
encode two alternative routes for quinone formation (Okamoto et al. 2009). However, it is 
still uncertain whether this alternative route via 2 could give pleuromutilin as the end 
product or if this is just a shunt reaction that would stop at a certain point of biosynthesis.  
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Figure 3.2 showing biosynthetic pathway of pleuromutilin. Two oxidation routes were 
involved in the biosynthesis of 4 either through the main route or the shunt pathway. In the 
absence of P450-1, the shunt pathway followed branches starting from metabolite 2 as 
enclosed in the box (Alberti 2015; Yamane et al. 2017). However, further analysis of the 
















































Current knowledge gained from works done by Bailey et al. (2016) and Alberti et al. (2017) 
has shed light on the previously unknown enzymatic mechanism in pleuromutilin 
biosynthesis. Seven tailoring genes which include GGS, Cyclase, P450-1, P450-2, P450-
3, SDR and ATF were inferred to be responsible for generating this molecule. Although 
the role of those genes in the pathway has been characterized, the order of the reactions is 
still uncertain. Moreover, Alberti (2015) in his study found two shunt products which 
suggested that the tailoring enzymes could have a certain degree of substrate flexibility, 
perhaps giving rise to an alternative route for pleuromutilin biosynthesis. The work 
described in this chapter aimed to study possible alternative routes in pleuromutilin 
conversion steps.  
An approach in which heterologous expression of the desired combination of pleuromutilin 
genes was undertaken to explore the ability of the pleuromutilin tailoring enzymes in 
producing new analogs. The aim was to make a series of A. oryzae strains, including all 
genes, but lacking a specific gene of interest. This would deliver the same outcome as gene 
disruption which was not possible in C. passeckerianus. Results from this study will aid 
understanding and provide a technical basis for further engineering of this pathway to 






The expression vectors carrying cDNA of the various pleuromutilin biosynthetic genes 
have been constructed in plasmids by Dr. Fabrizio Alberti through yeast-based homologous 
recombination using pTYGS plasmid as the backbone. This plasmid backbone had a 
selection marker of either arginine (argB) or adenine (adeA) or basta (bar) and was 
provided by Dr. Colin Lazarus (University of Bristol). A summary of the plasmids that 
have been constructed previously is shown in Table 3.1.  
Table 3.1 Summary of pre-existing plasmids constructed by Dr. Alberti to express genes from C. 
passeckerianus in A. oryzae. Selectable marker argB: A. nidulans ornithine carbamoyltransferase 
(OCTase) gene; adeA: A. oryzae gene which encodes an enzyme involved in purine biosynthesis; 
bar: Streptomyces spp. phosphinothricin acetyl-transferase gene. Promoter Padh: A. oryzae alcohol 























Padh P450-1 pTYGSadeP1 
Padh P450-2 pTYGSadeP2 





Padh ATF pTYGSbarATF 
Padh SDR pTYGSbarSDR 
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Following the success of using the step-wise heterologous expression to synthesize 
pleuromutilin intermediates shown by Alberti et al. (2017), the same strategy was 
attempted in this study. Previously, our research group demonstrated the use of a 
premutilin-producing strain carrying the key genes GGS and Cyclase as the host to further 
express downstream genes of pleuromutilin cluster. Thus, to carry out the expression of 
additional selected genes, the same host strain harboring the two genes, A. oryzae GC TR5 
was used throughout this chapter unless otherwise stated.   
3.3.2 The absence of P450-1 from pleuromutilin gene cluster 
The expression of all pleuromutilin genes except P450-1 was carried out by using the pre-
existing plasmid pTYGSadeP2P3 and pTYGSbarATFSDR exploiting adeA and bar 
selectable markers (Figure 3.3). Eight µL of pTYGSadeP2P3 and 2 µL of 
pTYGSbarATFSDR were co-transformed in A. oryzae GC TR5 strain already harboring 
GGS and Cyc. 
Sixteen transformants were generated from the transformation of the two plasmids in A. 
oryzae GC. All of the transformants named as A. oryzae GCP2P3AS were screened for the 
presence of the two genes, P450-2 and ATF which represent both plasmids, by PCR 
amplification as shown in Figure 3.4. Five transformants, TR1, 2, 3, 5 and 9, positive for 
the two genes, were grown individually in 100 mL CMP medium for 10 days. The 
fermentations were extracted with ethyl acetate and subjected to HPLC analysis. The ELSD 
chromatogram of the five extracts revealed that all the samples have distinct chemical 
profiles compared with the 7-genes A. oryzae strain. The chromatogram showed the 
absence of pleuromutilin, which is the product of the 7-genes strain. Instead, one new major 
metabolite, called metabolite 9, was observed in the extracts eluted at Rt = 14.50 min 








































ATF    : 5651-6784 
SDR    : 7585-8346 
 
Figure 3.3 Plasmids for the expression of P450-2 and P450-3 (top) and ATF and 












Figure 3.4  PCR amplification product of P450-2 and ATF for gDNA extracted from A. oryzae 
GCP2P3AS transformant strains. Five transformants TR1, 2, 3, 5 and 9 showing the presence 
of both genes. A. PCR amplification of the P450-2 gene B. PCR amplification of the ATF gene. 
Lane 1-16 contain PCR products of the extracted gDNA from A. oryzae transformants. H: 
contain 5 µL of hyperladder I, C+: Appropriate plasmid (the same used for the transformation) 
used as the template, C-: gDNA of A. oryzae NSAR1. PCR products expected size. P450-2: 
1578 bp, ATF: 1134 bp. 
A
A 
  H   1    2    3    4    5   6   7    8    9  10  11  12  13 14  15  16  C+ C- 








Figure 3.5 ELSD chromatograms of pleuromutilin standard and crude extracts from A. 
oryzae strains. A. One of the five positive transformants, A. oryzae GCP2P3AS TR5, was 
presented here showing a unique metabolite at 14.5 min (metabolite 9). The same chemical 
profile was also observed in the other four transformants B. A. oryzae 7-genes transformant 
C. Pleuromutilin standard D. A. oryzae NSAR1 WT. 
 
A. oryzae GCP2P3AS TR5 was chosen to be used in large-scale fermentation in order to 
isolate metabolite 9. The transformant was cultured in a litre of CMP broth for 10 days 
prior to extraction with ethyl acetate. The isolation of the new product was carried out 
through column chromatography. The fungal extract was eluted with petroleum ether/ ethyl 
acetate (1:9) in silica gel column chromatography and separated into 45 fractions. Based 
on the TLC screening which developed in petroleum ether-ethyl acetate (1:1), the 
compound was observed to elute in fraction 22-38. Thus, the fractions were pooled and 
concentrated in vacuo. By using this procedure, 18 mg of metabolite 9 (white precipitate) 












The NMR data indicated that this metabolite showed similar shifting patterns with 
pleuromutilin. Twenty-two carbon signals were observed in the 13C-NMR, which strongly 
suggested that this molecule was a pleuromutilin-related compound (Table 3.2, Appendix 
B). Additionally, one quaternary carbon resonating at δc 217.8 matched with the C-3 of 
pleuromutilin, thus it was assumed to be bound to a ketone group. The other carbon signals 
were also consistent with pleuromutilin 13C-NMR, apart from two carbons which resonated 
at δc 21.5 and 42.4. These two signals however, were like those seen previously in 
metabolite 8 and 10 13C-NMR spectra where hydroxyl groups were absent from C-11 and 
C-22.  The 1H-NMR together with 2D-NMR analysis provided additional support for the 
proposed chemical structure of 9. (Figure 3.6). This shows that ATF can act without pre-
hydroxylation at C-11. Somewhat surprisingly, despite the presence of P450-3, there was 


































 Figure 3.6 Conversion of metabolite 8 to 9 upon the activity of the enzyme 
ATF. 
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Table 3.2 NMR data comparison between 9 with 8, 10 and pleuromutilin in CDCl3. The 1H-
NMR and 13C-NMR data between the four compounds proved that 9 has a similar chemical 

















13C(d) mult. 1H(d) 13C(d) 1H(d) 13C(d) 1H(d) 13C(d) 1H(d) 








1.58, m 1.54 1.46 1.67 








  1.84  
3 217.8 qC  218.6  77.7 4.56 216.8  
4 58.4 CH 2.19, s 59.5 2.10 51.4 1.56 58.1 2.07-2.15 
5 38.4 qC  42.2  41.5  41.8  
6 36.4 CH 1.63, m 37.1 1.67 37.1 2.2 36.6 1.68 








1.63, m 1.47 1.47 1.55 








1.68, m 1.62 1.96 1.8 
9 45.1 qC  39.9  46.4  45.4  
10 30.6 CH 2.21, d 31.5 1.97 36.0 2.06 36.0 2.36 








1.60, d 1.57   
12 41.3 qC  45.4  45.3  44.0  








2.02 1.85 1.97 2.07-2.15 
14 68.6 CH 5.57 67.6 4.25 70.2 5.57 69.8 5.85 
15 14.5 CH3 1.48 13.5 1.40 17.3 1.15 14.8 1.45 
16 19.0 CH3 0.93 18.2 0.98 18.0 0.81 16.6 0.72 
17 15.9 CH3 0.74 19.7 0.90 12.6 0.72 11.5 0.91 
18 31.6 CH3 1.00 32.7 0.96 26.5 1.23 26.3 1.19 
19 145.7 CH 6.21 146.0 5.83 140.1 6.57 138.8 6.51 








5.17 5.26 5.33 5.38 
21 169.1 qC    170.5  172.2  

























3.3.3 Expression of all pleuromutilin biosynthetic genes except SDR.  
The three P450s and ATF genes were expressed in the previously used host, A. oryzae GC 
TR5 to investigate the impact of omitting SDR from the gene cluster.  The transformation 
was achieved by co-transformation of two pre-prepared plasmids pTYGSadeP450s (8 µL) 
and pTYGSbarATF (2 µL) carrying the three P450s and ATF respectively. The plasmid 
map of the expression vectors used was shown in Figure 3.7.  
Transformation of the two plasmids was confirmed by PCR amplification of P450-1 and 
ATF representing each plasmid. Twenty-three transformants, called A. oryzae 
GCP1P2P3A, were generated from the co-transformation of the two plasmids in A. oryzae 
GC (Figure 3.8). Five transformants positive for both genes, TR3, 5, 8, 12 and 18, were 
cultured in 100 mL CMP for 10 days. The chemical products were then extracted and 
analyzed by using HPLC. Three of the transformants (TR3, 5 and 18) accumulated a novel 
metabolite that eluted at a retention time of Rt = 14.00 min with 409 m/z was observed in 
the negative ion mode (ES-) as shown in Figure 3.9 and Appendix C. Based on the m/z 
value, it was inferred that this compound has molecular mass (Mr) of approximately 364 g 
mol-1 as the molecule was being ionised by the addition of formic acid (Mr=46) and loss of 






































































ATF    : 5651-6784 
 





























Figure 3.8 Gel photos of PCR amplification for P450-1 and ATF from gDNA 
extracted from A. oryzae GCP1P2P3A transformant strains. TR3, 5, 8, 12 and 18 were 
tested positive for the genes. A. PCR amplification of the ATF gene B. PCR 
amplification of the P450-1 gene. Lane 1-23 contain PCR products of the extracted 
gDNA from A. oryzae transformants. Lane H: contain 5 µL of hyperladder I, C+: 
Plasmid, the same used for the transformation was used as the template, C-:gDNA of 
A. oryzae NSAR1 WT. PCR products expected size. ATF:1134 bp, P450-1: 1572 bp. 
 
H       1      2       3      4       5       6       7       C+    C-     
 H   8   9  10  11 12 13 14 15 16 17 18 19 20 21 22 23 C+ C- 
H    1     2      3     4     5    6     7     8     9    10   11    12   C+  C- 









































Figure 3.9 Detection of metabolite 10 in selected GCP1P2P3A transformants. A. shows 
the chromatogram of one of the positive transformant, A. oryzae GCP1P2P3A TR3 where 
a novel metabolite 10 was eluted at 14 min. B. A. oryzae 7-genes transformant C. 
Pleuromutilin standard D. A. oryzae NSAR1 WT E. ES- spectrum indicates metabolite 10 











In order to characterize metabolite 10, large-scale extraction in ethyl acetate was carried 
out on a liter culture of GCP1P2P3A TR3 in CMP medium after 10 days of incubation. 
The purification of metabolite 10 was done through preparative HPLC which yielded 20 
mg of white precipitate product. The chemical structure of the purified metabolite was 
characterized by comparing the 1H-NMR and the 13C-NMR spectra for this compound with 
metabolite 10 and those obtained for 14-O-acetyl-mutilin (6), 3-dihydro-mutilin (4) and 
pleuromutilin (1) isolated from the A. oryzae transformants in a previous study (Alberti 
2015). Analysis of the NMR data for 10 revealed the presence of two hydroxyl groups. 
From the spectrum, it appeared that this molecule was similar to the previously 
characterized 4, but instead of having 20 carbons, this compound has an extra two carbons 
which can be observed in the 13C-NMR spectrum (Appendix D). The carbon shifts of these 
two carbons were matched with the chemical shifts of C-21 and C-22 atoms from 6 and the 
1H- NMR data also demonstrated that C-14 atom is substituted by acetyl group giving 10 
(Figure 3.10, Table 3.3). These results showed that C-14 acetylation catalyzed by SDR 
could still occur even though C-3 was attached to the hydroxyl, not the carbonyl group. As 
with metabolite 9, it is noteworthy that the acetate group on C-14 was not then oxidized 















Figure 3.10 Conversion of 4 to 10 upon the activity of the enzyme ATF. 
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Table 3.3 NMR data comparison between 10 with 4, 6 and pleuromutilin in CDCl3. The 1H-NMR 
and 13C-NMR data between the three compounds proved that 10 has a similar chemical structure 










13C(d) mult. 1H(d) 13C(d) 1H(d) 13C(d) 1H(d) 13C(d) 1H(d) 








1.46, m 1.47-1.54 1.64 1.67 








1.84, m 1.72   
3 77.7 CH 4.56, t 77.9 4.54 217.3  216.8  
4 51.4 CH 1.56, s 52.2 1.57-1.59 58.3 2.07 58.1 2.07-2.15 
5 41.5 qC  42.4  41.7  41.8  
6 37.1 CH 2.2, m 37.1 2.25 36.8 1.64 36.6 1.68 
7 28.1 CH2 







1.47, m 1.47-1.50 1.53 1.55 








1.96, m 1.95-1.99 1.77 1.8 
9 46.4 qC  46.4  45.5  45.4  
10 36.0 CH 2.06, dd 36.4 1.8 36.0 2.37 36.0 2.36 








 1.33-1.40   
12 45.3 qC  45.9  44.0  44.0  








1.97, s 1.87-1.94 2.06 2.07-2.15 
14 70.2 CH 5.57, d 68.5 4.2 67.9 5.72 69.8 5.85 
15 17.3 CH3 1.15, s 16.7 1.14 14.9 1.46 14.8 1.45 
16 18.0 CH3 0.81, d 18.9 0.96 16.6 0.73 16.6 0.72 
17 12.6 CH3 0.72, d 12.4 0.84 11.5 0.88 11.5 0.91 
18 26.5 CH3 1.23, s 28.9 0.94 26.2 1.17 26.3 1.19 
19 140.1 CH 6.57, dd 140.4 5.82 139.2 6.53 138.8 6.51 








5.33, dd 5.21 5.35 5.38 
21 170.5 qC    170.0  172.2  



























3.3.4 Expression of pleuromutilin biosynthetic genes except for P450-2 
In order to generate a transformation system carrying all the biosynthetic genes of 
pleuromutilin except for P450-2, two pre-constructed plasmids together containing genes 
P450-1, P450-3, ATF and SDR were co-transformed in A. oryzae GC TR5. The two 
plasmids, pTYGSadeP1P3 and pTYGSbarATFSDR, as shown in Figure 3.11 were used to 
achieve the outcome to omit P450-2 from the cluster. Respectively, 2 and 8 µL of both 
plasmids were transformed into the selected host.  
Sixteen transformants were generated and six of them (TR1, 2, 4, 11, 15, 16) were 
confirmed positive for the presence of the genes P450-1 and SDR representing the two 
plasmids (Figure 3.12). 100 mL culture in CMP broth was set up for the six transformants. 
After 10 days, the cultures were extracted with ethyl acetate and the crude extracts were 
then analyzed in HPLC as shown in Figure 3.13. The ELSD chromatogram of all the 
extracts failed to show any new peak that could be related to pleuromutilin. Although 
several new compounds eluted between 17.57 to 20 min, these peaks were also presented 
in previous transformant strains A. oryzae GCP2P3AS and GCP1P2P3A. Thus, the 







































Figure 3.11 Plasmids constructed to harbor P450-1 and P450-3 (top) and ATF and SDR genes 
(bottom). 





ATF    : 5651-6784 















































































































































































































Figure 3.13 ELSD chromatograms of crude fungal extracts against pleuromutilin standard. 
A. No new pleuromutilin-related compound can be detected in A. oryzae GCP1P3AS B. A. 
oryzae 7-genes transformant C. Pleuromutilin standard D. NSAR1 WT. 
Figure 3.12 Six transformants of A. oryzae GCP1P3AS (TR1, 2, 4, 11, 15, 16) showing 
the presence of P450-1 and SDR by PCR screening. A. PCR amplification of the P450-1 
gene B. PCR amplification of the SDR gene. Lane 1-16 contain PCR products of the 
extracted gDNA from A. oryzae transformants. Lane H: 5 µL of hyperladder I, C+: PCR 
product of appropriate plasmid (the same used for the transformation) as a positive 
control, C-: PCR product of gDNA of A. oryzae NSAR1 WT as a negative control. PCR 








H      1     2      3     4    5      6     7     8      9    10   11   12    13   14    15   16    C+  C-   









It was expected that the transformants generated in this section would produce a compound 
with the absence of C3-ketone as shown in Figure 3.14. Even if the P450-3 and ATF did 
not work, this transformation system would at least be expected to make metabolite 4 as it 
was the product from the expression of GGS, cyclase and P450-1 alone. However, none of 
the expected compounds were detected including metabolite 4. Thin layer chromatography 
(TLC) was then attempted to test for the presence of the premutilin 2 (Figure 3.15). It was 
shown that all the positive transformant strains were producing metabolite 2 confirming 
the activity of GGS and Cyc. Thus, it could be hypothesized that the expression of the 











































Figure 3.14 Predicted pleuromutilin biosynthetic shunt pathway which bypasses P450-2. 
However, none of these tailoring products can be detected from the expression system as 
shown by the red-crosses. 
Figure 3.15 Thin layer chromatography analysis shows the accumulation of premutilin 2 
in all of the positive transformant strains. From left C2: purified metabolite 2; A. oryzae 
GCP1P3AS TR1,2,4,11,15,16; WT: A. oryzae NSAR1. 
 64 
3.3.5 Feeding studies 
Expression of all genes except P450-1 or SDR from the pleuromutilin cluster showed 
production of new products, 9 and 10, however, it was noted that the final reaction of 
hydroxylation on C-22 catalysed by P450-3 did not happen as would have been expected. 
To confirm the hypothesis, an attempt to feed 9 and 10 as substrates to A. oryzae strain 
harboring P450-3 was initially intended. However, both 9 and 10 cannot be reproduced 
from the original transformant strains A. oryzae GCP1P2P3A TR2 and A. oryzae 
GCP2P3A TR5 respectively after some time and were not enough to carry out feeding 
studies. Thus, intermediates 8 and 4 produced in a reaction step before 9 and 10 























































Figure 3.16 Schematic diagram of the shunt pathway for pleuromutilin biosynthesis. 
Metabolites 4 and 8 will be individually supplemented into A. oryzae AP3 culture to test 
if hydroxylation by P450-3 could be catalyzed. 
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3.3.5.1 Generation of A. oryzae AP3 strain 
Generation of the expression system for the feeding study was performed by co-
transformation of plasmid pTYGSadeP3 and pTYGSbarATF into A. oryzae NSAR1 
(Figure 3.17). These plasmids carry two genes P450-3 and ATF respectively which vital to 
tailor the last two steps in the biosynthetic pathway as metabolite 4 and 8 would be used as 
substrates. The expression of the genes was done by transforming 2µL of plasmid 
pTYGSadeP3 and 8µL of pTYGSbarATF in A. oryzae NSAR1. Eight out of 46 
transformants were shown to be positive for the presence of both genes by PCR. Four of 
these TR1, 19, 26 and 29 were then cultured in 100 mL CMP supplemented with 100 mg 
L-1 of mutilin 5 for 10 days to test for the conversion to pleuromutilin. Each culture was 
then extracted using ethyl acetate and analyzed by HPLC. Pleuromutilin was detected in 
all extracts and the conversion efficiency was calculated. 
Table 3.4 showed the amount of pleuromutilin recovered from each of the fungal extracts. 
From the table, the highest amount of pleuromutilin that could be recovered was 7.6 mg 
from A. oryzae AP3 TR1. As this strain gave >70% of pleuromutilin conversion, it can be 
confirmed that the P450-3 and ATF in this system are working efficiently. Thus, A. oryzae 
























































ATF    : 5651-6784 
 
Figure 3.17 Plasmid map of expression vectors harboring P450-3 (top) and ATF genes (bottom). 
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Table 3.4 A. oryzae P3ATF strains fed with mutilin 5 and the amount of pleuromutilin 
that could be recovered from the strains. 
A. oryzae strain Pleuromutilin recovered (mg/100 mL) 
A. oryzae P3ATF TR1 7.6 
A. oryzae P3ATF TR19 5.7 
A. oryzae P3ATF TR26 6.2 
A. oryzae P3ATF TR29 5.5 
 
3.3.5.2 A. oryzae AP3 fed with metabolite 4 
Metabolite 4 was a product from the expression of GGS, Cyclase, P450-1 and P450-2 in 
A. oryzae. The strain was generated previously by Dr. Alberti. To gather 10 mg of 
compound 4 to be used in the feeding study, the compound was re-isolated from a litre 
culture of A. oryzae GCP1P2 strain. After 10 days of incubation, 23 mg of 4 was 
successfully purified from the crude extract. The identity of 4 was confirmed by 1H-NMR 
before 100 mg L-1 was fed via the fermentation broth of A. oryzae AP3 TR1 for 10 days. 
The ethyl acetate extract of the A. oryzae AP3 fed culture was analyzed by HPLC.  From 
the ELSD chromatogram, a major peak was eluted having the same m/z as compound 10 
(Figure 3.18). An attempt to find any traces of the predicted final product (P1) as shown in 
Figure 3.19 from the bioconversion of 10 was done by mass searching of the respective 
m/z in the MS spectrum. The mass of the expected P1 was calculated to be 380 g mol-1. 
Considering the formation of molecular adduct with formic acid in the mass spectrometry, 
the m/z unit of product P1 was predicted to be equal to Mr + formic acid - H+ = 380 + 46 – 
1 = 425 m/z following the calculation used previously by Dr. Alberti. The predicted m/z 
value was scanned throughout the MS spectrum using MassLynx software but failed to 















Figure 3.18 ELSD chromatograms of crude extracts from fungal strains. A. A. oryzae   
AP3 TR1 fed with metabolite 4 was showing accumulation of the previously identified 
metabolite 10, yet no hydroxylated 10 can be detected; B. A. oryzae NSAR1 WT; C. ES- 








Figure 3.19 Conversion of P1 was predicted to happen upon the activity of P450-3, but no 
such product could be observed. 
 
3.3.5.3 A. oryzae AP3 fed with metabolite 8 
In order to test whether the final bioconversion of 9 could happen, an attempt to feed 
metabolite 8 to A. oryzae AP3 was carried out. Metabolite 8 was isolated from a litre culture 
of 10-day old A. oryzae strain harboring GGS, Cyc and P450-2 and SDR (GCP2S). This 
strain gave 7 mg of metabolite 8. Although the recommended concentration of substrate to 
be fed into fungal host was 100 mg L-1, the feeding study for compound 8 was continued 
despite the lower amount of 8. A 100 mL of A. oryzae AP3 TR1 culture was supplemented 
with 7 mg of 8 and incubated for 10 days. 
The culture was subjected to ethyl acetate extraction, and the crude extract was analyzed 
by LCMS. As shown in Figure 3.20, this strain produced a major product with identical Rt 
and m/z unit with 9, thus revealing this metabolite is 9 itself. Three minor peaks were 
observed in the chromatogram eluting at 11.7, 13.1 and 17.21 min, however none of these 
were shown to be related to pleuromutilin based on the m/z. To be noted, a major peak also 
accumulated at 18.82 min, however peaks eluting after 18 min have been present in most 
of the transformants generated in this thesis. Thus, it was suggested this compound is likely 
a stress product of the host resulting from the insertion of foreign genes and not a product 
of the gene expression. The mass of P2 was calculated to be 362 g mol-1. Assuming the 
expected final product, P2 (Figure 3.21) would follow the same behaviour as compound 9 
and 10, where the m/z shown in ES- spectrum was equal to Mr + formic acid - H+ = 362 + 
46 – 1 = 407 m/z. This predicted m/z was then scanned throughout the spectrum, but no 
equivalent product was found. Therefore, as with modification of 4 by A. oryzae AP3, 





































Figure 3.21 P2 was predicted as the end product from the fed culture of A. oryzae AP3 






































Figure 3.20 ELSD chromatograms of standard and crude extracts from fungal strains. A. 
Feeding A. oryzae AP3 TR1 with 8 successfully gave acetylated 9, but no 22-OH product, 
P2 was observed. Compounds with (*) were not related to pleuromutilin based on the m/z 









3.3.6 Antimicrobial activity of pleuromutilin-related products 
Pleuromutilin and its analogs were assayed for antibiotic activity against Bacillus subtilis 
ATCC 6633. Agar disc diffusion assay was carried out by pipetting 100, 25, 5 and 1 µg of 
each product, dissolved in an appropriate volume of dichloromethane, on individual 6 mm 
filter paper discs. The discs were then dried until all solvent was evaporated and applied 
on a lawn of B. subtilis as shown in Figure 3.22. The lawn was prepared by pouring 20 mL 
of TSA agar as the base and overlaid with 5 mL of over pour media (TSA containing 0.1% 
of B. subtilis pore suspension). Diffusion of the compounds and growth of bacteria 
happened simultaneously resulting in a circular zone of inhibition. The diameter of the 




Pleuromutilin 1 showed the highest antimicrobial activity followed by 6 (Figure 3.23). This 
indicates that a substitution at C-22 of the pleuromutilin strongly enhances the activity of 
the pleuromutilin against the bacteria. Addition of hydroxyl at this position appears to be 
superior, although the difference is small. The loss of acetate from C-14 pleuromutilin had 
a big impact on the activity as can be seen in 3, 4, 5, 7 and 8. Mutilin 5 showing half the 
activity of pleuromutilin while earlier intermediates with reduction of ketone and absence 
of hydroxyl group from C-3 on 4 and 3 respectively resulted in an almost complete loss of 
activity. Similar activity was also observed in 7 and 8, although 8 possesses a slightly 
stronger inhibition.
Figure 3.22 A schematic diagram of the agar disc diffusion assay of pleuromutilin analogs 
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The structure-activity relationship of the pleuromutilin analogs was further investigated on 
the other incomplete products. As it was shown previously, loss of any mature substituent 
from the core structure resulted in a reduction in the activity against bacteria. This has also 
been observed in the activity of all shunt products. Comparing 10 and 6, shows that the 3-
ketone position does impact on the activity while the difference between 9 and 6 
highlighted the importance of C-11 OH in preventing the bacterial growth. 
3.3.6.1 Analysis of semi-synthetic analogs 
In accordance with results obtained from the comparison of 10 and 6, the presence of 
ketone on C-3 gave a big impact on the biological activity. It was speculated whether 
substitution of this group with other functional groups would improve the activity. Also, 
as C3-keto and the other carbons in the five-membered ring of pleuromutilin are prone to 
attack by liver P450, modification at this position could create a more stable active form.  
Thus, attempts to replace the C-3 ketone and dehydrogenate C1-C2 of pleuromutilin were 
made synthetically by Jonathan Davies and Edith Rodriguez Venegas (University of 
Bristol) from mutilin as the starting material. Two mutilins, 3-methyl mutilin and 3-
hydroxy mutilin were engineered to have methyl and hydroxyl group respectively on C-3, 
while one mutilin 13 was modified to still feature ketone on C3 but has 1,2-alkane.  The 
three modified compounds were then used in biotransformation by feeding each metabolite 
to A. oryzae AP3 for further conversion at C-14. Four analogs were successfully produced: 
3-methyl acetylmutilin 11, 3-hydroxy acetylmutilin 12 and two analogs of the 1,2 alkene 
mutilin 14-15. The chemical structure of the new synthetic analogs is shown in Figure 3.24. 
It is worth noting that compounds 12 and 10 are the same but 10 was synthesized naturally 
























The synthetic compounds were assayed against B. subtilis in comparison with the naturally 
occurring 1, 6 and 5 as shown in Figure 3.25 published in Alberti et al. (2017). Loss of 
activity was observed when the 3-OH was substituted with a methyl group. Compound 12 
exhibited moderate activity as had been seen with the naturally produced 10, comparable 
to that of mutilin 5 and 13. Remarkably, greater activity was shown by compound 15 which 
is higher than the pleuromutilin 1 itself. This was also observed in 14, although the activity 
was slightly reduced compared with 15, it is far more potent than 6 which also lacks C-22 
OH. 
3.4 Summary of the pleuromutilin biosynthetic pathway  
A linear biosynthetic pathway for pleuromutilin was confirmed to involve seven reaction 
steps to generate pleuromutilin (Bailey et al. 2016; Alberti et al. 2017). Additionally, two 
alternative pathways to pleuromutilin biosynthesis have been identified throughout this 
work. The biosynthetic pathway of pleuromutilin is summarized as in Figure 3.26.  
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Pleuromutilin and its derivatives have been reported to have antibiotic properties that 
can inhibit bacterial protein synthesis. Thus, much effort has been focused on the 
synthesis of novel pleuromutilin analogs from its unique tricyclic skeleton. Recently, 
the biosynthetic gene cluster of pleuromutilin has been identified from C. 
passeckerianus and was then introduced to A. oryzae NSAR1 by heterologous 
expression (Bailey et al. 2016). Several novel shunt products isolated by Alberti et al. 
(2017) suggest some of the enzymes could possess a certain degree of substrate 
flexibility. Furthermore, this also indicates that other routes could be followed to 
synthesize pleuromutilin rather than a simple linear pathway. Understanding the 
detailed biosynthesis of pleuromutilin is essential in order to synthesize derivatives of 
pleuromutilin.  
The work described in this chapter aimed to identify all the possible pleuromutilin 
intermediate compounds that can be generated along the pathway. A strategy was 
developed to examine the impact of omitting each gene in turn from the cluster by 
generating A. oryzae strains carrying the desired gene combinations. Heterologous 
expression was performed to analyze the pleuromutilin genes in A. oryzae.  
Alberti (2015) in his study proposed a shunt pathway that branches from precursor 2 
where the activity of P450-1 was absent. He encountered two intermediates, 7 and 8 
along the route and it was hypothesized that further conversion of these products could 
be obtained by the expression of the remaining tailoring enzymes. Thus to prove this 
hypothesis, pleuromutilin gene cluster was then heterologously expressed the in A. 
oryzae without the P450-1 gene. In the absence of P450-1 from the pleuromutilin gene 
cluster, a further new pleuromutilin derivative, 9 which exhibited structure like 8 but 
has the acetyl on C-14 could be obtained in the generated strain. A similar outcome 
was attained when SDR was omitted, the transformant strain showed the accumulation 
of a new compound 10. It appeared that although the activity of P450-1 and SDR were 
blocked or missing, alternative pathways could be followed bypassing the catalytic 
reaction of the missing enzymes. Both 9 and 10 were acetylated on C-14 by the ATF 
suggesting this enzyme possesses relaxed substrate specificity. This makes it a useful 
biocatalyst to generate novel pleuromutilin analogs. This system harboring ATF and 
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P450-3 was used to generate semi-synthetic pleuromutilin analogs, one of which was 
reported to have higher antibacterial activity than pleuromutilin published in Alberti et 
al. (2017). It must also be noted that the P450-2 and SDR exhibited low substrate 
specificity as two pleuromutilin analogs were found along the shunt pathway. 
Somewhat surprisingly, all these alternative pathways were blocked after the ATF 
activity. The last hydroxylation which should be catalyzed by P450-3 did not happen 
as expected. It was possible that the P450-3 was expressed at a lower level in both 
strains, hence producing a very low amount of compound that cannot be detected in 
the HPLC. Therefore, to circumvent this problem, compounds 4 and 8 were fed into A. 
oryzae AP3 strain. Fermentation of the strain with the supplemented substrates was 
able to convert the substrates to 10 and 9 but failed to reveal new hydroxylated 
products. In contrast, when mutilin 5 was fed into the same A. oryzae AP3 strain, P450-
3 could efficiently hydroxylate the substrate suggesting that it was fully functional.  
Similar results were also observed previously when the three P450s were expressed 
together with the core genes, GGS and cyclase in A. oryzae. Only P450-1 and P450-2 
hydroxylated pleuromutilin core while no modification was catalyzed by P450-3 
(Alberti 2015). Hence it can be speculated that the P450-3 was very selective on the 
substrate since it failed to hydroxylate 9 and 10. The major difference between the two 
substrates 4 and 8 with mutilin 5 was solely on the 3-ketone and 11-OH of mutilin. 
This gives a hint that these side chains might play an important role in generating a 
conformation that could make specific interactions with the P450-3 substrate binding 
pocket. Lacking this side chain could result in the compound not acting as a substrate 
for P450-3. In contrast with the biosynthetic pathway of the communesins, enzymes 
encoded by the gene cluster were more versatile (Lin et al. 2015). This can be seen 
from the conversion of intermediate shunt products of mutant cnsE and cnsJ, which 
can progress until the last reaction steps in the pathway leading to the production of 
communesin derivatives.  
Although it was hypothesized that P450-3 might have limited substrate activity, it is 
worth noting that the gene was expressed under the control of enolase promoter which 
has shown comparatively weak expression (Alberti 2015). The low level of suboptimal 
substrates coupled with low level of the enzyme might prevent detectable levels of 
product from being obtained. It may be possible to replace the enolase promoter with 
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a stronger promoter from a more highly expressed gene like the one used for GGS in 
this study, which potentially allows for the complete conversion of the precursor to the 
final product. Zhou et al. (2014) have shown that by replacing with a stronger promoter, 
Pcpc560, functional proteins were produced at an increased level up to 15% in the 
cyanobacterium Synechocystis sp. 
In addition, considering the dikaryotic nature of the basidiomycete C. passeckerianus, 
it is possible that a gene could be derived from two different alleles which give proteins 
with a different efficiency of catalysis. As shown in Brassica rapa, three copies of 
BrAOP2 were identified to encode proteins responsible for the dehydrogenation of 
methylsulfinyl alkyl glucosinolate to alkenyl glucosinolates. Although the genes 
exhibited the same function, one of them showed a somewhat altered pattern of 
expression (Zhang et al. 2015). Thus, it is worth to study the other allelic version of 
P450-3 to test its activity for converting pleuromutilin. While the P450-3 used in this 
study was known to function, it has certain limitation of activity towards different 
substrates other than 6. By expressing the different allelic version of the P450-3 in A. 
oryzae it could possibly determine a more efficient catalytic activity.  
When an attempt was made to investigate the ability of pleuromutilin enzymes to 
catalyze the reactions when P450-2 was omitted from the pleuromutilin cluster, 
surprisingly, apart from the precursor 2 being observed, no other pleuromutilin 
intermediates were synthesized in the engineered strain. It was predicted that ATF 
would able to add the acetyl group on the C-14, or at least the intermediate 3 could be 
observed from this system as certainly the P450-1 would have expected to work, but 
none of these reactions happened. Obviously, SDR would not possess any reaction in 
this system due to the absence of 3-OH. It was speculated that this happened due to the 
low efficiency of the engineered strain, as only five transformants could be generated 
that contained all the genes GGS, Cyc, P450-1, SDR, ATF and P450-3. There is a 
chance that the expression level of P450-1 and ATF was very weak in this 
transformants, inhibiting the production of the predicted compound. Thus, more 
transformant strains need to be generated to investigate this problem. 
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The work described in this chapter suggested that further pleuromutilin derivatives or 
intermediates may be obtained by expressing desired pleuromutilin genes in A. oryzae, 
offering a strategy for the production of pleuromutilin analogs with different side chain. 
While pleuromutilin has been reported to show potent activity against microorganisms, 
the activity of the various pleuromutilin intermediates was unknown. It was 
demonstrated by Eustaquio et al. (2004) that the side chain of a compound could 
contribute to the antimicrobial activity. To investigate the structure-activity 
relationships of the pleuromutilin analogs, all the pathway products were assayed 
against B. subtilis. The results revealed that the removal of the acetyl group from C-14 
of the pleuromutilin had a big impact as the activity was dropped to half with respect 
to the pleuromutilin itself. This is an agreement with the previous study showing that 
the antimicrobial activity of the pleuromutilin would depend on the C-14 side chain 
(Egger and Reinshagen 1976). Furthermore, Egger and Reinshagen (1976) also 
reported substitution of the C-14 with thioesters significantly improved the activity. 
Although the importance of the C-14 side chain has been long known, few studies 
indicated that it was also important to retain the 3-ketone and 11-OH of pleuromutilin. 
As shown by the new products 9 and 10, both compounds retained the 14-acetyl group 
and still exhibited a weak inhibition against B. subtilis.  
To further investigate the structure-activity relationship of pleuromutilin, the 
antibacterial assay was extended on several semi-synthetic pleuromutilin compounds 
prepared by Jonathan Davies and Edith Rodriguez Venegas (University of Bristol). The 
compounds were synthesized chemically with modification was solely focused on the 
5-membered ring of pleuromutilin. Remarkably, semi-synthetic derivatives 14 and 15, 
which retained the 3-ketone, 11-OH and 14-acetyl features, were observed to be more 
active against B. subtilis when compared with pleuromutilin. Both compounds have a 
ketone substituent on the 5-membered ring of pleuromutilin which makes them more 
active than pleuromutilin. Compound 13 otherwise showed a smaller inhibition zone 
due to the loss of 14-acetyl from the pleuromutilin core. The attempt to substitute 3-
ketone with methyl group clearly did not improve the antimicrobial activity of 
compound 11 as it showed the smallest inhibition zone among the other pleuromutilin 
derivatives. Thus, it can be concluded that retaining the environment of the three 
pleuromutilin side chains, 3-ketone, 11-OH and 14-acetyl, was important to maintain 
the bioactivity of the pleuromutilin analogs. However, further modification can be done 
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on the C-14 to improve its activity as was reported by Egger and Reinshagen (1976). 
These results have opened new ways to explore semi-synthetic compounds. 
In conclusion, a more detailed picture of the biosynthetic pathway for pleuromutilin 
was obtained. The pleuromutilin biosynthetic pathway was mapped by genetic-
omission studies, which led to the isolation of two new pleuromutilin analogs. Also, 
P450-3 was shown to have strict substrate specificity while ATF was less stringent. 
Heterologous expression in A. oryzae has proved to be a flexible platform for 
developing modified analogs. This approach, when combined with synthetic studies, 




Chapter 4. Exploring combinatorial biosynthesis: Expression of 
other fungal cytochrome P450 in the A. oryzae strain harboring 
pleuromutilin GGS and CYC  
4.1 Introduction  
The emergence of microorganisms which are tolerant to many antibiotics has spurred 
interest in finding new antibiotic compounds. However, although many natural 
compounds showed potent antibacterial properties and a broad spectrum of activities, 
many of them failed in the clinical setting mostly due to metabolic instability or toxicity 
reasons. Often, this problem can be improved through structure modification. For 
example, alteration of the functional group of rifamycin B, an inactive compound 
isolated from Amycolatopsis mediterranei, resulted in the development of a more stable 
molecule named rifampicin. The modified compound was not only active when 
administered orally but was remarkably potent against tuberculosis (Sensi 1983). It was 
also reported that modification on the ibogan part of vinblastine successfully produced 
novel anticancer products called vinorelbine as shown in Figure 4.1A (Baweja et al. 
2006). Looking at these results, it proved structural modification is often important to 
enhance the natural products properties not only for the pharmacokinetics but also the 
spectrum of activity.  There are two possible ways to modify the compound structure. 
Usually, a chemical approach is used, however due to the complexity of natural 
products, chemical modification sometimes is very challenging.  Alternatively, 
combinatorial biosynthesis can be carried out. 
Combinatorial biosynthesis uses a genetic engineering approach to manipulate 
biosynthetic pathways aiming to synthesize novel and diverse products with potential 
pharmaceutical value. Several combinatorial methods that can be used in which the 
foremost are precursor-directed biosynthesis, enzyme-level modification and pathway-
level recombination (Sun et al. 2015). Precursor-directed biosynthesis incorporates 
non-native building blocks or precursors in a host strain expressing desired biosynthetic 
cluster to produce various natural product analogs while enzyme-level modification 
swap of the entire domains, modules, or subunits of an enzyme. Pathway-level 
alteration undertaken in this project was done by introducing additional genes from 
other fungal species in an attempt to generate combinatorial pathways. This strategy 
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has proved to be able to synthesize hybrid products, thus offering greater opportunities 
for expanding the structural diversity of natural products. For instance, one of the early 
examples of combinatorial biosynthesis was reported by Eustáquio et al. (2003).  They 
described the biosynthesis of the clorobiocin analogs in Streptomyces 
roseochromogenes var. oscitans from a hybrid pathway of clorobiocin and novobiocin 
(Figure 4.1). The production of 8-methylnovclobiocin was achieved by replacing gene 
clo-hal in clorobiocin cluster with novO encoding methyltransferase from novobiocin 
biosynthetic genes. A similar strategy was used by the group to produce a novobiocin 
derivative but this time by swapping gene novO in novobiocin pathway for clo-hal from 
clorobiocin pathway. The altered gene cluster of novobiocin was heterologously 
expressed in S. coelicolor M512 resulting the production of 8-cloronovclobiocin 
(Eustaquio et al. 2004). Another remarkable success involving combinatorial 
biosynthesis was described by Moses et al. (2014) where they combined cytochrome 
P450 monooxygenase from Bupleurum falcatum and Medicago truncatula individually 
in a yeast strain expressing β-amyrin synthase from Glycyrrhiza glabra and 
Arabidopsis thaliana cytochrome P450 reductase to produce various saponin analogs. 
The successful series of structural modifications through combinatorial biosynthesis 
illustrate the potential of using this approach in the development of pleuromutilin. 
Major chemical modifications that have been implemented on pleuromutilin were 
mainly focusing on its C-14 positions as the substitution on this position was reported 
to increase its solubility and minimum inhibitory concentration (MIC) (Egger and 
Reinshagen 1976). Of the pleuromutilin derivatives that have been developed across 
the years, the most successful were the semi-synthetics retapamulin, tiamulin and 
valnemulin. Despite the improved antimicrobial activity in the new semi-synthetic 
compounds, they were easily metabolized by host cytochrome P450 enzymes when 
they were orally administered, which limited their bioavailability. As reported by Yang 
et al. (2014), analogs of valnemulin were found in urine and faeces samples of rats, 
chickens and pigs just 24 hours after the administration suggesting valnemulin suffers 
extensive and rapid metabolism. In addition, UPLC-Q/TOF-MS detected 2β-
hydroxyvalnemulin and 8α-hydroxyvalnemulin which revealed the main metabolic 


























Figure 4.1 A. Structure of the bioactive compounds vinblastine, clorobiocin, 
novobiocin and their semisynthetic analogs. The red substituent indicates part of which 
modification took place. B. Map of the novobiocin gene cluster compared to the 
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The interaction of pleuromutilin with liver cytochrome P450 is problematic as it 
inactivates the antibiotics thus affecting the development of the systemic pleuromutilin 
antibiotics in human medicine. It could be anticipated that similar problem would be 
observed in other pleuromutilin derivatives. One possible way to overcome the 
degradation issue is through modification of the pleuromutilin structure particularly at 
the C-2 and C-8 positions which may prevent the molecule from being metabolized by 
the cytochrome P450 enzyme in the liver. Bright et al. (2013) have shown a potential 
chemical-microbial method to be used for developing improved oral bioavailability 
drugs. The strategy was first to establish an oxidative molecule in which the oxidative 
site was replaced with a fluorine atom through fluorination. However, instead of using 
a chemical approach to synthesize the oxidative compound, the researchers employed 
the catalytic activity of cytochrome P450 enzymes in the fungus Cunninghamella 
elegans and the bacterium Streptomyces griseus to carry out regiospecific 
hydroxylation on the selective site of the compound. The biosynthetic compound then 
served as the starting point for fluorination by chemical means. It was shown that 
fluorination on the carbon sites targeted for rapid P450-catalyzed metabolism would 
prevent further oxidation by the enzyme in vivo (Purser et al. 2008; Bright et al. 2013; 
Gillis et al. 2015; Obach et al. 2016).  
 
Figure 4.2 Valnemulin is extensively metabolized in the liver into various oxidized 
products. Compounds V1 and V2, in which hydroxylation occurred at C-2 and C-8 positions 
respectively, were the major metabolites detected in rats and swine. Figure adapted from 
Yang et al. (2014). 
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The potential of using P450 enzymes in drug development has been well recognized 
and has been extended to bioremediation purposes. For example, biotransformation has 
been widely utilized to produce hydrocortisone from cortexolone by fermentation with 
Curvularia sp. (Sonomoto et al. 1983; Manosroi et al. 2006; Lu et al. 2007). It was 
shown that the fungus could catalyze 11β-hydroxylation by the activity of a P450 
enzyme. In addition, statin biotransformation has also been achieved to convert 
compactin into pravastatin by using E. coli producing a P450 enzyme (Fujii et al. 2009). 
The P450 enzymes have also been used widely to produce the drug taxol and to develop 
the anti-cancer drug perillyl alcohol from limonene through a semi-synthetic approach 
by the expression of the cytochrome P450, CYP153, into Pseudomonas putida (van 
Beilen et al. 2005). Many of the antibiotics currently on the market have cytochrome 
P450s involved in their biosynthesis including erythromycin, amphotericin B and 
avermectin (Ikeda et al. 1999; Byrne et al. 2003; Zhang et al. 2010). All the examples 
above supported the prospect of P450s that can be explored to develop new 
pleuromutilin derivatives. 
In order to test the ability of P450 enzymes from other fungi to catalyze oxidation on 
pleuromutilin, the genes encoding these monooxygenases would be introduced into an 
A. oryzae transformant strain that was producing the pleuromutilin precursor 2, 3-
deoxo-11-dehydroxy-mutilin, the first intermediate of the biosynthetic pathway for 
pleuromutilin (Figure 4.3A). As the premutilin has the lowest hydroxylation on the 
structure, this would allow for more available carbon positions for modification. 
The P450 enzymes used in this study were chosen randomly from other diterpene 
pathways in ascomycete fungi. The first three P450s -Ff-P450-1, Ff-P450-2, Ff-P450-
3- were involved in the gibberellin biosynthetic pathway giving the oxidase activity to 
convert ent-kaurene to ent-kaurenoic acid and further to GA12 aldehyde (Tudzynski and 
Hölter 1998). The P450s were isolated from the rice pathogen Fusarium fujikuroi. The 
other four P450 enzymes played an important role in the synthesis of indole diterpenes, 
lolitrem B (Ef-ltmP and Ef-ltmQ) and paxilline (Pp-PaxP and Pp-PaxQ) in Epichloe 
festucae and Penicillium paxilli respectively. The Ef-ltmP and Ef-ltmQ appear to be 
homologues of Pp-PaxP and Pp-PaxQ, but they catalyzed different reactions on the 
indol diterpene resulting in accumulation of distinctive analogs of indole diterpenes 
(Saikia et al. 2007; Saikia et al. 2012). Another P450, Pa-vrtK, involved in the 
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biosynthesis of tetracycline-like compound viridicatumtoxin derived from Penicillium 
aethiopicum was also tested in this study. Chemical structure of the reaction products 














































































Figure 4.3 A. Premutilin 2, having the lowest number of hydroxyl substituents B. 




The work described in this chapter aimed to investigate the potential of exploiting the 
pleuromutilin-producing Aspergillus oryzae secondary host system as a platform to 
achieve further derivatization of the core scaffold of pleuromutilin. To achieve this an 
approach which combines the core genes of pleuromutilin with P450s from other 
diterpene pathways in an A. oryzae host was attempted.  
The cytochrome P450 from several diterpene-producing fungi were selected as 
candidate genes to attempt hydroxylation of the pleuromutilin ring. The diterpene-
producing fungi have been reported before as being able to catalyze various oxidation 
reactions on diterpene cores at different sites. The ability to add hydroxyl group at other 
carbon position on premutilin could open the possibility of further altering the 
compound which could prevent degradation by liver microsomes and so could enable 













4.3.1 Candidate cytochrome P450 genes used to transform A. oryzae GC 
Various fungal cytochrome P450 genes from diterpene pathways were selected to be 
transformed into premutilin-producing A. oryzae GC. This strain was chosen as the 
premutilin, 2 has the most backbone sites available for further oxidation. The selection 
of these P450 enzymes was based on the fact that they were involved in diterpene 
production, so their substrates would be related to pleuromutilin except for the Pa-vrtK 
gene. Since they could modify diterpene compounds as described by Tudzynski and 
Hölter (1998) and Saikia et al. (2012) and are of an ascomycete, they likely to be active 
in A. oryzae and could catalyze reactions on the pleuromutilin precursor. A summary 
of the selected genes and associated details are reported in Table 4.1. 
 
Table 4.1 A summary of the length of both the genomic sequence and the cDNA 
sequence for each P450 genes isolated from various diterpene-producing fungi. 

















Ff-P450-1 1737 1581 526 3 Y15277.1 
Ff-P450-2 1904 1575 524 6 Y15278.1 
Ff-P450-3 1457 1167 388 3 Y15279.1 
Epichloe festucae 
Fl1 (PN2278) 
Ef-ltmP 1829 1497 498 5 JN613319.1 




Pp-PaxP 1849 1548 515 5 HM171111.1 













4.3.1.1 Construction and transformation of the plasmids harboring P450 genes 
from F. fujikuroi into the A. oryzae GC strain 
Three plasmids pTYGSade-FfP450-1, pTYGSade-FfP450-2 and pTYGSade-FfP450-3 
carrying Ff-P450-1, Ff-P450-2 and Ff-P450-3 genes respectively from F. fujikuroi were 
successfully constructed in yeast (Figure 4.4). Primers PadhFfP1 FF/TenoFfP1 RR 
were used to amplify Ff-P450-1 from cDNA of F. fujikuroi in yeast homologous 
recombination while Ff-P450-2 and Ff-P450-3 genes were amplified using primers 
PadhFfP2 FF/TenoFfP2 RR and PadhFfP3 FF/TenoFfP3 RR. Both plasmids 
pTYGSade-FfP450-1 and pTYGSade-FfP450-2 were subjected to restriction digestion 
using XbaI enzyme to test for the correct construction of plasmid while pTYGSade-
FfP450-3 was digested with NdeI. The digestion produced band sizes of 6003, 4909, 
2279 and 131 bp for pTYGSade-FfP450-1, 6003, 4909, 1573, 620, 131 and 80 bp for 
pTYGSade-FfP450-2 and 6310, 2857, 2825 and 916 bp for pTYGSade-FfP450-3. 
Correct construction of the three plasmids was assessed through the restriction digestion 
as shown in Figure 4.4.  
Seven microliters of each plasmid pTYGSade-FfP450-1, pTYGSade-FfP450-2 and 
pTYGSade-FfP450-3 were used to transform A. oryzae GC TR5 strain in independent 
reactions exploiting the selectable marker adeA. Twenty, 16 and 20 transformant 
colonies were rescued from A. oryzae GC FfP450-1, GC FfP450-2 and GC FfP450-3 
strains respectively. PCR amplification was performed on gDNA of the transformants 
with the primer pairs used in yeast plasmid analysis as described above to test for the 
presence of transgenes.  The PCR screening showed 15, 10 and 8 transformants of A. 
oryzae GC FfP450-1 (TR2,3,4,5,7,8,9,10,12,13,14,17,18,19,20) GC FfP450-2 
(TR1,3,4,5,6,7,8,11,12,13) and GC FfP450-3 (TR1,2,4,5,10,11,12,15) strains 
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Location of Ff-P450-2 on map: 
5651-7225  



















Location of Ff-P450-2 on map: 
5651-6817 
Figure 4.4 A, B and C showing plasmid maps of pTGSade-FfP450-1, pTGSade-FfP450-
2 and pTGSade-FfP450-3 carrying gene Ff-P450-1, Ff-P450-2 and Ff-P450-3 
respectively from F. fujikuroi. In II, correct construction of plasmids was achieved as 
shown in the restriction digestion. Restriction enzymes used to digest each plasmid were 




























H    1    2     3    4     5     6    7     8     9   10    C+  C-   
Wamplification products of (A) SoyC and (B) SoyB for 
H   11   12   13  14   15   16   17  18   19   20   C+  C-   




H   1    2    3   4    5    6    7   8    9   10  C+  C- H  11  12  13  14   15  16  C+ C- 
B 
1575 bp 
C H   1    2    3   4    5   6    7    8   9   10   C+  C- 
H  11  12  13 14  15  16  17  18  19 20  C+  C- 
1167 bp 
1167 bp 
Figure 4.5 PCR amplification products of A. Ff-P450-1 B. Ff-P450-2 C. Ff-P450-3 for gDNA 
extracted from the transformants. H: 5 µL of hyperladder I; lanes 1-16: extracted gDNA from A. 
oryzae transformants was used as a template; C+: the same plasmid used for the transformation 








4.3.1.2 Construction and transformation of the plasmids harboring each of Ef-
ltmP and Ef-ltmQ gene from E. festucae into the A. oryzae GC strain 
Constructions of plasmid pTYGSade-EfltmP and pTYGSade-EfltmQ were done in 
yeast. Amplification of the Ef-ltmP and Ef-ltmQ genes was carried out using primers 
PadhEfltmP FF/ TenoEfltmP RR and PadhEfltmQ FF/ TenoEfltmQ RR respectively. 
Both plasmids were digested with EcoRV enzyme which gave band sizes of 4550, 3533, 
3444, and 1711 bp for pTYGSade-EfltmP and 4027, 3533, 3402, 1711 and 1082 bp for 
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A. oryzae GC TR5 strain was transformed with plasmid pTYGSade-EfltmP or 
pTYGSade-EfltmQ, exploiting the selectable marker adeA in each vector. Thirteen A. 
oryzae GC Ef-ltmP transformant colonies transformant colonies were generated while 
12 colonies of A. oryzae GC Ef-ltmQ were rescued. PCR amplification was carried out 
to amplify both Ef-ltmP and Ef-ltmQ genes from the transformant strains. Six 
transformants of A. oryzae GC Ef-ltmP TR3,5,6,9,10 showed the presence of transgene 
while seven transformant colonies (TR3,4,7,8,9,10) were confirmed to carry the 
inserted gene in A. oryzae GC Ef-ltmQ (Figure 4.7). 
 
Figure 4.6 showing the plasmid maps of pTGSade-EfltmP (AI) and pTGSade-EfltmQ 
(BI). AII and BII presented the restriction digestion of the plasmids using EcoRV. 
Correct construction of the plasmids was confirmed based on the digestion patterns. 
H: Hyperladder; C: undigested plasmid; 1: digested plasmid with EcoRV. 
Location of Ef-ltmQ on map: 
5651-7264 
BI BII 

























4.3.1.3 Construction and transformation of plasmids carrying Pp-PaxP and Pp-
PaxQ genes from P. paxilli into A. oryzae 
Pp-PaxP and Pp-PaxQ gene were amplified from cDNA of P. paxilli using primers 
PadhPpPaxP FF/TenoPpPaxP RR and PadhPpPaxQ FF/TenoPpPaxQ respectively. 
Plasmids pTYGSade-PpPaxP and pTYGSade-PpPaxQ were successfully constructed 
through yeast homologous recombination. Restriction digestion was carried on both 
plasmids to confirm the correct construction. The pTYGSade-PpPaxP plasmid was 
digested with BamHI enzyme and gave band sizes of 6474, 4026, 1017, 829, 703 and 
541 bp while 5165, 3533, 2781, 1711 and 638 bp of band size were observed in 
pTYGSade-PpPaxQ after digestion with EcoRV. This has confirmed the expected 
construction of Pp-PaxP and Pp-PaxQ gene in the backbone as shown in Figure 4.8.  
A. oryzae GC TR5 strain was transformed with either pTYGSade-PpPaxP or 
pTYGSade-PpPaxQ and transformants were subjected to PCR amplification to screen 
for the presence of the transgenes. Nine out of 22 A. oryzae GC Pp-PaxP transformant 
colonies (TR3,4,5,8,9,11,14,15,16) were showed to carry Pp-PaxP gene while nine out 
of 20 A. oryzae GC Pp-PaxQ transformants (TR4,5,8,9,11,17,18,19,20) were positive 
for the presence of Pp-PaxQ gene as assessed by PCR amplification (Figure 4.9).  
Figure 4.7 Gel photos for PCR products of (A) Ef-ltmP and (B) Ef-ltmQ from A. oryzae 
GC Ef-ltmP and GC Ef-ltmQ strains respectively. H: 5 µL of hyperladder; Lanes 1-13: 
extracted gDNA of the transformants was used as a template; C+: the same plasmid used 
for the transformation was used as a positive control; C-: the extracted gDNA from A. 
oryzae NSAR1 was used as a negative control.  
 H   1     2    3    4     5     6    7      8    9    10   11  12   13   C+   C- 









































































Figure 4.8 Construction of plasmid pTGSade-PpPaxP (A) and pTGSade-PpPaxQ (B) as 
shown in the plasmid map. Correct construction was assessed through restriction enzyme 
digestion. Gel photos of the plasmid digestion in II revealed correct constructions were 
achieved with BamHI and EcoRV. H: Hyperladder; C: undigested plasmid; 1: plasmid 
was digested with chosen plasmid as shown in the plasmid map. 
Location of Pp-PaxP on map: 
5651-7198 

















4.3.1.4 Construction and transformation of plasmid harboring Pa-vrtK gene 
from P. aethiopicum into A. oryzae GC strain 
Yeast homologous recombination was performed to construct plasmid pTYGSade-
PavrtK harboring Pa-vrtK gene from P. aethiopicum. To obtain the plasmid, a pair of 
primer PadhPavrtK FF/TenoPavrtK RR was used to amplify the Pa-vrtK gene from 
cDNA of P. aethiopicum. Restriction digestion of the plasmid using EcoRV enzyme 
produced band sizes of 8102, 3533 and 1711 bp. This has confirmed the correct 







H     1     2    3     4    5     6    7    8     9   10  11   C+  C- 
H    12   13  14  15  16   17   18  19   20  21   22  C+  C- 
H     1    2     3    4     5    6    7     8     9   10   11  C+  C- 







Figure 4.9 PCR screening carried out on A. oryzae GC Pp-PaxP and GC Pp-PaxQ 
transformants. (A) showing Pp-PaxP PCR products and (B) exhibiting Pp-PaxQ amplicons. 
H: 5 µL of hyperladder; Lanes 1-22: gDNA of A. oryzae transformants; C+: plasmid 


















Plasmid pTYGSade-PavrtK was used to transform A. oryzae GC TR5 strain exploiting 
the selectable marker adeA. Seventeen transformant colonies were rescued and the PCR 
screening showed 12 transformants of A. oryzae GC Pa-vrtK strains 
(TR1,3,4,5,6,7,8,10,14,15,16,17) were observed to carry the expected Pa-vrtK gene 
(Figure 4.11).  
4.3.2 Chemical analysis of the A. oryzae transformants carrying GGS and 
cyclase from C. passeckerianus and P450 genes from various fungi 
The A. oryzae transformants that tested positive for the presence of the P450 genes were 
grown in 100 mL of CMP for 10 days at 28 °C and subsequently subjected to chemical 
extraction using ethyl acetate. The crude extracts were analyzed by HPLC for the 
production of new pleuromutilin derivatives.  
 
A B 




Figure 4.10 Plasmid map of pTGSade-PavrtK was shown in A. Restriction digestion 
using EcoRV showed a correct construction of the plasmid was established (B). H: 
Hyperladder; C: undigested plasmid of pTGSade-PavrtK; 1: digested pTGSade-PavrtK 
with EcoRV. 













4.3.2.1 Chemical analysis of A. oryzae GC Ff-P450-1, GC Ff-P450-2 and GC Ff-
P450-3 strains   
Three genes, Ff-P450-1, Ff-P450-2 and Ff-P450-3 from F. fujikuroi have been 
transformed heterologously in A. oryzae GC strain and the chemical extracts of the 
transformants carrying the transgenes were analyzed in HPLC.  
Seven transformants of A. oryzae GC Ff-P450-1 TR2,3,4,5,7,8,9, GC Ff-P450-2 
TR3,4,5,6,7,8,11 and GC Ff-P450-3 TR1,2,4,5,10,11,12 that had been shown to present 
the P450 genes from F. fujikuroi revealed no readily apparent accumulation of new 
products in the ELSD chromatogram. Minor changes were noted in a few strains as 
shown in Figure 4.12 and Appendix E-G.
H   1    2     3    4    5    6     7    8    9   10  C+  C- 
H   11     12    13    14    15    16    17    C+   C- 
1605 bp 
1605 bp 
Figure 4.11 A. oryzae GC Pa-vrtK transformants were screened for the presence of Pa-
vrtK gene by PCR. H: 5 µL of hyperladder I; Lanes 1-17: extracted gDNA from A. 
oryzae transformants was used as a template; C+: plasmid pTYGSadePavrtK; C-: gDNA 











































































































































































A very weak peak can be observed in two of A. oryzae GC Ff-P450-1, TR4 (Figure 
4.13A) and TR5 strains (Appendix E) at 12.93 min. The identity of this compound could 
not be predicted due to very low titer and the poor quality of the MS spectrum. In 
addition, there were also multiple peaks present between 17 to 20 min. However, these 
peaks were presented in most of the A. oryzae transformants produced in this 
investigation.  Thus, they could not be the product of gene expression.   
Purification of the new product eluted at 12.93 min was attempted from a liter culture 
of A. oryzae GC Ff-P450-1 TR4 strain in CMP. However, the isolation of this product 
was very challenging due to the low amount. The crude extract of A. oryzae GC Ff-
P450-1 TR4 was submitted to 1H-NMR which is sufficiently sensitive to screen for the 
presence of any shared chemical features of the crude extract with A. oryzae GCP1 
product (metabolite 3 in pleuromutilin pathway) based on the proton shifting profile. 
Unfortunately, the two 1H-NMR profiles failed to show any shared features that could 
suggest the new compound was a pleuromutilin derivative. Thus, the characterization 
of this product was discontinued.  
4.3.2.2 Chemical analysis of A. oryzae GC Ef-ltmP and GC Ef-ltmQ strains   
Five and six transformants of each A. oryzae GC Ef-ltmP and GC Ef-ltmQ respectively 
harboring the transgenes were subjected to chemical extraction to further analyze in 
LCMS. The five transformants of A. oryzae GC Ef-ltmP TR3,5,6,9,10 showed a similar 
chemical profile with the wild type A. oryzae and the host strain A. oryzae GC except 
for the peaks eluted after 17 min which are common features observed in most of the 
A. oryzae transformants generated in this study (Figure 4.13A, Appendix H). No other 
significant peak can be observed in this transformant strains. In contrast, production of 
a new peak, at 5.40 min was detected in three (TR4,8,9) out of five positive 
transformants of A. oryzae GC Ef-ltmQ (Figure 4.13B, Appendix I). However, from the 
MS spectrum, it was shown that this compound exhibited m/z value of 200, thus has the 
putative mass of 155 g mol-1 (155 - formic acid + H+ = 408 - 46 + 1 = 155 g mol-1) 
which was smaller than the pleuromutilin precursor 2 (291 g mol-1), indicating this 
compound is not a pleuromutilin. Hence, purification of the product was not attempted. 
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4.3.2.3 Chemical analysis of A. oryzae GC Pp-PaxP, GC Pp-PaxQ and Pa-vrtK 
strains   
Ten days old fermentation culture of transformants A. oryzae GC Pp-PaxP TR3,4,5,8,9; 
GC Pp-PaxQ TR4,5,8,9,17 and seven A. oryzae GC Pa-vrtK TR3,4,5,6,7,15,16 were 
extracted by using ethyl acetate and subjected to chemical analysis in HPLC. Figure 
4.14, 4.15 and Appendix J-L depict the chemical profile of the transformants against 
the control strains. Unfortunately, no new product was observed in any of the 















Figure 4.13 showing ELSD chromatograms for A. A. oryzae GC Ef-ltmP TR3; B. A. oryzae 
GC Ef-ltmQ TR4; C. A. oryzae GCP1; D. A. oryzae GCP2; E. A. oryzae GC; F. Wild-type 
strain A. oryzae NSAR1. Unique metabolite at 5.40 min (*) can be observed in A. oryzae 

























































































































































































































































































































4.3.2.4 TLC analysis of A. oryzae transformants carrying the P450 genes 
The HPLC analysis of A. oryzae GC transformants showed that transformation with 
other fungal P450-genes failed to produce novel pleuromutilin-related products. 
Although two new compounds were observed to be produced by A. oryzae GC Ff-
P450-1 and GC Ef-ltmQ strains, the NMR and MS data of the compounds indicated 
that these two molecules could not be related to pleuromutilin. Thin layer 
chromatography (TLC) was then carried out on each transformant extract to test 
whether the pleuromutilin precursor, metabolite 2 was retained in the extracts. The 
TLC strip was developed in petroleum spirit-ethyl acetate (9:1) and showed all the 
transformants were still producing 3-deoxo-11-dehydroxy-mutilin A. oryzae GC Ff-
P450-3 TR4 and GC Pp-PaxQ TR4 (Figure 4.16) although it is worth noting the amount 
of 2 in A. oryzae GC Ff-P450-3 TR4 and GC Pp-PaxQ TR4 was reduced. This 
suggested that no further conversion was likely to have taken place on 3-deoxo-11-
dehydroxy-mutilin. However, partial conversion of 2 may have happened in A. oryzae 
GC Ff-P450-3 TR4 and GC Pp-PaxQ TR4 based on the yield of 2. Yet, no new products 




M2 GC   1    2     3   M2 GC   4    5    6  7 
Metabolite 2 (3-deoxo-11-
dehydroxy-mutilin) 
Figure 4.16 Thin layer chromatography analysis of chemical extracts from A. oryzae 
transfromants showing no new pleuromutilin-related compound as the production of 
pleuromutilin precursor was retained. However, it is apparent that the production of 
metabolite 2 was low in extract 3 and 7. Sample 1-7: Chemical extract of A. oryzae 
GC Ff-P450-1 TR4, GC Ff-P450-2 TR4, GC Ff-P450-3 TR4, GC Ef-ltmP TR3, GC 
Ef-ltmQ TR4, GC Pp-PaxP TR3 and GC Pp-PaxQ TR4. M2: pleuromutilin precursor 
metabolite 2 (3-deoxo-11-dehydroxy-mutilin), GC: Chemical extract of A. oryzae GC 
TR5. 
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4.3.2.5 Expression analysis of A. oryzae GC transformants carrying fungal 
P450 genes 
Since the incorporation of fungal P450 genes in the secondary host A. oryzae GC failed 
to give new pleuromutilin derivatives, it was speculated that the lack of activity 
preventing the hydroxylation on the precursor molecule could be due to poor gene 
expression itself. There is a possibility that the P450 genes may not be expressed 
correctly in the A. oryzae GC host. Therefore, five transformants for each P450 gene 
were subjected to RT-PCR. The cDNA of each transformant was generated and used 
as a template to set up the standard RT-PCR reaction. Primers amplifying the coding 
region of the gene were designed to amplify the transgenes. Production of full length 
cDNA for the P450 genes was observed in all five transformants selected for each 
transformant strain except for A. oryzae GC Pp-PaxP and GC Pa-vrtK strains where it 
was present in 4/5 transformants (Figure 4.17). Therefore, despite no pleuromutilin 
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Figure 4.17 RT-PCR amplification products of P450 genes for cDNA from A. 
oryzae transformants. Lanes 1-5 contain RT-PCR product of: (A) Ff-P450-1 gene 
from cDNA of A. oryzae GC Ef-P450-1 TR3,4,5,7,8. (B) Ff-P450-2 gene from 
cDNA of A. oryzae GC Ef-P450-2 TR3,4,5,6,7. (C) Ff-P450-3 gene from cDNA of 
A. oryzae GC Ef-P450-3 TR2,4,5,10,11. (D) Ef-ltmP gene from cDNA of A. oryzae 
GC Ef-ltmP TR3,5,6,9,10. (E) Ef-ltmQ gene from cDNA of A. oryzae GC Ef-ltmQ 
TR3,4,7,8,9. (F) Pp-PaxP gene from cDNA of A. oryzae GC Pp-PaxP TR3,4,5,8,9. 
(G) Pp-PaxQ gene from cDNA of A. oryzae GC Pp-PaxQ TR4,5,8,9,11. (H) Pa-vrtK 
gene from cDNA of A. oryzae GC Pa-vrtK TR1,3,4,5,6. H: 5 μL of hyperladder I; 
C+: the same plasmid used for the transformation was used as the template; C-: 











Pleuromutilin and its derivatives suffer from rapid metabolism by cytochrome P450 in 
the liver. The developments of pleuromutilin antibiotics now are mostly aiming to 
achieve longer half-life and increase metabolic stability while retaining its bioactivity. 
This is with the ultimate goal to develop a pleuromutilin antibiotic that could be used 
orally and systematically in humans. Due to the versatile function exhibited by P450, 
it might be possible to use the enzyme to provide oxidation on the pleuromutilin core. 
The success of a similar strategy has been shown in synthesizing antibiotic molecule 
(Lu et al. 2007; Fujii et al. 2009). 
A. oryzae already carrying two genes GGS and Cyclase from C. passeckerianus was 
used as the secondary host throughout the work described in this chapter. Each of the 
P450 enzyme from different fungi was expressed separately in the host A. oryzae GC.  
It was hypothesized that at least one of these P450 enzymes could catalyze 
hydroxylation on the precursor compound. From the HPLC analysis, it appeared that 
only two strains, A. oryzae GC Ff-P450-1 and GC Ef-ltmQ were showing accumulation 
of new compounds. However, the two purified compounds showed no relation to the 
pleuromutilin chemical profile based on the 1H-NMR and they appeared to have only 
five and six carbons in the 13C-NMR whereas the pleuromutilin core should contain 20 
carbons.  Thus, it can be concluded that these compounds are not the product of the 
catalytic reaction of Ff-P450-1 and Ef-ltmQ enzymes on the precursor pleuromutilin.  
It was initially anticipated that the unsuccessful combinatorial biosynthesis was 
because the P450 enzymes were not expressed correctly in the host A. oryzae GC. Thus 
RT-PCR was performed on the cDNA of transformant strains showing the presence of 
the P450 genes to test whether all the genes were expressed correctly in the A. oryzae 
host. The P450 genes transcripts were detected in the majority of transformant strains 
confirming there was no issue with the gene expression. However, the level of 
expression of each gene was not analyzed in this study. It is possible that the lack of 
activity of the P450s was due to the low level of expression. In order to test this theory, 
RT-qPCR analysis should be performed on the cDNA of each transformant to measure 
the transcript abundance compared to a housekeeping gene such as b-tubulin.  
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It was noted that fewer than ten A. oryzae transformants were extracted and analyzed 
in HPLC in this study. It could be the number of transformants being screened was not 
sufficient to see any production of a converted molecule. A higher number of 
transformants would be needed to screen for a strain with a sufficiently highly-
expressed gene to accumulate a new compound. Practically, at least fifteen positive 
transformants should be tested to have a more reliable result. However, as described in 
the previous study of this thesis (Chapter 3), five transformants was sufficient to 
observe the accumulation of a new compound. Thus, it is doubted that more 
transformants are needed for this study. 
Other speculation could be the proteins could not recognize the pleuromutilin precursor 
as a substrate, hence no enzymatic reaction was catalyzed on the precursor molecule 
leading to no modified metabolite being produced. Mafua et al. (2016) studied the 
enzymatic reaction of ent-kaurene oxidase (KO) from different plant species on ent-
kaurene analogs. According to their report, the KO from Oryzae sativa appeared to 
have strict activity on only ent-(iso)kaurene, although the same enzyme from 
Arabidopsis thaliana was able to accept ent-(iso)kaurene as substrate. This result might 
reflect the failed attempt of oxidative P450 to hydroxylate premutilin possibly due to 
the strict substrate specificity exhibited by the enzymes. 
It is possible that the heterologous P450s do not function properly in the expression 
system. This often happens when genes from basidiomycetes are expressed in 
ascomycetes due to the variances in the gene content. Besides, there is also a possibility 
that the genes may be considered as foreign by the host, leading to the degradation of 
the protein.  (Nakajima et al. 2012; Casado et al. 2016). However, the P450 genes used 
in this study were obtained from ascomycete fungi, minimizing the possibility of 
protein degradation. To assess this problem, RT-qPCR could be employed to 
quantitatively measure the gene expression. Alternatively, a fusion construct of P450 
with fluorescent reporters such as GFP would allow for visual determination of the 
problem via fluorescence microscopy. 
While TLC analysis of the transformant crude extracts still showed the production of 
the precursor 3-deoxo-11-dehydroxy-mutilin, two of the transformants, A. oryzae GC 
Ff-P450-3 TR4 and GC Pp-PaxQ TR4 show less production of precursor 2. Although 
no new product can be detected through HPLC, the low yield of 2 in the crude extracts 
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could suggest some of the compounds have been metabolized and modified, but the 
production might not be sufficient to be detected by the HPLC. It also possible that the 
transformation of P450s has an impact on the substrate supply. Use of a more sensitive 
detector such as liquid chromatography-tandem mass spectrometry (LC-MS/MS) could 
help in the detection of low yield compound. 
The potential toxicity of P450s has also been looked into further. Although expression 
of P450s from other fungi would be expected to introduce hydroxylation on the 
pleuromutilin core which should not produce any toxic product, there is a possibility 
that the heterologous P450s would hydroxylate other Aspergillus compounds which 
may produce toxic products. However, normal growth was observed in all of the 
transformants expressing the P450s, suggesting that the introduction of these genes was 
not detrimental to growth. Thus, the possibility of that toxic compounds were produced 
can be ruled out.  
The failure to establish a functional system for derivatization of pleuromutilin 
illustrates the challenge of using combinatorial synthesis in modifying a compound. A 
better understanding of the mechanisms of the enzymes used is essential to exploit the 
full potential of combinatorial biosynthesis and ensure the desired activities are 
achieved.
 112 
Chapter 5. Exploring combinatorial biosynthesis by heterologous 
expression of pleuromutilin and lepistal gene cluster  
5.1 Introduction 
Attempts to introduce various cytochrome P450s from different fungi into the 
pleuromutilin-producing fungus A. oryzae in the previous chapter failed to produce any 
new products. The presumed reason for failure was likely due to the enzyme-substrate 
specificity where the structure of the compound used by the P450s was different from 
pleuromutilin core. Thus, the possibility for the enzyme to accept the pleuromutilin 
precursor as the substrate was low. 
In this chapter, another attempt to modify pleuromutilin was performed involving the 
use of enzymes from the fungus Lepista sordida. A previous investigation by Banks 
(2016) identified a pleuromutilin-like gene cluster from the fungus through genomic 
analysis. Due to the high similarity of this cluster to pleuromutilin, it was anticipated 
that the enzymes involved in the cluster could catalyze reactions on pleuromutilin 
intermediates in a combinatorial study. 
5.1.1 Background of Lepista sordida 
Lepista sordida is a basidiomycete from the Tricholomataceae and was first described 
in 1821 by Elias Magnus Fries. L. sordida was well known to cause ‘fairy ring’ disease 
on lawns which can develop either as rings of dark green and fast-growing grass or 
slow-growing or wilting turf (Terashima and Fujiie 2007). This is due to the excessive 
accumulation of nitrogen in the soil as a result of the decomposition activity of the 
fungus. A large amount of nitrogen in the ground affects the growth of plants resulting 
in taller and darker plants. 
Among the Tricholomataceae family, Lepista sp. are one of the most important 
members exhibiting potent activity against many bacterial and fungal species. In 
antimicrobial studies carried out by Banks (2016), this fungus revealed the inhibition 
of growth on several microorganisms including B. subtilis, E. coli, S. cerevisiae, K. 
pneumonia and S. aureus. The author also reported the inhibitory effect of L. sordida 
against several soil-dwelling bacteria of Bacillus sp.  
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L. sordida was described to produce compounds with antimicrobial, anticancer and 
antitumor properties. Mazur et al. (1996) isolated two active metabolites, lepistal and 
lepistol from a German isolate of L. sordida and these were shown to have cytotoxic 
activity on human promyelocytic leukemia (HL-60) and human histiocytic lymphoma 
(U 937) cells. In addition, lepistal was also active against Streptomyces sp. ATCC 
23836, Bacillus subtilis, Rhodotorula glutinis, Saccharomyces cerevisiae S288c, 
Penicillium notatum, Fusarium oxysporum, Muco miehei, and Nematospora coryli. 
Futhermore, Luo et al. (2012) and Miao et al. (2013) reported that polysaccharide from 
this fungus exhibited potent immunoregulatory effects on macrophages and could 
induce apoptosis. Meanwhile, a few other studies also described the production of new 
metabolites from the basidiomycete such as lepistatins A-C, lepistamides A-C and a 
known diatretol (Chen et al. 2011; Kang et al. 2017). Figure 5.1 shows the metabolites 
that have been isolated from the fungus L. sordida.  
 
Figure 5.1 Chemical structure of metabolites isolated from L. sordida 
 
5.1.2 The diterpene gene cluster from L. sordida 
Genomics analysis has revolutionized the way in which the research on secondary 
metabolites biosynthesis is accomplished. The advance in next-generation sequencing 













Lepistamide A, R1= Me, R2= H
Lepistamide B, R1=R2= H


































the identification of gene clusters encoding the biosynthesis of specific classes of 
secondary metabolites. By sequencing the whole genome of the fungus, it can uncover 
the full inventory of all biosynthetic gene clusters. Examples of successful 
identification of secondary metabolite gene clusters through the whole genome 
sequencing include the discovery of the paxilline gene cluster from P. paxilli (Saikia 
et al. 2007), viridicatumtoxin and griseofulvin from P. aethiopicum (Chooi et al. 2010), 
and gibberellin from F. fujikuroi (Tudzynski and Hölter 1998). 
Recently, the genome sequence of L. sordida has been assembled by Banks (2016). 
Based on analysis through the antibiotic and Secondary Metabolite Analysis SHell 
(antiSMASH) and local BLASTable databases, 14 putative terpenoid gene clusters 
were detected in L. sordida. As it has been reported that this species produced diterpene 
lepistal and lepistol (Mazur et al. 1996),  candidate genes related to diterpene 
biosynthesis were searched for in the L. sordida genome sequence. Through such 
analysis, a full diterpene gene cluster was identified from the genome sequence of this 
fungus. Interestingly, the identified diterpene gene cluster contains the same genes as 
pleuromutilin genes including GGS, Cyclase, three cytochrome P450, ATF and SDR. 
The high similarity between the two clusters was not only in the order and orientation 
of the genes but also in the distribution of introns within each gene.  Figure 5.2 shows 
the putative diterpene gene cluster from L. sordida and the pleuromutilin gene cluster 




Figure 5.2 A. Putative diterpene gene cluster from L. sordida (Banks 2016) B. 
Pleuromutilin gene cluster from C. passeckerianus. The two gene clusters show the same 




Due to the high similarity between the two biosynthesis gene clusters, it was anticipated 
that the enzymes encoded by the genes from both clusters would be functionally 
interchangeable so could accept intermediates produced by the other cluster. As has 
been described by Eustaquio et al. (2004), enzymes from related pathways could be 
exchanged resulting in novel compounds. Eustaquio et al. (2004) replaced the novO 
gene with halogenase clo hal-, which gave novel novclobiocin in Streptomyces 
spheroides. 
Although the previous attempt to modify pleuromutilin precursor using P450s from 
other fungi failed as described in the previous chapter, it would be interesting to see if 
enzymes from such a closely related pathway could biosynthesize novel pleuromutilin-
like products. 
5.2 Aims 
The works described in this chapter aimed to biosynthesize novel pleuromutilin 
derivatives through a combinatorial approach. By exploiting the premutilin-producing 
A. oryzae as a host, it was investigated whether the enzymes encoded by the presumed 
lepistal gene cluster from L. sordida could replace pleuromutilin precursor enzymes 
and further modify the pleuromutilin core.  
Banks (2016) tried to detect lepistal from the L. sordida extract, but the attempt failed 
to detect the compound. It is unknown whether this fungal strain is making diterpene 
lepistal or other terpenes that could be associated with the diterpene gene cluster 
identified in this fungus. Thus, reconstruction of lepistal biosynthetic pathway in A. 
















5.3.1 Recreating lepistal biosynthetic pathway in A. oryzae 
The pleuromutilin-like biosynthetic gene cluster from L. sordida revealed the presence 
of seven genes, Ls-GGS, Ls-cyclase, three Ls-P450, Ls-ATF and Ls-SDR. In addition 
to the cluster, FAD-dependent oxidoreductase, hypothetical and tRNA structural genes 
were also found upstream and downstream of the diterpene cluster. RNA-seq analysis 
done by Dr. Alice Banks allowed the detection of intron sites to help determine the 
full-length cDNA for each gene of interest (Banks 2016) (Table 5.1). Synthetic 
versions of cDNA for each gene were obtained from Invitrogen GeneArt Gene 
Synthesis in plasmids also carrying a gene coding for ampicillin resistance in E. coli.  
 
Table 5.1 A summary of genomic analysis for seven genes of pleuromutilin-like gene 
cluster from L. sordida (Banks 2016). 
Amplified gene gDNA length (nt) 
cDNA length 
(nt) 
Ls-GGS 1501 1218 
Ls-Cyclase 3073 2919 
Ls-P450-1 2234 1668 
Ls-P450-2 2374 1446 
Ls-P450-3 2656 1239 
Ls-SDR 960 612 
Ls-ATF 1314 1149 
 
The seven synthetic genes were constructed in two independent expression vectors 
through yeast homologous recombination. Four genes Ls-GGS, Ls-cyclase, Ls-P450-
3 and Ls-ATF were built in the pTYGSarg backbone while the other three genes, Ls-
P450-1, Ls-P450-2 and Ls-SDR were assembled in pTYGSade. The construction of 
the two plasmids was carried out previously by Dr. Alice Banks. Correct construction 
of the plasmids was confirmed by enzyme digestion using BglII enzyme which gave 
expected fragments of 2198, 6009 and 12 191 bp for pTYGSarg Ls-GCP3A and 1458, 


















Figure 5.3 A-I. pTYGSarg Ls-GCP3A plasmid map. This plasmid was built from the 
backbone pTYGSarg to contain four synthetic genes, Ls-GGS, Ls-Cyclase, Ls-P450-3 and 
Ls-ATF from L. sordida. B-I. pTYGSade Ls-P1P2S plasmid map constructed from the 
backbone pTYGSade carrying three synthetic genes, Ls-P450-1, Ls-P450-2, Ls-SDR from 
L. sordida. Restriction enzyme digestion of plasmids using BglII showed the correct 
construction of plasmid pTYGSarg Ls-GCP3A and pTYGSade Ls-P1P2S as presented in 
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5.3.1.1 Co-transformation of lepistal genes into A. oryzae 
Both plasmids were initially co-transformed in A. oryzae NSAR1 exploiting the 
selectable marker argB and adeA. A mixture ratio of 1:1, 7:3 and 8:2 for a final volume 
of 10 µL of pTYGSarg Ls-GCP3A:pTYGSade Ls-P1P2S plasmids were used to 
transform into A. oryzae NSAR1. The plasmids mixture ratio of 1:1 and 7:3 however, 
did not give stable fungal transformants, and thus were discontinued. The 8:2 plasmid 
ratio was able to generate 12 transformants which were called A. oryzae coLs-7. 
However, it was noted that although stable transformants were rescued, slow growth 
was observed in most of the transformant strains and the formation of hyphae was 
somewhat retarded. This could be due to the incompatibility of the plasmids to be co-
expressed together in the same machinery, generating weak transformant strains. PCR 
screening was carried out on the gDNA of the transformants to test for the presence of 
lepistal genes. Among the 12 transformants, only five transformants A. oryzae coLs-7 
TR1, 5, 6, 7 and 12 showed the presence of Ls-GGS in the first screening (Figure 5.4). 
Nevertheless, further PCR amplification on the five transformant colonies revealed that 
Ls-cyclase was missing from all the transformant strains though some of the 
transformants were still carrying Ls-P1, Ls-P2 and Ls-SDR. Due to the issues with 
fungal growth and lower number of transformants generated, a sequential 


















































H      1     2      3      4     5     6     7     8      9     10   11    12   C+  C- 
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H        1        5          6        7      12      C+     C-   
 
Ls-GGS 
             Ls-P450-1                             Ls-P450-2                         Ls-SDR 
             Ls-P450-3                             Ls-ATF                         Ls-SDR 
Ls-cyclase 
Figure 5.4 Gel photos showing PCR products of Ls-genes from gDNA of A. oryzae 
coLs-7 transformants. Ls-GGS amplification was carried out on the twelve 
transformants while PCR for the other genes was done only on positive transformants 
carrying Ls-GGS (TR1,5,6,7,12). Gene Ls-cyclase was missing from all the five 
transformants tested. H: Hyperladder, 1-12: gDNA of A. oryzae coLs-7 transformant 
was used as the template, C+: plasmid as the template (the same used for 






5.3.1.2 Sequential transformation of lepistal genes into A. oryzae 
Plasmid pTYGSade Ls-P1P2S was used to transform initially into A. oryzae NSAR1 
exploiting selectable marker adeA. Twenty-six transformants of A. oryzae Ls-P1P2S 
were rescued (Figure 5.5). Transformant 7, 16, 19, 20, 21 and 25 were shown to carry 
Ls-P450-1. Among the six transformants only three colonies, A. oryzae Ls-P1P2S 
TR20, 21 and 25 revealed the presence of other Ls-P450-2 and Ls-SDR genes.  A. 




    H    1    2     3     4    5    6    7     8    9  10   11  12   13  14   15  16  17   C+  C- 
   H   18  19   20   21  22  23   24  25   26  C+  C- 
   H     7     16   19    20   21    25   C+  C-   7   16   19    20    21  25   C+   C-    
Ls-P450-2 Ls-SDR 
Figure 5.5 PCR amplification products from gDNA of A. oryzae Ls-P1P2S 
transformant strains. In (A) shows the amplification products of Ls-P450-1. Lane 1-26: 
gDNA of transformants. In (B) PCR amplification of Ls-P450-2 and Ls-SDR was 
carried out on the positive transformants carrying Ls-P450-1 gene 
(TR7,16,19,20,21,25). Transformant 20,21,25 showed the presence of the three genes. 





Transformation of A. oryzae Ls-P1P2S TR20 with plasmid pTYGSarg Ls-GCP3A 
successfully generated 46 A. oryzae sLs-7 transformant colonies in several batches. 
PCR amplification of Ls-cyclase showed the presence of the gene in 13 transformants 
(Figure 5.6). Further screening for genes Ls-GGS, Ls-P450-3 and Ls-ATF on these 
transformants showed seven A. oryzae sLs-7 TR21, 22, 30, 42, 44, 45 and 46 contained 
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 H     15    21    22    30    32    33   35    38   42    43   44    45    46    C+   C- 
 H   15    21    22    30    32   33    35    38   42    43   44    45    46    C+   C- 
 H    15    21    22    30    32    33   35     38   42    43    44    45    46    C+   C- 
Figure 5.6 PCR results to test for the presence of Ls-GGS, Ls-cyclase, Ls-P450-3 and 
Ls-ATF from gDNA of A. oryzae sLs-7 transformant strains. (A) shows the amplification 
products of Ls-cyclase. Lane 1-46: gDNA of transformants. In (B, C, D) PCR 
amplification of Ls-GGS, Ls-P450-3 and Ls-ATF was carried out on the 13 transformants 
positive for Ls-cyclase gene. Transformant 21, 22, 30, 42, 44, 45, 46 show the presence 
of all four genes. H: Hyperladder; C+: pTYGSadeLs-GCP3A plasmid; C-: gDNA from 





5.3.1.3 Chemical analysis of the A. oryzae sLs-7 transformant strains 
The positive transformants (TR 21,22,30,42,44,45,46) carrying all the seven genes 
from L. sordida biosynthetic gene cluster were individually cultured in 100 mL CMP 
for 10 days and subjected to ethyl acetate extraction. Of the seven transformants, five 
(TR30,42,44,45,46) showed the presence of two distinct peaks at 5.73 and 7.01 min, 
while additional peaks were observed at 11.84 and 13.73 min in the transformant TR 
42 (Figure 5.7). However, the peak at 5.75, 11.84 and 13.73 min have been 
accumulated previously in other A. oryzae transformant strains generated in this study, 
having the same Rt and m/z values of 102, 576 and 600. This suggests they could be 
host-derived stress products resulted from the expression of foreign genes. 
Interestingly accumulation of metabolite at 7.01 min was also seen in L. sordida WT 
(Figure 5.7) thus it was possibly the product of the cluster. A large-scale extraction was 
carried out on one litre culture of TR42 grown for 10 days before being extracted using 
ethyl acetate. Attempts to purify the compounds was made using preparative HPLC. 
Roughly 0.9 mg of metabolite at 7.01 min, called Ls1, was successfully isolated 
through preparative HPLC. The ES- spectrum of the compound showed three m/z 
values thus making identification of the compound difficult. Further analysis was done 
using NMR. 
The quality of NMR data for metabolite Ls1 was very poor. It was anticipated that the 
metabolite was not a pure single compound but comprises multiple metabolites. This 
can be explained by the multiple m/z peaks present in the ES- spectrum. The 13C-NMR 
profile showed the presence of five major resonances at different chemical shift and 
undistinguishable small peaks resulting in difficulties to interpret the structure. Due to 










Figure 5.7 Total ion chromatograms of fungal extracts. A. Chromatogram of A. oryzae sLs-
7 TR42 is shown representing the other four transformants tested (TR30,44,45,46) which also 
showing similar chromatogram profile except for the accumulation of compounds at 11.84 
and 13.73 min (with *) B. L. sordida WT C. A. oryzae NSAR1 D. ES- spectrum of metabolite 
Ls1. Characterization of metabolite with * were not carried out. 
* * 
Ls1 
A. oryzae sLs-7 TR42 
L. sordida WT 









5.3.2 Expression of Ls-GGS and six pleuromutilin genes in A. oryzae 
A comparison of the pleuromutilin gene cluster and the putative lepistal gene cluster 
from L. sordida showed a high level of similarity in the order and orientation of the 
genes present (Banks 2016). The alignment of predicted proteins of GGS from both 
biosynthetic pathways in ClustalX revealed a highly homologous sequence was found 
between them as shown in Figure 5.8. Thus, the gene Ls-GGS was expected to be 
capable of synthesizing a diterpene precursor that could be accepted by pleuromutilin 
enzymes. To investigate the hypothesis, the Ls-GGS gene was introduced in A. oryzae 






Figure 5.8 Alignment of the predicted protein sequence of Ls-GGS from L. sordida 
(top sequence) and the pleuromutilin Pl-GGS protein sequence (bottom sequence). 
 
 
Plasmids harboring the three Pl-P450s, Pl-ATF and Pl-SDR were readily available 
from the previous study of Dr. Fabrizio Alberti. In order to express the new Ls-GGS 
gene, an expression vector carrying the Ls-GGS and Pl-cyclase has to be constructed. 
Backbone plasmid pTYGSarg with argB selectable marker was used and the two genes 
were put under the control of promoter adh and eno respectively. Primers PadhLs-
Ls-GGS    1 MRVPNLFLSYLRQVATDGTLSSCTGTKPRKQVSHLPFDGPDPTGQASIVNGDNYDRILEP 
Pl-GGS    1 MRIPNVFLSYLRQVAVDATLSSCSGVKSRKPVIAYGFDDS----QDSRVD-ENDEKILEP 
 
 
Ls-GGS   61 FDYYRHLLKGKSARTVLMQCFNQFLQLPDDWVTGVTKAIEDLHNASLLIDDIEDESALRR 
Pl-GGS   56 FGYYRHLLKGKSARTVLMHCFNAFLGLPEDWVIGVTKAIEDLHNASLLIDDIEDESALRR 
 
 
Ls-GGS  121 GQPSAHIKFGTALTINAGNLVYFTVLQDVYDLGMRVGGELTANDMACIYTEELIELHRGQ 
Pl-GGS  116 GSPAAHMKYGIALTMNAGNLVYFTVLQDVYDLGMKTGGTQVANAMARIYTEEMIELHRGQ 
 
 
Ls-GGS  181 GIEIWWRDHRSPPTVDQYVHMLEQKTGGLLRLGARLLQCHPSLDGRVDLSEISLRIGVYY 
Pl-GGS  176 GIEIWWRDQRSPPSVDQYIHMLEQKTGGLLRLGVRLLQCHPGVNSRADLSDIALRIGVYY 
 
 
Ls-GGS  241 QLRDDYINLMSTSYHDERGFAEDITEGKYTFPMLHSMKRSPDSGLREILDRKPADVASKK 
Pl-GGS  236 QLRDDYINLMSTSYHDERGFAEDITEGKYTFPMLHSLKRSPDSGLREILDLKPADIALKK 
 
 
Ls-GGS  301 GAIAIMHETGSLHATRNLLGAVRNDLGRLVAEQRGDNYAISAPLERFLEKLYKIE 
Pl-GGS  296 KAIAIMQETGSLVATRNLLGAVRNDLSGLVAEQRGDDYAMSAGLERFLEKLYIAE 
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GGS/TgpdALs-GGS were used to amplify Ls-GGS while Pl-cyclase was amplified 
using a pair of primers Peno-cyc/Teno-cyc. Yeast homologous recombination was then 
carried out to construct the plasmids. Restriction digestion of the plasmid with HindIII 
showed a correct construction of the plasmid, giving four distinct bands: 1221, 1680, 






















Transformation of plasmid pTGSargLs-GGS Pl-Cyc in A. oryzae successfully 
generated 20 transformants. Four transformants showing the presence of both genes 
through PCR amplification, as shown in Figure 5.10, were cultured in 100 mL CMP 







H       1        C 
Figure 5.9 A. pTGSargLs-GGS Pl-Cyc plasmid map. This plasmid carries two genes, 
Ls-GGS and Pl-cyclase. B. Restriction enzyme digestion of the plasmid using HindIII 
showed correct construction of the plasmid with the expected fragments of 1221, 1680, 
3954 and 9910 bp. H: Hyperladder; C: undigested plasmid; 1: digested plasmid with 
HindIII. 























   H    1      2     3     4     5     6     7     8     9     10   C+   C- 
     H   11    12   13   14   15   16   17    18   19   20   C+   C- 
 H    1     2     3     4    5     6     7     8     9    10   C+  C- 
      H    11   12   13   14  15   16  17   18   19   20   C+  C- 
A 
B 
Figure 5.10 PCR screening of A. oryzae LsG-PlC transformant strains. (A) the amplification 
products of Pl-cyclase while (B) showing the Ls-GGS PCR products. Lane 1-20: gDNA of 
transformants. H: Hyperladder; C+: plasmid pTGSargLs-GGS Pl-Cyc; C-: gDNA from A. 






The extracts of transformant 2, 4, 8 and 17 were tested for the production of precursor 
diterpene compounds. TLC analysis was used to test the transformant strains as they 
were expected to be making the same precursor as in the pleuromutilin pathway, 3-
deoxo-11-dehydroxy-mutilin (metabolite 2) due to the cyclization activity of the Pl-
cyclase. It has been reported previously that the precursor metabolite could not be 
analyzed in HPLC (Alberti 2015) thus TLC analysis was used. The extracts were run 
along with the extract of A. oryzae GC TR5 for comparison as it is known to make 
metabolite 2. The samples were developed in petroleum ether:ethyl acetate (8:2) and 
revealed that there was no accumulation of precursor 2 in the transformant extracts 
(Figure 5.11). However, a new spot with Rf = 0.6 can be observed in three out of four 
transformants. Attempt to purify the compound named metabolite lgpc1 was made 
from 1 L culture of A. oryzae LsG-PlC TR2. The purification of the compound carried 
out using 20x20 cm preparative TLC developed in the same solvent systems, 
successfully collected 0.8 mg of metabolite lgpc1. The NMR data of the compound 
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Figure 5.11 A. TLC plate of extracts from A. oryzae LsG-PlC TR2, 4, 8, 17. Three of 
the tested transformants were accumulating metabolite lgpc1. C1: purified precursor of 
pleuromutilin, C2: A. oryzae GC strain yyseharboring Pl-GGS and Pl-cyclase. 
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Although the structure of metabolite lgpc1 was not able to be elucidated, it was 
hypothesized that a product from the expression of Ls-GGS and Pl-cyclase. Thus, the 
other downstream six genes of pleuromutilin biosynthesis were further transformed 
into the A. oryzae LsG-PlC TR 17 strain using plasmid ptYGSadeP450s and 
pTYGSbarATFSDR that were used previously in chapter 3. The transformation gave 
rise to 11 transformants of A. oryzae LsG-Pl6. PCR screening was done only for the 
two genes that represent the two plasmids being transformed into A. oryzae LsG-PlC 
TR 17. Only two transformant strains were shown to carry the two transgenes based on 
the PCR amplification as shown in Figure 5.12. A 100 mL culture of each A. oryzae 












  H      1     2      3     4     5     6     7      8     9    10   11   C+ C- 
 H      1     2      3     4     5     6     7     8     9     10   11   C+ C- 
Pl-P450-3 
Pl-ATF 
Figure 5.12 PCR products of Pl-P450-3 and Pl-ATF amplification from A. oryzae LsG-
Pl6. Only two transformants A. oryzae LsG-Pl6 TR7 and TR10 were showing the 
presence of the two transgenes. Lane 1-11: gDNA of A. oryzae LsG-Pl6 was used as 
the template, H: Hyperladder, C+ (top): plasmid pTYGSadeP450s, C+ (bottom): 




Based on the total ion chromatogram of A. oryzae LsG-Pl6 TR7 and TR10, a new peak 
was eluted at 11.61 min in both transformant extracts (Figure 5.13). It was also noted 
that several small peaks were accumulated between 15-16 min which were not present 
in the wild-type A. oryzae, however the purification of these products was not pursued 
due to the low titre and the fact that they were very close to each other. Metabolites of 
A. oryzae LsG-Pl6 TR7 were extracted from a large-scale culture (1L). The compound 
at 11.61 min was isolated through preparative HPLC and 0.95 mg was collected. The 
metabolite was analyzed in NMR for characterization. 
 
Figure 5.13 depicted total ion chromatogram from A. oryzae LsG-Pl6 TR 7 against 
wild-type L. sordida and A. oryzae NSAR1. Metabolite lgpl6_1 was accumulated in 
the transformant strain. 
 
Metabolite lgpl6_1 exhibited a clean NMR profile suggesting a single compound was 
isolated. The 1H-NMR profile showed some similar characteristics with the data 
obtained from pleuromutilin analysis especially for the two doublet peaks observed 
between 3.5-4 ppm (Figure 5.14). Looking at the 13C-NMR data, only 17 carbon peaks 
were present in the spectrum despite 20 carbons should be seen for a diterpene. 
However, the carbons exhibited weak signals and the peaks were small. It is possible 
that there were additional signals that could be misinterpreted as background noise. 
Repeat analysis was done for the 13C-NMR but failed to get a better spectrum profile.  
Metabolite lgpl6_1 








Figure 5.14 NMR analysis of metabolite lgpl6_1 from A. oryzae LsG-Pl6 TR7. A. 
shows 1H-NMR profile which has similar characteristics with proton-NMR of 
pleuromutilin, B. presents the carbon signals exhibited by the metabolite. The 13C-
NMR demonstrated 17 carbon signals as opposed to 20 carbons contained by diterpene. 
 




5.3.3 Expression of Ls-cyclase and Pl-GGS genes in A. oryzae 
The next attempt of gene swapping was carried out by replacing the cyclase gene of 
pleuromutilin biosynthesis genes with cyclase from L. sordida. Alignment of the 
predicted protein sequence of cyclase from both diterpene pathways shows 83% 
similarity between them (Figure 5.15). The other six-genes of pleuromutilin synthesis 
were retained and transformed together with Ls-cyclase in A. oryzae. A new 
recombinant plasmid was constructed to contain Pl-GGS and Ls-cyclase based on 
pTYGSarg. Correct construction of the plasmid was confirmed by enzyme digestion 
using HindIII. Expected bands were observed in the gel photo showing the size of 3954 
and 12685 bp (Figure 5.16). 
Transformation of the plasmid into A. oryzae generated 34 transformants. The presence 
of both Pl-GGS and Ls-cyclase genes in the transformants was screened by PCR 
(Figure 5.17). Amplification of Pl-GGS was observed in most of the transformants. In 
contrast, only three transformants out of 34 (TR27,30,33) were shown carrying the Ls-
cyclase genes suggesting the instability of the gene in the transformant strains. 
Chemical extraction was carried out on 100 mL culture of these transformants. 
As described previously, the production of the pleuromutilin-related precursor 
compound could not be detected in LCMS. Thus, TLC analysis was carried out on the 
three transformant strains. The samples were developed in petroleum ether:ethyl 
acetate (8:2). Unfortunately, no new compound was detected that could be related to 
pleuromutilin (Figure 5.18). It was hypothesized that the genes might not be expressed 
correctly in the host. Due to the issue with missing Ls-cyclase and because of no 






Figure 5.15 Alignment of the predicted protein sequence of Ls-cyclase from L. sordida 
(top sequence) and Pl-cyclase from C. passeckerianus (bottom sequence) using 
clustalX. Both shared high similarity of sequence as shown in the black box. 
 
 
Ls-cyclase    1 MGLSEDLHTRARTLMQTLESALNTPGSRGIGTANPTIYDTAWVAMVSRTTGGTKTFVFPE 
Pl-cyclase    1 MGLSEDLHARARTLMQTLESALNTPGSRGIGTANPTIYDTAWVAMVSREIDGKQVFVFPE 
 
 
Ls-cyclase   61 SFSYIYENQEPDGSWAGDGSLIDSIVNTLACLLAFKIHESNATEPDIPSRARAAQKYLTD 
Pl-cyclase   61 TFTYIYEHQEADGSWSGDGSLIDSIVNTLACLVALKMHESNASKPDIPARARAAQNYLDD 
 
 
Ls-cyclase  121 ALKRWDIVETERVAYEMIVPCLLKELEGYDITFTFPHRDLLYNMYAGKLAKLNWEAIYAK 
Pl-cyclase  121 ALKRWDIMETERVAYEMIVPCLLKQLDAFGVSFSFPHHDLLYNMYAGKLAKLNWEAIYAK 
 
 
Ls-cyclase  181 NSSLLHCMEAFVGVCDFDRMPHLLRDGNFMATPSTTAAYLIKATKWDDRAEDYLRHVIDV 
Pl-cyclase  181 NSSLLHCMEAFVGVCDFDRMPHLLRDGNFMATPSTTAAYLMKATKWDDRAEDYLRHVIEV 
 
 
Ls-cyclase  241 YAPHGRGVVPNLWPMTFFEIVWALSSLYDNNLNFDQMDRDCLDRIARTLREYLVKGNGVY 
Pl-cyclase  241 YAPHGRDVVPNLWPMTFFEIVWSLSSLYDNNLEFAQMDPECLDRIALKLREFLVAGKGVL 
 
 
Ls-cyclase  301 GFVPGTTHDADMSSKTLMLLQVLDHPYSHDEFVAEFEAPTYFKCYSFERNASVTVNANCL 
Pl-cyclase  301 GFVPGTTHDADMSSKTLMLLQVLNHPYAHDEFVTEFEAPTYFRCYSFERNASVTVNSNCL 
 
 
Ls-cyclase  361 MSLLHAPDINKYESQIVKIATFVADVWWTSAGIVKDKWNVSEWYSSMLSSQALVRLLWEH 
Pl-cyclase  361 MSLLHAPDVNMYESQIVKIATYVADVWWTSAGVVKDKWNVSEWYSSMLSSQALVRLLFEH 
 
 
Ls-cyclase  421 GKGNLKSVSEELLARISMACFTMTSRILQNQKPNGSWGCAEETSYALITLANVASLPTCD 
Pl-cyclase  421 GKGNLKSISEELLSRVSIACFTMISRILQSQKPDGSWGCAEETSYALITLANVASLPTCD 
 
 
Ls-cyclase  481 LIRDQINKVIEDAKAFLTPIFYARPAATPEDRLWIDKVTYSVESFRDAYVVSALNVPIPR 
Pl-cyclase  481 LIRDHLYKVIESAKAYLTSIFYARPAAKPEDRVWIDKVTYSVESFRDAYLVSALNVPIPR 
 
 
Ls-cyclase  541 FDPASITTLPPVSQTLPKELSKFFGRLDWFKSAPEWRKLTWGIESALMGPELNRVPSLTW 
Pl-cyclase  541 FDPSSISTLPTISQTLPKELSKFFGRLDMFKPAPEWRKLTWGIEATLMGPELNRVPSSTF 
 
 
Ls-cyclase  601 ARAEKGEMGKWFKFLPYMTIAPSSLEGTPISAQGMLDVLVLIRGLYNTDDYLDMTLIKAT 
Pl-cyclase  601 AKVEKGAAGKWFEFLPYMTIAPSSLEGTPISSQGMLDVLVLIRGLYNTDDYLDMTLIKAT 
 
 
Ls-cyclase  661 GDELDELKKEINDLFADPNSFKELKEISDDRMPTHLEFIERFTYSFLDYPRIQLASDNDK 
Pl-cyclase  661 NDDLNDLKKKIRDLFADPKSFSTLSEVPDDRMPTHIEVIERFAYSLLNHPRAQLASDNDK 
 
 
Ls-cyclase  721 TILRSEIQHYFLSAIGQCEENILLRQRGTDALRHGTSHYRWTHFIGVDNVAGPIALSFAL 
Pl-cyclase  721 ALLRSEIEHYFLAGIGQCEENILLRERGLDKERIGTSHYRWTHVVGADNVAGTIALVFAL 
 
 
Ls-cyclase  781 CLLGHQINEERGTKDRVDVFPTPVLKYIFNDCMMHFGAFSRLANDLHSIPRDYREVNLNS 
Pl-cyclase  781 CLLGHQINEERGSRDLVDVFPSPVLKYLFNDCVMHFGTFSRLANDLHSISRDFNEVNLNS 
 
 
Ls-cyclase  841 VMFSEFTGPGSGTDTEKAREAALLELVKYERKATDDGFENLVGLLTPHVGSKRARDAINI 
Pl-cyclase  841 IMFSEFTGPKSGTDTEKAREAALLELTKFERKATDDGFEYLVKQLTPHVGAKRARDYINI 
 
 
Ls-cyclase  901 LRVTYLHTALYDDLGRLTRDDISNANSEYTNGKVTTNGNGTTNGNGITKRNGLKRESHGV 
Pl-cyclase  901 IRVTYLHTALYDDLGRLTRADISNANQEVSKG---TNGVKKANG---SATNGIK-----V 
 
 
Ls-cyclase  961 MTNGAKRIKTAA 

















































H         C         1 
 H    1    2   3   4    5   6   7    8    9  10  11  12 13 14 15  16  17  C+ C- 
 H   18 19 20  21  22  23  24  25 26 27 28  29 30 31  32  33 34  C+ C- 
A 
Figure 5.16 A. pTGSargPl-GGS Ls-Cyc plasmid map. This plasmid carries two genes, 
Pl-GGS and Ls-cyclase. B. Restriction enzyme digestion of the plasmid using HindIII 
confirmed correct construction of the plasmid with the expected fragments of 3954 and 
12685 bp. H: Hyperladder; C: undigested plasmid; 1: digested plasmid with HindIII. 
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Figure 5.17 PCR screening of A. oryzae PlG-LsC for the presence of Pl-GGS 
and Ls-cyclase genes. A. Amplification of Pl-GGS, B.  Amplification of Ls-
cyclase. Three transformants were screened positive for the presence of both 
genes (TR27, 30,33). 
Figure 5.18 TLC analysis was carried out on transformants of A. oryzae PlG-






A pleuromutilin-like gene cluster has been identified from L. sordida (Banks 2016). It 
has been speculated that the cluster could be associated with the biosynthesis of the 
diterpene lepistal (Banks 2016). Lepistal was reported made by L. sordida and 
exhibited strong anticancer properties (Mazur et al. 1996). The putative biosynthetic 
cluster has equivalent genes as in the pleuromutilin cluster containing seven genes of 
GGS, cyclase, P450-1, P450-2, P450-3, ATF and SDR. Although the gene cluster was 
hypothesized to be involved in lepistal biosynthesis, attempts to verify the role of the 
cluster has never been made, either by gene silencing or cloning into different hosts. 
Thus, to investigate this, the putative genes were transformed into the secondary host 
A. oryzae NSAR1 to recreate the biosynthetic pathway. A. oryzae NSAR1 has been 
shown to be a good system to allow expression of diterpene genes as described in the 
previous chapter.  
The synthetic genes of the putative lepistal cluster were constructed in two expression 
vectors and transformed into A. oryzae NSAR1. The initial attempt to co-express the 
two plasmids generated transformants in which most of them exhibited growth issues. 
Furthermore, the method was unable to produce strains that harbored all the seven 
genes. Perhaps the transformant strains are making something toxic which would 
explain the absence of some genes and impairment in the growth of the transformants. 
Isolation of the toxic intermediate compound either from the transformants, different 
heterologous hosts or from the wild-type L. sordida itself could be done to screen for 
the toxicity. It would be interesting to determine the cause of the toxicity, if detected, 
as this could lead to the development of antifungal compounds. 
The next attempt was to transform the plasmids into A. oryzae sequentially. 
Fortunately, seven transformants were successfully rescued, containing all the lepistal 
genes. Four new compounds were detected and subjected to purification. However, the 
incapability to isolate compounds eluted at 11.84 and 13.73 min for structure 
characterization due to the inconsistency of the production limiting progress. 
Furthermore, after checking the m/z value and comparing the results from HPLC 
analysis with the other A. oryzae transformants made during this study showed that the 
two compounds had been previously detected in the other samples. There is no doubt 
that these two peaks are not related to the product of seven genes but potentially a stress 
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compound made by the host. Metabolite Ls1 was purified through preparative HPLC 
and analyzed through NMR. The NMR data show that the metabolite Ls1 has five 
carbons which could not be a diterpene. The proton-NMR also was very complicated 
for analysis due to the high background. Thus, further characterization was not pursued.  
The chemical analysis failed to detect any compounds related to lepistal or other 
diterpenes in the samples, and this could have happened due to several reasons. 
Initially, it was anticipated that there was an issue with the expression of Ls-cyclase 
due to the expression vector pTYGSarg has to be modified in order to accommodate 
four genes in the plasmid. The Ls-cyclase was put under the control of amyB promoter 
replacing the ccdB gene which was used previously as part of GatewayTM cloning 
system. Such an arrangement has never been made previously in the pleuromutilin 
studies. However, this promoter was shown to work very well to drive the expression 
of aspyridone A and tenellin biosynthesis genes in A. oryzae (Heneghan et al. 2010; 
Wasil et al. 2013). Thus, there should be no problem to express Ls-cyclase under the 
control of amyB.  
Secondly, although several attempts to screen metabolites from local L. sordida strain 
were used in this study, they failed to show any detection of lepistal-related compound 
(Banks 2016), yet a German isolate of L. sordida was described to produce the 
metabolite (Mazur et al. 1996). In fact, lepistal has never been reported to produce in 
other isolates such as those from China and Korea (Chen et al. 2011; Kang et al. 2017). 
Thus, it may not be the case that the putative gene cluster identified from the local 
isolate was involved in the biosynthesis of lepistal. It could be speculated that the 
identified gene cluster was producing pleuromutilin due to the high similarity with 
pleuromutilin gene cluster. A mass search of pleuromutilin and its intermediates was 
performed by looking for the presence of m/z related to pleuromutilins in the mass 
spectrum data of L. sordida and A. oryzae expressing the lepistal gene cluster. This 
strategy however, failed to find any m/z value that could be related to pleuromutilin 
indicating the cluster is probably not involved in pleuromutilin biosynthesis.  
Throughout this study, HPLC was used to analyze the extracts of A. oryzae Ls-7 strains 
while in other studies, gas chromatography-mass spectrometry (GCMS) has been 
performed to detect diterpene compounds (Popova et al. 2010; Wang et al. 2018). 
While HPLC analyzes thermally unstable molecules, GCMS otherwise uses for the 
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analysis of volatile compounds. As most terpenes are volatiles, it may be worth running 
the transformants extracts in GCMS to screen for the production of lepistal or any 
diterpene-related compound that could be associated with the putative pathway product 
from L. sordida. However, to be noted without the availability of lepistal standard, the 
chemical screening for this compound would be challenging and isolation of expected 
lepistal, if present, would need to be carried out to identify the compound. 
Thirdly, there is a possibility that the genes in this cluster were wrongly predicted. 
Although RNAseq of L. sordida was available, mapping of the generated datasets on 
the genomic sequence was complicated due to the poor quality of genome assembly 
(Banks 2016). The high level of allelic variation may also be one of the contributing 
factors to the difficulties, which may lead to the misinterpretation of the cluster as well 
as possible mis-calling of exon-intron boundaries. As synthetic genes of L. sordida 
cluster were used in this study, it is important to efficiently recognize the exon-intron 
boundaries to ensure correct transcripts are produced and avoid the potential of 
producing defective proteins. It may be worth repeating the genome assembly using 
different parameters from the ones used by Banks (2016) to have a better reference 
genome for the mapping so that accurate prediction can be made. Otherwise, the 
biosynthetic genes can be amplified from the cDNA of L. sordida itself to avoid the 
misinterpretation of the exon-intron boundaries.  
The stepwise heterologous expression of putative lepistal gene cluster was initiallya 
done with the plasmid harboring the tailoring genes, P450-1, P450-2 and SDR. The 
expression of these genes could not allow for the production of any intermediate to be 
detected. As the expression analysis was not carried out, it is unknown whether the 
strain that was used for further expression of the second plasmid has a good expression 
for all the three genes. If the genes were not expressed, production of lepistal or other 
diterpenes would be not be observed after adding the second plasmid, and this would 
hamper the analysis. 
It was also hypothesized that the CMP medium used was not ideal for the accumulation 
of sufficient lepistal to be detected in the HPLC system. However, the same medium 
was used in the pleuromutilin studies of A. oryzae and shows abundant production of 
pleuromutilin suggesting a suitable environment condition was achieved to activate the 
promoters, thus the hypothesis can be ruled out. 
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The two genes of L. sordida, Ls-GGS and LS-cyclase were suggested to be the core 
synthesis genes encoding the enzymes responsible for the synthesis of the precursor 
compound based on the knowledge gathered from pleuromutilin studies. Ls-GGS was 
hypothesized to be responsible for the generation of GGPP while Ls-cyclase was 
suggested to be involved in cyclization of GGPP to the specific diterpene precursor.  
Due to the high homology of Ls-GGS and L-cyclase with the ones in the pleuromutilin 
gene cluster, a question was raised if the lepistal core genes are functionally 
interchangeable with Pl-GGS and Pl-cyclase. To investigate this, the next step in this 
study involved the construction of A. oryzae transformant strains harboring different 
combinations of pleuromutilin and L. sordida GGS and cyclase genes. Although the L. 
sordida putative biosynthetic pathway has failed to be recreated in A. oryzae, it was 
worth seeing if the GGS and cyclase from L. sordida could work together with either 
Pl-GGS and Pl-cyclase in order to create novel precursors. 
Homology analysis of the predicted protein sequence for GGS and cyclase genes in 
both diterpene pathways shows that GGS in lepistal and pleuromutilin cluster shares 
79% of sequence similarity while Ls-cyclase shows 83% homolog with Pl-cyclase. The 
first hybrid plasmid was prepared to contain Ls-GGS and Pl-cyclase and transformed 
into A. oryzae NSAR1. The hybrid expression was expected to be making 
pleuromutilin precursor as the cyclisation activity by Pl-cyclase was retained. 
However, no production of the precursor was detected in the TLC analysis, although 
low titre of a new product, lgpc1 was accumulated. Unfortunately, after purification, 
the NMR data of the new compound was too complex to be characterized due to the 
presence of impurities. It was anticipated at this stage that the precursor was produced 
but in a very low titre to be analyzed.  
Further transformation with the remaining six-tailoring genes of pleuromutilin was 
carried out on the A. oryzae strain harboring the two genes, A. oryzae LsG-PlC TR 17. 
Analysis of the LCMS shows the production of metabolite lgpl6_1. The 
characterisation of this product revealed that this metabolite possesses only 17 carbons 
instead of 22 carbons that should be contained by diterpene compound. Based on the 
number of carbons, it could be hypothesized that this compound is potentially a 
sesquiterpene although it is also possible that the number of carbon signals could be 
misinterpreted due to the small shifting peaks. Further analysis might need to be carried 
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out in order to elucidate the metabolite structure and confirm the hypothesis. A more 
sensitive NMR system such as the one operating at 600 MHz could be used to 
characterize the metabolite structure further or a larger volume culture could be set up 
to collect more compound lgpl6_1 from the A. oryzae transformant for chemical 
analysis. It would be interesting to elucidate the structure of the compound in the future 
and determine whether it could be connected to the expression of the hybrid genes. 
The second hybrid expression system carried Pl-GGS and Ls-cyclase as the core 
synthesis genes. The recombinant plasmid harboring the two precursor genes were 
initially expressed in A. oryzae NSAR1. TLC analysis of the transformants revealed no 
production of new compounds. It was suggested at this stage that the expression of Ls-
cyclase was at a very low level in the transformants. Furthermore, amplification of the 
Ls-cyclase gene can only be seen in three transformants even though it was carried by 
the same expression vector as Pl-GGS, which gene is present in most of the A. oryzae 
strain. Due to the failure to produce any precursor, the next step to transform the other 
five genes of pleuromutilin was not pursued. However, it is worth to check the 
expression level of Ls-cyclase as it was hypothesized that the failure to produce 
precursor compound was caused by the poor expression of Ls-cyclase. Furthermore, a 
higher number of transformants might need to be generated that carry both of the genes 
to screen for the production of the precursor. At least 15 positive transformants 
harboring the genes need to be screened to have a reliable outcome. But again in the 
previous Chapter 3, although only a few transformants were screened, the detection of 
the new compound was achieved in most of the samples. 
From these results, it was suggested that the two core synthesis genes, GGS and cyclase 
from lepistal and pleuromutilin biosynthetic pathways could only function effectively 
in specific pathway contexts and do not fit together universally. As shown by Menzella 
et al. (2005) who expressed 154 gene combinations from eight PKS pathways in E. 
coli, more than half of the gene combinations failed to mediate biosynthesis of new 
polyketides. Moreover, it is common in many biosynthetic pathways, where different 
enzymes may combine to form one functional multi-enzyme complex, working 
together to biosynthesize the products of the pathway. For instance, in the biosynthesis 
of a lipid, a multi-enzyme complex involving malic enzyme, fatty acid synthase, ATP: 
citrate lyase, acetyl-CoA carboxylase, pyruvate carboxylase and malate dehydrogenase 
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is formed during the lipid accumulation phase (Shuib et al. 2018). Inactivation of one 
enzyme likely inactivates the unit as a whole.  
As lepistal has never been identified in the L. sordida strain used in this study, it is 
unknown whether the diterpene biosynthetic genes found in this fungus could be linked 
to lepistal. There is a possibility that the gene cluster is non-functional as 
polymorphisms have been reported in many other clusters including the gibberellin 
gene cluster in Fusarium oxysporum, the fumonisin gene cluster in Fusarium fujikuroi, 
the aflatoxin gene cluster in Aspergillus flavus (Lind et al. 2017) and the bikaverin gene 
cluster in Botrytis cinerea (Campbell et al. 2012). A similar scenario was described by 
Campbell et al. (2012). They discovered two biosynthetic clusters highly similar in 
sequence with the same gene order and orientation in two unrelated fungi B. cinerea 
and Fusarium spp (F. fujikuroi, F. oxysporum and F. verticillioides). The cluster 
identified in B. cinerea however, was not functional. Based on the synteny 
conservation, nucleotide composition, and phylogenetic analyzes of the cluster genes, 
it was found that some of the genes in the bikaverin cluster were pseudogenes. This 
result supports the possibility that the lepistal gene cluster found in L. sordida could be 
non-functional. However, further analysis as shown by Campbell et al. (2012) needs to 





Chapter 6. Discussion 
Since the golden age of antibiotics, the selection pressure placed on bacteria has led to 
many isolates showing high levels of resistance to the commonly used antibiotics. As 
the number of resistant bacteria has rapidly escalated, there are urgent needs to develop 
new antibiotics to combat resistance. One potential resource for drug development is 
natural products from fungi. Among the fungi species, basidiomycetes hold an 
excellent biological source of new compounds with promising antimicrobial activities 
such as the diterpene pleuromutilin.   
Pleuromutilin was discovered from the basidiomycete Clitopilus passeckerianus 
(Kavanagh et al. 1952). The pleuromutilin characterized by a tricyclic diterpene core 
inhibits the formation of peptide bonds between amino acids by binding to a specific 
domain of the 50S ribosome subunit which is responsible for peptidyl transferase 
activity (Davidovich et al. 2007). This binding was unique in contrast to other 
antimicrobial agents and probably best explains why pleuromutilin has lack of cross-
resistance with the other antibiotics. Given the potential of pleuromutilin to be 
developed as new drugs, it is important to have a comprehensive knowledge of how 
this antibiotic was biosynthesized in the native host. Most of the newly developed 
derivatives were synthesized in a very low yield. Thus, a more efficient way needs to 
be developed to scale up the pleuromutilin intermediates from the fermentation culture. 
It is crucial to understand the biosynthetic pathway of pleuromutilin for the effective 
production of metabolites to be used as starting material in the synthetic studies.  
Although reconstruction of the biosynthetic pathway responsible for pleuromutilin 
production has been achieved (Alberti et al. 2017), the knowledge is still limited to a 
linear pathway. As seen in other terpene biosynthetic pathways, a shunt pathway is 
often present (Saikia et al. 2007; Saikia et al. 2012). In order to identify gaps in the 
knowledge on the biosynthesis of pleuromutilin, the first aim of this PhD project was 
to use a heterologous host system that expresses sets of genes lacking one pleuromutilin 
gene. This approach could generate the same result as gene deletion in the antibiotic-
producing fungus and allows one to find any alternative routes to pleuromutilin 
formation. 
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The second aim of this thesis was to investigate the potential of pleuromutilin 
derivatization from a combination of biosynthetic genes of pleuromutilin and genes 
from other diterpene pathways. This approach has been widely used to synthesize other 
desired metabolites (Menzella and Reeves 2007) and would potentially modify 
substituent groups on the pleuromutilin core.  
6.1 Improving knowledge on pleuromutilin biosynthesis 
A rational approach to the improvement and development of new pleuromutilin drugs 
requires an understanding of the biosynthetic pathway and identification of the reaction 
steps that may be susceptible to manipulation. To date, a pleuromutilin biosynthetic 
gene cluster consisting of seven genes was identified (Bailey et al. 2016). The 
characterization of each gene has led to the accumulation of pleuromutilin 
intermediates along the pathway by heterologous expression (Alberti et al. 2017). Four 
classes of the enzyme involved in the pleuromutilin biosynthetic pathway; terpene 
cyclase, P450 monooxygenases, acetyltransferase (Pl-ATF) and dehydrogenase (Pl-
SDR). The precursor compound was synthesized by cyclization of GGDP catalyzed by 
two terpene synthesis enzymes, Pl-GGS and Pl-cyclase. The involvement of two P450 
enzymes has been shown to hydroxylate C-3 and C-11, the other P450-3 adds hydroxyl 
on C22-acetate of pleuromutilin while Pl-ATF and Pl-SDR enzymes play a role in the 
addition of acetate group on C-14 and oxidation of C3-OH substituent respectively. 
In addition to the linear characterization, Alberti (2015) also suggested the presence of 
an alternative pathway in relation to the accumulation of a shunt product. However, no 
further investigation was attempted to study the other possible route that might arise 
from the linear pathway. In order to evaluate the presence of alternative routes that 
might lead to pleuromutilin formation, heterologous expression of selected 
pleuromutilin gene combinations in the secondary host A. oryzae was attempted to 
accumulate the intermediates. This approach has been undertaken previously to express 
pleuromutilin genes and it has proved to be efficient in producing intermediate 
products. The successful use of this strategy to study biosynthetic pathways has also 
been shown by other researchers like Tagami et al. (2014) and Fujii et al. (2011). In 
both cases, intermediates of the aflatrem and aphidicolin biosynthetic pathways 
respectively were obtained after expressing the desired gene combinations of 
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respective clusters which were cloned from the native aflatrem-producing Aspergillus 
flavus and aphidicolin-producing Phoma betae in the secondary host A. oryzae.  
Heterologous expression of the selected pleuromutilin genes was carried out in a 
premutilin-producing transformant of A. oryzae. The expression of six-genes of 
pleuromutilin pathway excluding the P450-1 and SDR in independent reactions, 
revealed two short shunt routes giving the intermediate metabolite 9 (11-
dehydroxyacetylmutilin) and 10 (3-hydroxyacetylmutilin). The enzymes involved in 
the new routes showed relaxed substrate specificity as they can use the shunt 
intermediates as the substrate except for the P450-3, which the last reaction catalyzed 
by this enzyme in the shunt pathway did not happen. To validate the results, appropriate 
substrates of the earlier-eluting products, intermediates 8 and 4, were fed individually 
to A. oryzae harboring ATF and P450-3 (AP3) to test if the P450-3 was functioned to 
initiate hydroxylation. A parallel experiment was also set up using mutilin 5 as a 
control. Again, no 22-hydroxylated compound can be detected from the AP3 culture 
supplemented with either 8 and 4, instead metabolites 9 and 10 which lacking 22-OH 
were synthesized as before. In contrast, pleuromutilin (a 22-hydroxylated product) was 
produced by the AP3 culture fed with mutilin 5 indicates that the P450-3 is working 
which rules out the initial hypothesis that it was inactive. 
It is possible that the P450-3 enzyme might have stringent substrate specificity and 
does not recognize the metabolites other than 14-acetylmutilin 6, which blocks the 
conversion to the final product. Many studies have reported the flexibility of P450 
enzymes towards various substrates (Durairaj et al. 2016), though the substrate 
structural requirements sometimes are strict for some enzyme and could impact the 
substrate-enzyme binding. A study reported the importance of the carboxyl group of 
benzoate to positions the molecule into the active site of CYP51A. Lacking this feature 
or having the carboxyl further away from the aromatic ring would bearing the effective 
substrate binding (Podobnik et al. 2008). Moreover, the side substituents also greatly 
influence the substrate conversion. As shown by Faber et al. (2001), only restricted 
number of benzoate derivatives were being oxidized by CYP51A which mostly having 
smaller substituent like fluoro-, methyl- and hydroxyl-while bulkier side like methoxy- 
however, was not able to act as the CYP51A substrate. These studies may shed some 
light on why there was no 22-hydroxylated product could be detected when either 3-
 145 
carbonyl or 11-hydroxyl was absent. P450-3 might requires both groups to have a tight 
binding of the substrate on the active site. This hypothesis however, would still need 
to be investigated further.  
Another assumption could be made from the feeding study is the expression of P450-
3 might not be up to the level that was sufficient to catalyze a reaction on the substrate. 
This is based on the previous investigation by Alberti (2015) on the enolase promoter 
showing that it exhibited weak catalytic activity to drive the expression of the 
pleuromutilin gene. This could be the reason why only partial conversion of 6 to 
pleuromutilin can be observed in the strain expressing 7-genes of pleuromutilin. As the 
same promoter was used to drive the expression of P450-3 in the shunt pathway study, 
the similar problem may arise, hampering the results. Several experiments could be 
done in the future in order to further investigate P450-3 before concrete conclusions 
can be made upon its inefficient activity. The use of a stronger promoter like the one 
for P450-1 (alcohol dehydrogenase) could be used to drive high levels of P450-3 
expression and would likely increase the chance to accumulate a detectable yield of 
22-hydroxylated shunt product. Such strategy has been used by Zhou et al. (2014) who 
used a super-strong promoter Pcpc560, driving the expression of heterologous genes in 
the cyanobacterium S. 6803 with yield increases up to 15%. Besides that, it is worth to 
investigate the function of other P450-3 from different allele in the genome of 
pleuromutilin-producer C. passeckerianus as it has never been clearly understood why 
it present in the genome (Alberti 2015). Although these P450-3s have shown to have a 
high similarity of protein sequence, it is possible that the proteins would have a 
different level of activity as shown by Zhang et al. (2015) for BrAOP2 from Brassica 
rapa. They found an increased level of expression was detected in BrAOP2.1 at the 
seedling stage compared with the other two copies of the same gene. Thus, even though 
it was known that the P450-3 used in this study was functional, it was not very efficient. 
It may be worth expressing the other allelic version of P450-3 in order to test if it could 
exhibit a higher level of expression. 
Apart from the investigation to omit P450-1 and SDR from the pleuromutilin 
biosynthetic genes, an attempt was also made to omit P450-2 in the A. oryzae 
expression system. However, the transformants harboring the pleuromutilin 
biosynthetic pathway without the P450-2 failed to produce the expected compound, 
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giving only precursor 2. Since very few transformants were generated from this 
experiment, a conclusion whether this route which bypasses the P450-2 could be 
followed cannot be drawn.  
While the function of each gene has been characterized and two shunt pathways have 
been described through the work in this thesis, the order of the tailoring reaction is yet 
to be confirmed. For some genes like SDR and P450-3, both were always known to act 
after P450-2 and in the last step of the pathway respectively. However, for gene P450-
1, P450-2 and ATF, it is still uncertain which enzyme act first and there is a possibility 
that ATF could also modify the premutilin due to its broad substrate specificity. In 
order to investigate this, an expression system carrying GGS, cyclase and ATF could 
be generated. If an acetylated product is obtained, it can be fed back to A. oryzae 
harboring P1 or P2 alone to see if a further conversion can be observed. Alternatively, 
a feeding study could be set up for A. oryzae harboring P450-1 alone and supplemented 
with the shunt product, metabolite 9 to test if the hydroxylation on C-11 can still occur. 
It will give an idea whether P450-1 could act at the later stage in the pathway. The 
same method has been used extensively in the past to generate intermediates and 
validate the proposed steps of a biosynthetic pathway, for instance, to define the 
biosynthesis of paxilline, several proposed paxilline intermediates were fed to P. paxilli 
deletion mutant strains lacking either paxQ or paxP, and this has confirmed that the 
substrates involved in the paxilline biosynthetic pathway (Saikia et al. 2007). 
Looking at the yield of the pleuromutilin precursor 2 from A. oryzae GC strain, it can 
be concluded that this expression system was efficient enough to synthesize the other 
intermediate products along the pathway. However, further modification could be 
made to improve the yield and subsequently increase the titer of pleuromutilin and its 
intermediates. As described in Chapter 3, the same enolase promoter as for P450-3 was 
used to drive the expression of cyclase and it is thought that this promoter possessed 
weak activity. Replacing with a stronger promoter would be an option which might 
lead to an increased yield of pleuromutilin. 
Ultimately, this work allowed identification of two pleuromutilin biosynthetic shunt 
pathways alongside the linear route which had been reported previously. An improved 
understanding of the reaction mechanism of pleuromutilin biosynthesis was achieved. 
However, more studies need to be done in the future to expand the knowledge of 
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biosynthesis of pleuromutilin. It is critical to have a detailed picture of a biosynthetic 
route, for this would be useful in the manipulation of the pathway.  
6.2 Reconstruction of the putative lepistal biosynthetic pathway 
A cluster with seven biosynthetic genes and highly similar in sequence and order to 
pleuromutilin cluster was identified from the unrelated fungus L. sordida. This cluster 
was hypothesized to produce the diterpene lepistal based on the previous report by 
(Mazur et al. 1996). Due to inability to detect any lepistal-related compound from the 
native fungus L. sordida, reconstruction of the biosynthetic pathway was attempted in 
A. oryzae.  
The reconstruction of the lepistal biosynthetic pathway in A. oryzae however failed to 
deliver any detectable compound related to lepistal or other diterpenes such as 
pleuromutilin. There are a number of conclusions that could be made from this result. 
Firstly, it was anticipated that inefficient transformation systems generated too few 
transformants to have any that make the diterpene compound. In this study, only seven 
transformants were confirmed to have the seven genes of lepistal cluster and analyzed 
for the metabolite production. To screen for the production of diterpene in heterologous 
systems, a higher number of transformants usually 15+ strains needed to be tested 
before a firm conclusion can be made.  
Secondly, the stepwise heterologous expression of putative lepistal gene cluster was 
done starting with the plasmid harboring the tailoring genes, P450-1, P450-2 and SDR 
and not the core synthesis genes. The expression of these genes could not allow for the 
production of any diterpene intermediate to made. As expression analysis was not 
carried out, it is unknown whether the strain used for further expression of the second 
plasmid has a good expression for all the three genes. If the genes were not express, 
production of lepistal or other diterpenes would be not be observed after the second 
plasmid transformation and this will hamper the analysis. A qRT-PCR could be carried 
out to test for the level of genes expression and would confirm if the lack of products 
detection was due to the problem with gene expression.  
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Furthermore, if good expression was achieved, there is a possibility that the production 
of the end product could be very low and not accumulating at a level that could be 
detected in the HPLC system. Alternatively, a more sensitive detector, for instance, 
LC-MS/MS could be used as this system has the function of MS/MS which could 
provide sensitivity up to ng/mL of compound concentration. Otherwise, GCMS can be 
performed if volatile diterpenes are produced as it has been proved to be able to detect 
a wide range of diterpene compounds in many other natural product studies (Popova et 
al. 2010; Wang et al. 2018).  
While the RNAseq data of the putative lepistal gene cluster confirmed the expression 
of the biosynthetic genes, attempts to map RNAseq data on the genomic sequence of 
L. sordida was difficult. This is due to the poor quality of genome assembly and could 
lead to the misinterpretation of the genes and also exon/intron boundaries (Banks 
2016). Basidiomycete genomes are often difficult to assemble if based on the dikaryotic 
starting material, as there are high numbers of SNPs between the two alleles for each 
locus. Since synthetic genes were used in this study, it is important to correctly predict 
the exon/intron boundaries to avoid defective proteins being produced. Repeating the 
genome assembly with altered parameters would provide a better reference genome 
data which could be used to map with RNAseq. This is to have an accurate prediction 
for the genes to be made. Instead, amplification of the genes from cDNA of L. sordida 
could be carried out and would ensure coding sequence of the genes were amplified.   
To be noted, the growth of most transformants strains harboring the seven genes from 
lepistal cluster was somewhat retarded, possibly indicating toxic compounds are 
produced. A toxicity test could be done on the extract from the native fungus L. sordida 
or A. oryzae transformants expressing the lepistal gene cluster. If the extracts are 
confirmed to present the toxic compound, purification of related metabolites could be 
attempted to deduce their structure. Further analysis could then be done to determine 





6.3 Attempts for further derivatization of pleuromutilin 
Pleuromutilin products undergo commercial drug development through chemical 
modification, especially on the C-14, to improve activity prior to commercialization. 
An alternative way of obtaining new pleuromutilin analogs is through combinatorial 
biosynthesis where selected biosynthetic genes of pleuromutilin can be replaced with 
genes of related functions from other diterpene pathways in the secondary host A. 
oryzae. This approach has already been adopted for other antibiotics development and 
has achieved a successful outcome, for example in the biosynthesis of novobiocin and 
clorobiocin derivatives. By combining the clohal gene from clorobiocin gene cluster 
with novobiocin biosynthetic genes, several hybrid compounds were produced  
(Eustáquio et al. 2003; Eustaquio et al. 2004).   
In this thesis, the initial derivatization attempt was focused on introducing hydroxyl 
groups on the premutilin core at different carbon position by using P450 enzymes from 
other fungal species. Enzymes from this family are widely distributed across fungal 
species and can be found involved in many secondary metabolite biosynthetic pathway 
including pleuromutilin (Chooi et al. 2010; Lin et al. 2015; Bailey et al. 2016). The 
P450 enzymes are known for their multi-function and flexibility so they might accept 
a broad spectrum of substrates (Durairaj et al. 2016). Due to the limited pleuromutilin-
like pathway could be found in nature, P450s involved in various diterpene biosynthetic 
pathways were chosen randomly for gene swapping in this investigation. To increase 
the chances of the substrate being modified by the P450s, the gene was expressed 
individually in the premutilin-producing A. oryzae harboring the synthesis genes of 
pleuromutilin (GGS and cyclase). This core premutilin 2 has the lowest number of 
hydroxyl substitutions of the premutilin core leaving more positions for the P450s to 
act on. 
Unfortunately, the chemical analysis of the positive A. oryzae transformants revealed 
no detectable modified premutilin.  It was shown from the TLC analysis that the 
production of premutilin 2 was retained in the transformants indicating further catalytic 
reaction by the P450 did not happen. The initial assumption was that these P450s were 
not expressed, however RT-PCR confirmed most of the inserted P450s were expressed 
in the transformation system, although the level of expression was not certain. It is 
possible that the P450 genes were expressed at a very low level in the transformation 
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system, hence yielded an undetectable product. However, it also must be noted that in 
Chapter 3, although a lower number of transformants were obtained, novel 
pleuromutilin derivatives can still be detected in at least three of the transformants. 
It was also hypothesized that the P450 enzymes might not recognize premutilin as the 
substrate due to the structural differences between the premutilin and the native 
diterpenes produced by the selected biosynthetic pathways. As described previously 
the chemical structure of a substrate plays a significant role in the enzyme uptake. 
Structure variations even in a slight difference may sometimes affect the activity of the 
enzyme in the sense that the substrate wouldn't fit the active site on the enzyme and 
subsequently not be modified. Another example of similar scenario was reported in a 
study in which a cytochrome P450 from Pinus taeda (PtAO) was independently 
expressed in sclareol-, cis-abienol- and manoyl oxide-producing yeast. No oxidized 
compounds were detected when PtAO was provided with sclareol and cis-abienol but 
three hydroxylated products were produced after the insertion of PtAO in manoyl oxide 
accumulating yeast (Ignea et al. 2015). The difference between sclareol and cis-abienol 
from manoyl oxide was solely on the 8-OH. This result demonstrated the influence of 
chemical structure on the enzyme activity.  
The second attempt for pleuromutilin derivatization involved manipulation of the key 
gene GGS and cyclase with the aim to biosynthesize new pleuromutilin precursors. To 
achieve this outcome, both genes were swapped with GGS and cyclase from the 
putative lepistal gene cluster in separate reactions. The genes shared high similarity of 
sequence based on the alignment of predicted proteins thus were expected to have 
similar purposes and would be functionally interchangeable. The gene combination of 
Ls-GGS/Pl-cyclase and Pl-GGS/Ls-cyclase were transformed into A. oryzae NSAR1. 
Further insertion of the other five genes of pleuromutilin biosynthetic cluster would 
then be carried out if a precursor was produced. One new product was able to be 
identified from the gene combination of Ls-GGS and the other six genes of 
pleuromutilin cluster, but disappointingly the NMR analysis revealed that it was not a 
diterpene but may be a host-derived sesquiterpene and obviously not the product 
resulted from the transgene expression. It can be inferred that A. oryzae has a gene 
cluster which produces this sesquiterpene compound. Recent genomic analyzes have 
revealed a large number of secondary metabolite gene clusters in the A. oryzae genome 
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and a number of sesquiterpenes have been reported so far being produced by this 
fungus for example astellolides and sesquiterpene alcohols (Wada et al. 1983; 
Shinohara et al. 2016). The other expressed gene combination (Pl-GGS/Ls-cyclase) did 
not give any detectable precursor, hence further transformation with the other five 
pleuromutilin biosynthetic gene was not performed.  
Looking at the number of transformants, very few (<5) were able to be generated from 
the transformation. As has been discussed earlier, at least 15 positive transformants 
need to be screened to have a reliable outcome. However due to time constraints, 
additional screening for a higher number of transformants could not be made. This may 
mask the conclusions that can be drawn from these results. Nevertheless, where 
transformants had been generated in a low number in the previous pleuromutilin shunt 
pathway study, at least one of the strains was able to produce a new product. Thus, 
several other aspects were then considered to explain the failure of the expression. 
Difficulties in mapping the RNA sequences on genomic data of L. sordida described 
by Banks (2016) may lead to misinterpretation for the prediction of Ls-GGS and Ls-
cyclase as well as the exons and introns boundaries. Any misinterpretation could affect 
the enzyme functionality given that these were designed as synthetic DNA constructs. 
It is also possible that the Ls-GGS is a pathway-specific gene which is closely 
associated with its own cyclase to catalyse the precursor compound. It is common in 
many biosynthetic pathways, where different enzymes may interact to form one 
functional multi-enzyme complex, working together to biosynthesize the products of 
the pathway. Inactivation or removal of one enzyme is likely to inactivate the unit as a 
whole. This has been reported by Shuib et al. (2018), a multi-enzyme complex 
involving malic enzyme, fatty acid synthase, ATP: citrate lyase, acetyl-CoA 
carboxylase, pyruvate carboxylase and malate dehydrogenase was detected during lipid 
accumulation phase.  
As lepistal has never been successfully found in the L. sordida strain used in this study, 
it is unknown whether the diterpene biosynthetic genes found in L. sordida are really 
linked to lepistal biosynthesis. There is a possibility that the gene cluster is non-
functional or may be involved in other diterpene production which does not share 
similar characteristics to pleuromutilin structure. As can be seen in this thesis when 
 152 
trying to express P450 involved in other diterpene pathways, no product can be 
detected from the transformation system.  
6.4 Conclusion 
As a conclusion, an improved knowledge regarding the biosynthetic pathway of 
pleuromutilin was achieved through heterologous expression. The A. oryzae 
heterologous system used in this study allowed accumulation of two new premutilin 
products which proved the flexibility and reliability of the host for gene manipulation. 
Thus, the same strategy of heterologous expression can be employed to characterize 
gene clusters and elucidate biosynthesis of other secondary metabolites from 
basidiomycetes and other fungi. This system could therefore enable to overcome the 
current issues related to the study of biosynthetic pathways in the native host and help 
in understanding the biosynthesis of pharmaceutically-relevant secondary metabolites 
produced from fungi.  
The presence of two shunt pathways branching from the main route of pleuromutilin 
biosynthesis proved a remarkable versatility in the enzyme activities which could 
provide future opportunities for metabolic engineering. The order of the biosynthetic 
reactions however remains unanswered and to be confirmed with further analysis.  
The failure of attempts to derivatize premutilin core highlighted some of the ongoing 
challenges for a synthetic biology approach to metabolite engineering, potentially 
where pathways have unknown (if any) function. One of the most significant 
bottlenecks in this process is the selection of enzymes capable of catalyzing substrates 
through the desired synthetic route. The ability to provide new sets of enzymes that 
could accept a wide range of substrates is important to efficiently synthesize new 
metabolites. Further insights into the interaction of dedicated enzymes with the 
substrates are required to choose the most promising candidates for combinatorial 
biosynthesis as the success of this approach is highly dependent on a complete 
understanding of enzyme-substrate susceptibility. 
Various enzymes from different pathways could be screened against numbers of 
different substrates to test for the versatility of their catalytic activity. For rapid and 
economical screening process, this could be done by feeding the substrates into a host 
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engineered to harbor the gene encoding the selected enzyme. The same strategy has 
also been adopted in work carried out in this thesis when testing the ability of Pl-P450-
3 to convert intermediates 9 and 10 to the final products. The outcomes from this study 
would potentially generate libraries of diverse candidate enzymes to be used in the 
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The rise in antibiotic resistance is a major threat for human health. Basidiomycete fungi
represent an untapped source of underexploited antimicrobials, with pleuromutilin—a
diterpene produced by Clitopilus passeckerianus—being the only antibiotic from these fungi
leading to commercial derivatives. Here we report genetic characterisation of the steps
involved in pleuromutilin biosynthesis, through rational heterologous expression in Aspergillus
oryzae coupled with isolation and detailed structural elucidation of the pathway intermediates
by spectroscopic methods and comparison with synthetic standards. A. oryzae was further
established as a platform for bio-conversion of chemically modified analogues of
pleuromutilin intermediates, and was employed to generate a semi-synthetic pleuromutilin
derivative with enhanced antibiotic activity. These studies pave the way for future char-
acterisation of biosynthetic pathways of other basidiomycete natural products in ascomycete
heterologous hosts, and open up new possibilities of further chemical modification for the
growing class of potent pleuromutilin antibiotics.
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P leuromutilin is a diterpene natural product with anti-microbial properties, whose tricyclic skeleton has served asa precursor for semi-synthetic derivatives used in veterinary
and human medicine. These antibiotics are active on Gram-
positive bacteria and their mode of action relies on binding to the
bacterial ribosome at the level of the peptidyl transferase centre,
therefore inhibiting protein synthesis1. Pleuromutilin was first
discovered by Kavanagh et al.2 from the two basidiomycete fungi
Pleurotus mutilis (synonymous to Clitopilus scyphoides f. mutilus)
and Pleurotus passeckerianus (synonymous to Clitopilus passeck-
erianus). It is now known to be also produced by a number of
other related species3 and its chemical structure and cyclisation
mechanism (Fig. 1a) were elucidated by independent work con-
ducted by Arigoni4, 5 and Birch et al.6. The semi-synthetic
pleuromutilin analogues tiamulin and valnemulin (Fig. 1a) have
been used for over three decades to treat economically important
infections in swine and poultry7–10 without showing any sig-
nificant development of resistance in their target bacteria. Reta-
pamulin (Fig. 1a), another pleuromutilin derivative, was approved
in 2007 for the use in human medicine as a topical treatment for
impetigo and other skin infections, being also active on
methicillin-resistant Staphylococcus aureus (MRSA)11. In recent
years extensive research including structure–activity relationship
(SAR) studies have been conducted with the aim of generating
new orally available pleuromutilin derivatives to be used sys-
temically in human medicine to treat acute bacterial skin and skin
structure infections12, 13, as well as multidrug-resistant tubercu-
losis14, with more than a thousand compounds being
synthesised15.
Since an increasing number of semi-synthetic derivatives of
this diterpene antibiotic are being produced, understanding the
biosynthetic pathway to pleuromutilin is an essential requirement
for the effective and robust large-scale production of the natural
product for use as starting material in these synthetic endeavours.
The biosynthetic pathway to pleuromutilin has so far only been
inferred through limited feeding experiments of the producing
fungi with isotope-labelled predicted precursors16, 17, but a full
picture of the pathway and a genetic characterisation of the
enzymes involved in catalysis of each step of the biosynthesis are
still lacking.
Biosynthetic pathways of fungal secondary metabolites are
often characterised through generation of silenced or knockout
mutant strains, where downregulation of biosynthetic genes or
targeted-gene-deletion lead to accumulation of intermediates, as
recently shown by Lin et al.18 for the pathway of the commu-
nesins. Heterologous expression of the biosynthetic genes for a
secondary metabolite of interest in a filamentous fungus sec-
ondary host is also an established alternative for characterising
gene function, as reviewed by Lazarus et al.19 and Alberti et al.20.
Aspergilli and other physiologically well-characterised fila-
mentous fungi are commonly employed for this purpose, as
effective engineering toolboxes are available for their transfor-
mation. Among these, Aspergillus oryzae is known to have a low
background in secondary metabolite production, despite having
the potential for producing the building blocks for all main fungal
secondary metabolites. A. oryzae has been successfully employed
to recreate partial or total biosynthesis of natural products from
other ascomycete fungi, such as the polyketide (PK) citrinin21, the
polyketide–non-ribosomal peptide (PK–NRP) hybrid tenellin22,
non-ribosomal peptide (NRP) siderophores such as ferrirhodin23,
the indole-diterpene paxilline24, the diterpene aphidicolin25 and
the meroterpenoid pyripyropene26.
The gene cluster for the antibiotic pleuromutilin (1) was
recently isolated in C. passeckerianus27. Total de novo biosynth-
esis of 1 was achieved through the expression of the entire gene
cluster in the secondary host A. oryzae, proving that the seven
genes isolated were sufficient for biosynthesis of the diterpene
antibiotic. However, this still did not provide insights into the
function of each individual gene, nor on the nature of the
intermediate compounds produced along the pathway. We report
here genetic characterisation of the steps involved in the bio-
synthesis of 1, through a logical stepwise expression of genes from
the pleuromutilin gene cluster in A. oryzae, coupled with isolation
and detailed structural elucidation of the pathway intermediates
by spectroscopic methods and comparison with synthetic stan-
dards. This pathway engineering approach has given insights into
pleuromutilin biosynthesis and creation of a panel of A. oryzae
strains designed to accumulate each pathway intermediate as a
final product. Furthermore, full elucidation of a biosynthetic
pathway of a basidiomycete natural product has been uncovered
using an ascomycete secondary host. We envisage our work will
pave the way for future characterisation of biosynthetic pathways
of other basidiomycete natural products in ascomycete hetero-
logous hosts, bypassing the need for genetic manipulation of
intractable basidiomycete species. Moreover, in industrial pro-




Pleuromutilin, HO = R














































Fig. 1 Pleuromutilin commercial derivatives and proposed cyclisation mechanism. a Structure of pleuromutilin and its commercial derivatives. b Outline of
cyclisation to the pleuromutilin tricyclic scaffold, as reported by Arigoni4, 5 and Birch et al.6. The class II terpene synthase domain of Pl-Cyc promotes ring
contraction during the protonation-dependent cyclisation of GGPP. The class I terpene synthase domain then catalyses formation of the 8-membered ring
through ionisation-dependent dephosphorylation. Trapping with water introduces the first hydroxy group of the molecule at C-14 of the tricyclic scaffold
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enzymatic biosynthesis represents an appealing and inexpensive
alternative, and is considered a way of reducing manufacturing
costs20. Here we show that our heterologous system can also be
employed as a chassis to generate semi-synthetic derivatives of
pleuromutilin, where a suitably engineered A. oryzae strain
accepts a chemically modified pleuromutilin intermediate and
takes the pathway to completion. This work led to generation of a
semi-synthetic derivative of 1, which exhibited enhanced anti-
biotic activity against Bacillus subtilis.
Results
Analysis of gene silencing for pathway elucidation. Silencing of
genes is a recognised molecular tool employed to study gene
function in fungi, as shown for example by Nakayashiki et al.28
for the ascomycete model Magnaporthe oryzae. Since silencing of
the genes of the pleuromutilin cluster was previously established
in C. passeckerianus29, we attempted detection of pleuromutilin
intermediates from the extracts of the silenced lines for the
pleuromutilin biosynthetic genes generated by Bailey et al.27.
However, whilst pleuromutilin production ceased in the trans-
formants, surprisingly no accumulation of pleuromutilin pre-
cursors could be detected from the crude extracts. RT-PCR from
RNA extracted under normal production conditions failed to
generate any products relating to pleuromutilin pathway genes—
even those genes that were not targeted in the silencing experi-
ment (Supplementary Fig. 1). This suggested that silencing of
individual genes from the cluster triggered the downregulation of
all the other genes known to be involved in biosynthesis of
pleuromutilin. Since gene silencing was not a suitable means to
achieve detailed functional characterisation of the genes of the
pleuromutilin cluster in C. passeckerianus, instead we set out to
undertake stepwise heterologous expression in the secondary host
A. oryzae to build the pathway.
A diterpene synthase creates 14-hydroxytricyclic terpene 2. In
order to heterologously express the genes of the pleuromutilin
cluster in A. oryzae, we generated expression vectors based on the
plasmids developed by Pahirulzaman et al.30. Because of the high
intron density in basidiomycete genes and possibilities of mis-
splicing from genomic clones, cDNA of these genes was used to
construct the expression cassettes (see Supplementary Methods
for details on vectors construction). Arigoni5 and Birch et al.6
showed that biosynthesis of pleuromutilin (1) proceeds via
cyclisation of geranylgeranyl diphosphate (GGPP) to generate a
C-14 carbocation, which is trapped with water to give 2 (Fig. 1b).
This proposed cyclisation mechanism has been supported by
isotopic labelling studies; for instance, Arigoni reported incor-
poration of label with [2-14C]-mevalonate at C-3, C-7, C-13 and
C-17 in pleuromutilin, fully consistent with the proposed cycli-
sation mechanism5. The gene cluster for 1 from C. passeckerianus
contains both a pathway-specific geranylgeranyl diphosphate
synthase (Pl-ggs) gene, expected to provide GGPP, and a cyclase
(or diterpene synthase, Pl-cyc) gene27. On the basis of homology
searches, the Pl-cyc was inferred to encode a bifunctional diter-
pene synthase, which catalyses the protonation-dependent cycli-
sation of GGPP—promoted by the class II terpene synthase
domain of the enzyme—as well as the ionisation-dependent
dephosphorylation reaction—catalysed by the class I terpene
synthase domain (Fig. 1b).
To investigate the first step in biosynthesis of 1, the cDNA of
Pl-ggs—for putative increased production of GGPP—and Pl-cyc
genes from C. passeckerianus were co-expressed in A. oryzae
NSAR1, generating the transformant strain A. oryzae GC (see
Table 1 for full a list of the strains generated, and Supplementary
Methods for A. oryzae transformation and analysis of transfor-
mants). Reverse-phase HPLC failed to detect any new products in
A. oryzae GC in comparison to untransformed controls, however
a new compound was apparent by thin-layer chromatography
(TLC) (Supplementary Fig. 2). Preparative TLC was used to
purify the product, yielding 5 mg from 1 L of culture. The
chemical ionisation (CI) mass spectrum gave m/z [M +H]+
291.2688 (C20H35O) and the structure of 14-alcohol 2 was
elucidated by extensive NMR studies (see Supplementary Figs. 3,
5 and 7–10 for NMR spectra and Supplementary Table 1 for
NMR assignment and chemical ionisation mass spectrometry
(CIMS) data).
To confirm the structure of alcohol 2 an authentic sample was
prepared from commercially available tiamulin (Fig. 2). Hydro-
lysis of tiamulin gave mutilin 5 which was protected as the 14-
monosilyl ether 8. The regiocontrol in the protection step was
confirmed by conversion of alcohol 8 to acetate 9 which showed a
characteristic downfield shift of the signal assigned to 11-H in the
1H-NMR spectrum. Following reduction of the 3-ketone to
alcohol 10, the 19,20-alkene was temporarily protected via
hydroboration and selective esterification of the resultant primary
alcohol giving 12. The 3- and 11-hydroxy groups were removed
via radical reduction and then pivoyl ester 13 was reduced to
alcohol 14. Following dehydration then deprotection of the silyl
ether 15, the target alcohol 2 was isolated. The 1H- and 13C-NMR
spectra of the synthetic sample 2 (see Supplementary Figs. 4 and 6
for NMR spectra) were identical to those of alcohol 2 isolated
from extracts from A. oryzae GC, confirming the structure of the
natural product.
Hence, we can conclude that heterologous expression in A.
oryzae of the Pl-ggs and Pl-cyc genes from the pleuromutilin gene
cluster gives alcohol 2 as the first cyclic intermediate on the
biosynthetic pathway to pleuromutilin. A similar reaction is
observed also in the first step of biosynthesis of aphidicolin, where
the aphidicolan-16β-ol synthase encoded by the PbACS gene
catalyses cyclisation of GGPP to give a tetracyclic product that
contains a hydroxyl function25. Like other fungal diterpene gene
clusters, such as that for aphidicolin in Phoma betae31, the gene
cluster for 1 contains a pathway-specific Pl-ggs gene27, pre-
sumably to provide increased levels of GGPP25, the 20-carbon
precursor of diterpenes that comes from isopentenyl diphosphate
and dimethylallyl diphosphate.
Table 1 List of Aspergillus oryzae strains generated
Aspergillus oryzae strain Heterologous genes from C. passeckerianus Compounds produced de novo Reference
GC Pl-ggs, Pl-cyc 2
GCP1 Pl-ggs, Pl-cyc, Pl-p450-1 3
GCP1P2 Pl-ggs, Pl-cyc, Pl-p450-1, Pl-p450-2 4 This work
GCP1P2S Pl-ggs, Pl-cyc, Pl-p450-1, Pl-p450-2, Pl-sdr 5
GCP1P2SA Pl-ggs, Pl-cyc, Pl-p450-1, Pl-p450-2, Pl-sdr, Pl-atf 6
NSAR1 7 Pl-ggs, Pl-cyc, Pl-p450-1, Pl-p450-2, Pl-sdr, Pl-atf, Pl-p450-3 1, 6 Bailey et al.27
The C. passeckerianus genes expressed heterologously in these strains are reported, as well as related compounds produced de novo
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Characterisation of later steps of pleuromutilin biosynthesis.
With a heterologous system established for the generation of the
first tricyclic biosynthetic intermediate (2) encountered along the
pathway, we aimed to characterise further metabolites produced
along the pathway. The gene Pl-p450-1—coding for a putative
Cytochrome P450 monooxygenase27—was expressed hetero-
logously in the Pl-ggs+Pl-cyc strain A. oryzae GC, generating
strain GCP1. Analysis of extracts by both TLC and HPLC
revealed a new product (Supplementary Fig. 11), which was
purified yielding 10 mg from 1 L of culture of 11,14-diol 3. The
1H-NMR spectrum of 3 displayed characteristic methine signals
at δ 3.33 (d, J 6.4 Hz) and δ 4.34 (d, J 8.3, Hz) (see Fig. 3b and
Supplementary Fig. 12) which on comparison with the spectrum
of mutilin, the 11,14-dihydroxy-3-ketone 5, correlated well with
the signals assigned to 11-H and 14-H respectively. Hence the
structure was tentatively assigned as 11,14-diol 3, which was
confirmed by further extensive NMR studies combined with MS
(see Fig. 4b and Supplementary Fig. 11 for HPLC–MS, Supple-
mentary Figs. 12–16 and Supplementary Table 2 for NMR
characterisation of 3).
Co-expression of Pl-p450-1 and Pl-p450-2 in the A. oryzae
strain that harboured Pl-ggs and Pl-cyc gave the transformant
strain GCP1P2. A product (18 mg from 1L of culture) that was
absent in strain GC was detected by HPLC and its structure
assigned as triol (4) by high-resolution mass spectrometry
(HRMS) combined with 1D and 2D NMR (see Fig. 4b and
Supplementary Fig. 17 for HPLC–MS and Supplementary Figs. 18,
20 and 22–24 and Supplementary Table 3 for NMR data and
Electrospray ionization (ESI)-HRMS). To confirm the proposed
structure of triol 4, a synthetic sample was prepared by reduction
of mutilin 5 (see Fig. 2 and Supplementary Figs. 19 and 21 for
NMR spectra of synthetic 4), and the stereochemistry of the 3-
hydroxy group established by nOe via irradiation of the signal
assigned to 3-H (δ 4.54) leading to enhancements of the signals
assigned to 2α-H, 4-H and 15-H3 (Supplementary Figs. 25 and 26).
For the conversion of triol 4 to pleuromutilin, oxidation of the
3-hydroxy group is required and the product of the gene Pl-sdr,
predicted from bioinformatics analysis to be a short-chain
dehydrogenase/reductase27 was proposed to catalyse this trans-
formation. Hence an expression cassette for Pl-sdr along with Pl-
p450-1 and Pl-p450-2 was transformed into the A. oryzae GC
strain. Following purification of the extract by HPLC–MS the
expected 3-ketone, mutilin (5) (15 mg from 1 L of culture) was
isolated and fully characterised by both spectroscopic methods
and comparison with an authentic sample prepared by semi-
synthesis (see Fig. 4a, 4b and Supplementary Fig. 27 for
HPLC–MS of 5, Supplementary Figs. 28, 30 and 32–34 and
Supplementary Table 4 for NMR and ESI-HRMS data of 5, and
Supplementary Figs. 29 and 31 for NMR spectra of synthetic
sample).
To complete the biosynthesis of pleuromutilin (1) acetylation
of the 14-alcohol to acetate 6, previously isolated from C.
passeckerianus32, followed by hydroxylation of the acetate is
required. The gene cluster for 1 includes a predicted acetyl
transferase (Pl-atf)27 and an additional P450 oxidoreductase (Pl-
p450-3 ). Thus an A. oryzae transformant expressing all genes
from the pleuromutilin cluster except Pl-p450-3 was generated,
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Fig. 2 Synthesis of proposed biosynthetic intermediates. Predicted biosynthetic intermediates 2, 4 and 5 were prepared and used as standards to confirm
the structures of the compounds produced de novo in A. oryzae in this study
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mg from 1 L of culture) and characterised (see Fig. 4b and
Supplementary Fig. 35 for HPLC–MS, and Supplementary
Figs. 36–40 and Supplementary Table 5 for NMR and ESI-
HRMS data). Furthermore, expression of all seven genes of the
cluster, including Pl-p450-3 gave pleuromutilin 1 as the final
product of the pathway (Fig. 4a)27.
Generation of bioactive derivatives of 1 within A. oryzae. In
order to study the metabolism of pleuromutilin intermediates to
1, as well as to carry out bio-conversion of chemically modified
analogues into pleuromutilin derivatives, we further established
A. oryzae as a platform to carry out selected late steps in pleur-
omutilin biosynthesis. We validated our system by converting 5
into 1 upon culturing of strain AP3 (harbouring Pl-atf and Pl-
p450-3 from C. passeckerianus) in the presence of 5 (100 mg L−1)
(see Supplementary Figs. 41 and 42 for NMR spectra). Interest-
ingly, triol 4—accumulated in strain GCP1P2—has not been
detected previously in extracts of C. passeckerianus or other
pleuromutilin-producing fungi. Hence to gain evidence that 4 is
an intermediate in the biosynthesis of 1 a feeding study was
conducted in the non-pleuromutilin producing A. oryzae
SAP3 strain (expressing Pl-sdr, Pl-atf and Pl-p450-3 from C.
passeckerianus, involved in the final three steps of the pathway).
SAP3 was cultured in the presence of 4 (100 mg L−1), which was
converted to both acetate 6 and pleuromutilin 1 (see Supple-
mentary Figs. 43–46 for NMR spectra) in accord with triol 4
being an intermediate in pleuromutilin biosynthesis.
Once we established a system for conversion of pleuromutilin
intermediates into pleuromutilin within A. oryzae, we further
investigated the capability of this chassis to generate semi-
synthetic analogues of 1 upon feeding with chemically modified
analogues of the naturally occurring intermediates. In order to do
so, we first prepared enone 18 starting from tiamulin (see
Supplementary Fig. 47 for chemical synthesis leading to 18). We
then cultured A. oryzae strain AP3 (containing Pl-atf and Pl-p-
450-3 genes from C. passeckerianus) in the presence of 18 (30 mg
in 300mL culture broth), and confirmed the conversion of the
enone into its ester 20 (18 mg, 51%) and hydroxy ester 21 (8 mg,
23%) (see Fig. 5a for a scheme of the bio-conversion, and
Supplementary Figs. 48–51 for NMR spectra of the purified
products). We thus investigated the antimicrobial activity of these
two semi-synthetic derivatives against B. subtilis via plate-based
bioassay (see Supplementary Methods for details on the
antimicrobial bioassay procedure). The ester 20 produced an
inhibition zone on the growth of B. subtilis of 12.7± 0.6 mm (see
Fig. 5b and Supplementary Table 6), comparable to that of
pleuromutilin 1 (12.8± 0.8 mm) and higher than that of 6 (10.3
± 0.3 mm). Remarkably, the hydroxy ester 21 generated an
inhibition zone on the growth of B. subtilis of 15.7± 1.8 mm,
which was greater than that of both naturally occurring 1 and 6,
as well as of that of its precursor 18 (8.0± 0.0 mm). Each
antimicrobial bioassay was carried out in triplicate.
Discussion
Antimicrobial substances produced by microorganisms are a
valuable resource for the development of semi-synthetic anti-
biotics. The diterpene antibiotic pleuromutilin has provided leads
for the only commercial antibiotic produced from a basidiomy-
cete fungus, specifically from C. passeckerianus and other related
species3, and has led to the generation of semi-synthetic deriva-
tives7, 8, 10 for human and veterinary use. The ongoing efforts
towards the development of pleuromutilin analogues to be used
systemically in human medicine suggests that this class of anti-
biotics is yet to be exploited to its full potential12–14.
In this study, we have shown genetic characterisation of all the
steps involved in pleuromutilin biosynthesis from GGPP by
rational heterologous expression in A. oryzae coupled with iso-
lation and detailed structural elucidation of the pathway inter-
mediates by spectroscopic methods and comparison with
synthetic standards, as well as feeding purified intermediates into
suitably engineered host strains. A first attempt to characterise
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Fig. 3 1H-NMR spectra of selected biosynthetic intermediates. The region δ 3.0–δ 5.5 ppm is shown for a 14-alcohol (2), b 11,14-diol (3), c 3,11,14-triol (4)
and d mutilin (5). Data were recorded in CDCl3 (500MHz)
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native producer C. passeckerianus failed to return any accumu-
lation of precursors. Transcript titres assessed by RT-PCR showed
this was due to the downregulation of all genes of the cluster
upon silencing of individual genes. This was unexpected,
although a similar occurrence has been reported in other fungal
secondary metabolite pathways33. As an alternative approach to
characterise the biosynthetic pathway, and with the knowledge
that full pleuromutilin production could be supported in A.
oryzae27, we adopted stepwise heterologous expression of the
genes of the cluster for 1. Similar strategies have been successfully
employed to characterise other fungal secondary metabolite
pathways21–26. This allowed us to show accumulation of each of
the five intermediates progressing to biosynthesis of 1 (Fig. 4),
including 3R,11S,14R-triol (4), showing that the C-3 keto is
derived in a two-step reaction via a hydroxy intermediate
requiring both Pl-p450-2 and Pl-sdr.
Heterologous expression in A. oryzae of the Pl-ggs and Pl-cyc
genes from the pleuromutilin cluster provided convincing evi-
dence that 14-alcohol 2 is the first tricyclic intermediate generated
on the pathway, as previously proposed by Arigoni4. The cyto-
chrome P450 oxidoreductases encoded by Pl-p450-1 and Pl-p-
450-2 catalyse stereospecific hydroxylation of C-11 and C-3
respectively, and co-expression of Pl-ggs, Pl-cyc, Pl-p450-1 and Pl-
p-450-2 in A. oryzae gave accumulation of the putative inter-
mediate 4. Rather than being a shunt product, triol 4 was shown
to be a precursor of 1, through a feeding experiment of an A.
oryzae strain harbouring Pl-sdr, Pl-atf and Pl-p450-3 , successfully
yielding pleuromutilin. Isolation of mutilin (5) in A. oryzae
GCP1P2S (Fig. 4) showed that 4 is further oxidised along the
pathway by the product of the gene Pl-sdr, indicating that Pl-sdr
is a short-chain dehydrogenase/reductase class of enzyme that
catalyses regiospecific oxidation of the 3-hydroxy group to a
ketone. The final intermediate in the biosynthesis of 1 was pro-
duced de novo in A. oryzae by adding the Pl-atf gene (encoding
an acetyl transferase) to the heterologous system that was pro-
ducing 5, achieving sole production of 14-acetate 6 in GCP1P2SA
(Fig. 4). By inference this shows that Cytochrome Pl-p450-3 is
responsible for hydroxylation of acetate 6 to pleuromutilin, as
production of 1 was observed before27 when expressing all the
seven genes of the pleuromutilin gene cluster in A. oryzae,
including Pl-p450-3 , which was lacking in A. oryzae GCP1P2SA
yielding 6.
The re-creation of a linear biosynthetic pathway to 1 by step-
wise gene addition, allowed us to prove the function of the genes
of the cluster from C. passeckerianus, and showed that bio-
synthesis of a basidiomycete secondary metabolite and its
intermediates can be studied in an ascomycete heterologous host.
Furthermore, we report here a full conversion of each inter-
mediate of the pathway to the next, with no bottleneck observed
in any of the biosynthetic steps (Fig. 4b), showing that our system
can allow for accumulation of each biosynthetic precursor in
amounts sufficient for consequent purification and full char-
acterisation. We envisage this approach could be employed in the
future to characterise the biosynthesis of other basidiomycete
secondary metabolites of pharmaceutical or agrochemical
relevance.
In this study, we also showed that the heterologous platform
recreated in the A. oryzae host can be employed to convert not
only pleuromutilin intermediates into 1, but also chemically
modified analogues into semi-synthetic derivatives, providing a
robust and flexible chassis for semi-synthetic derivatisation of
pleuromutilin. Using this system, the chemically modified enone
18 was successfully bio-converted into ester 20 and hydroxy ester
21 (Fig. 5), with the latter showing increased antibiotic activity
over pleuromutilin against B. subtilis.
In current commercial production of pleuromutilin derivatives
the C-14 side chain of the naturally occurring antibiotic is
removed, then replaced with the synthetic side chain. Deploy-
ment of the A. oryzae transformant strain that accumulates
mutilin 5 could find application in industrial production of
commercial pleuromutilins. Furthermore, the observation that a
suitably engineered A. oryzae strain can successfully take to
completion the pathway when fed with chemically modified
analogues of pleuromutilin intermediates, opens new avenues for
obtaining useful semi-synthetic derivatives of this antibiotic,
exploiting more fully the power of combining synthetic chemistry
and synthetic biology.
Methods
Reagents and conditions for growth of microorganisms. All chemicals were
purchased from either Sigma-Aldrich or Fisher Scientific, unless otherwise speci-
fied, and were of analytical grade. Ingredients for media were purchased from
Oxoid or Formedium, unless otherwise specified. All media, solutions, glassware
and plastic-ware were sterilised by autoclaving at 121 °C for 15 min before use. C.
passeckerianus ATCC 34646, producer of pleuromutilin, was maintained on PDA
plates (24 g L−1 potato dextrose broth, 15 g L−1 agar) at 25 °C. A. oryzae NSAR1
(genotype niaD−, sC−, ΔargB, adeA−)34, used as heterologous host, was maintained
on MEA plates with appropriate supplements (15 g L−1 malt extract, 1.5 g L−1
arginine, 1.5 g L−1 methionine, 0.1 g L−1 adenine, 2 g L−1 ammonium sulphate, 15 g
L−1 agar) at 28 °C. Saccharomyces cerevisiae BY4742 (genotype MATα, his3Δ1,
leu2Δ0, lys2Δ0, ura3Δ0)35, used for homologous recombination-based construc-
tion of plasmids, was maintained on YPAD plates (10 g L−1 yeast extract, 20 g L−1
bactopeptone, 20 g L−1 D-glucose, 40 mg L−1 adenine hemisulfate, 15 g L−1 agar).







































































Fig. 4 De novo production of pleuromutilin intermediates. a Proposed biosynthetic pathway to 1 in Clitopilus passeckerianus. b HPLC chromatograms
showing de novo production of pleuromutilin intermediates in Aspergillus oryzae strains. (i) A. oryzae GCP1, (ii) A. oryzae GCP1P2, (iii) A. oryzae
GCP1P2S, (iv) A. oryzae GCP1P2SA and (v) A. oryzae NSAR1 (recipient strain). Traces were recorded with evaporative light scattering detector
(ELSD)
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were used for propagation of plasmids by standard procedures. LB agar plates (10 g
L−1 NaCl, 10 g L−1 tryptone, 5 g L−1 yeast extract, pH 7) were used for growing E.
coli at 37 °C.
Genetic engineering of fungal strains. Silenced lines of C. passeckerianus used in
this study where those described in Bailey et al.27, where the antisense sequence of
each gene of the pleuromutilin cluster was placed under control of the Agaricus
bisporus gpdII promoter and expressed in C. passeckerianus. Expression vectors for
A. oryzae to contain the genes of the pleuromutilin cluster were constructed
through homologous recombination in yeast following the procedure described by
Ma et al.36. The seven genes of the pleuromutilin gene cluster—Pl-ggs, Pl-cyc, Pl-
p450-1 , Pl-p450-2 , Pl-p450-3 , Pl-atf and Pl-sdr—were amplified using high-fidelity
PCR from the cDNA of C. passeckerianus and cloned in pJET 1.2 cloning vectors
(see Supplementary Methods for details on cloning of the genes of the pleur-
omutilin cluster). Plasmids pTYGSarg, pTYGSade and pTYGSbar30 were used as
backbones to construct expression vectors with the intron-free genes of the
pleuromutilin cluster (plasmid maps and details of construction of expression
vectors are in Supplementary Methods), which were used to transform A. oryzae
NSAR1 and derived transformant strains. Protoplast-mediated transformation of
A. oryzae was carried out following an adapted protocol from the one described by
Halo et al.37. Details on the A. oryzae transformation procedure are reported in
Supplementary Methods. The vector pTYGSargGGSCyc (which included Pl-ggs
and Pl-cyc) was used for transformation of A. oryzae NSAR1, generating strain GC
(producer of 2). Further transformation of GC with pTYGSadeP1 (containing Pl-
p450-1 ) achieved production of strains GCP1 (producer of 3). Likewise, transfor-
mation of GC with pTYGSadeP1P2 (containing Pl-p450-1 and Pl-p450-2 ) returned
strains GCP1P2 (producer of 4). A combination of pTYGSadeP1P2 and pTYGS-
barSDR (containing Pl-sdr) was introduced into GC to produce strain GCP1P2S
(producer of 5), whereas a combination of pTYGSadeP1P2 and pTYGSbar-
ATFSDR (containing Pl-atf and Pl-sdr) was used to transform strain GC to achieve
GCP1P2SA (producer of 6). Strain AP3, used for feeding experiment with 5, was
generated by transforming A. oryzae NSAR1 with a combination of pTYGSadeP3
(containing Pl-p450-3 ) and pTYGSbarATF (containing Pl-atf), whereas strain
SAP3 used for feeding experiment with 4 was obtained by transforming A. oryzae
NSAR1 with a combination of pTYGSadeP3 (containing Pl-p450-3 ) and pTYGS-
barATFSDR (containing Pl-atf and Pl-sdr).
Synthetic chemistry. Selected proposed biosynthetic intermediates were synthe-
sised as presented in Fig. 2 and described in the main text, in order to confirm by
NMR the structure of the compounds produced de novo in engineered fungal
strains, as well as to give standards for HPLC–MS. Enone 18 was synthesised as
presented in Supplementary Fig. 47.
Chemical analysis on A. oryzae transformants. A. oryzae transformants were
analysed for production of metabolites. Each transformant strain was grown in 100
mL of CMP medium (35 g L−1 Czapek-dox liquid, 20 g L−1 maltose, 10 g L−1
peptone) at 28 °C for 10 days prior to proceeding with organic extractions with
ethyl acetate, concentrating the crude extract in vacuo and dissolving in methanol.
For the A. oryzae strains GC, AP3 (fed with 5) and SAP3 (fed with 4), the crude
extracts were analysed for detection of metabolites by using TLC. Fungal crude
extracts were transferred to 20 × 20 cm TLC plates (TLC silica gel 60 F254; Merck,
Darmstadt, Germany), which were developed in petroleum spirit-ethyl acetate (9:1
for strain GC, 1:1 for strains AP3 and SAP3). This led to 5 mg of 2 from the crude
extract of strain GC, 6 mg of 1 from the extract of AP3 (fed with 5), 4 mg of 1 and
3 mg of 6 from the extract of SAP3 (fed with 4). For the purification of the crude
extract of AP3 fed with the synthetic analogue 18 (30 mg in 300 mL broth) flash
column chromatography was employed, using a silica gel with pore size 60 Å and
particle size 40–60 µm (Sigma Aldrich). Fractions were collected in glass tubes,
pooled in a pre-weighed glass vial and concentrated in vacuo. Using this procedure,
purification of 18 mg of acetate 20 and 8 mg of hydroxy acetate 21 was achieved.
For all other strains the crude extracts were analysed with analytical HPLC–MS by
using a Waters 2767 HPLC system with a Waters 2545 pump system, and a
Phenomenex LUNA column (2.6 μ, C18, 100 Å, 4.6 × 100 mm) equipped with a
Phenomenex Security Guard precolumn (Luna C5 300 Å). A reverse-phase HPLC
with a gradient of solvents was used (A, HPLC grade H2O containing 0.05% formic
acid; B, HPLC grade CH3CN containing 0.045% formic acid) with the following
programme: 0 min, 10% B; 15 min, 90% B; 16 min 95% B; 17 min 95% B; 18 min
10% B, 20 min 10% B. Flow rate was set at 1 mLmin−1. Preparative HPLC–MS was
used to purify compounds from the crude extract of A. oryzae transformants that
were absent in the A. oryzae control strain. For this purpose a 1-L culture of the
chosen fungal strain was set up and extracted with the same conditions described
when undertaking analytical HPLC–MS. Fractions that contained target com-
pounds were purified using reverse-phase HPLC on a Waters mass-directed
autopurification system with a Waters 2767 autosampler and Waters 2545 pump
system, a Phenomenex LUNA column (5μ, C18, 100 Å, 10 × 250 mm) for reverse-
phase chromatography, equipped with a Phenomenex Security Guard precolumn
(Luna C5 300 Å), eluted at 16 mLmin−1. A gradient of solvents was used (A, HPLC
grade H2O containing 0.05% formic acid; B, HPLC grade CH3CN containing








































































































Fig. 5 Semi-synthetic bioactive pleuromutilin derivatives. a Bio-conversion of the enone 18 into its ester 20 and hydroxy ester 21. b Antimicrobial activity of
the semi-synthetic derivatives 20 and 21 against B. subtilis, compared to that of their precursor 18, and the naturally occurring 1 and 6. Error bars represent
standard deviation of the bacterial growth inhibition zone calculated from three independent replicates
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20 min, 90% B; 21 min 95% B; 26 min 95% B; 27 min 5% B, 30 min 5% B. Specific
fractions were collected in glass tubes, pooled in a pre-weighed glass vial and
concentrated in vacuo. Using this
procedure, purification of 10 mg of 3, 18 mg of 4, 15 mg of 5 and 6 mg of 6
was achieved. Details of the procedures used for ethyl acetate organic extractions,
TLC, analytical and preparative HPLC–MS are also reported in Supplementary
Methods.
Spectroscopic analyses of purified metabolites. The metabolites purified from
A. oryzae transformants were characterised by NMR spectroscopy. The samples
were dissolved in CDCl3 or CD3OD and spectra were obtained with an Agilent
VNMRS500 spectrometer (1H 500MHz, 13C 125MHz). Chemical shifts were
recorded in parts per million (ppm) and coupling constant (J) in Hz. Chemical
shifts for 1H-NMR are reported relative to the proton resonance δ 7.26 of CHCL3
or δ 4.78 of CH3OH, whereas shifts for 13C-NMR are reported relative to the
carbon resonance δ 77.16 of CDCl3. ESI-HRMS was performed with a
Bruker Daltonics microTOF focus using positive ESI. Chemical ionisation mass
spectrometry was performed with a VG/Micromass Autospec operated in positive
mode. NMR spectra and ESI-HRMS/CIMS data for the metabolites produced
de novo from the A. oryzae engineered strains are reported in Supplementary
Information.
Bio-conversion of precursors into 1 and derivatives. Liquid cultures of AP3 and
SAP3 were set up in 100 mL of CMP medium with the addition of 4 and 5 (100 mg
L−1) respectively, and grown for 10 days at 28 °C prior to proceeding with organic
extractions with ethyl acetate and concentration of the crude extracts in vacuo.
TLC was used to purify 1 from the crude extract of strain AP3 (fed with 5), as well
as 1 and 6 from the crude extract of strain SAP3 (fed with 4), and the structures
confirmed by 1H-NMR and 13C-NMR. For bio-conversion of 18, liquid cultures of
AP3 were set up in 100 mL of CMP medium with the addition of 18 (100 mg L−1).
Organic extractions with ethyl acetate and concentration of the crude extract
in vacuo were followed by column chromatography (10–20% EtOAc in petrol) for
purification of 20 (23 mg, 67%) and 21 (14 mg, 39%). 1H-NMR and 13C-NMR
were carried out to confirm the structures.
Data availability. All data is available from the authors upon reasonable request.
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